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General introduction
Four million people die from cardiovascular causes in Europe every year. Almost 
half of these deaths are attributable to coronary heart disease (CHD), which makes 
CHD the single most common cause of death in European citizens.1 CHD was 
estimated to cost the European Union €45 billion in 2003, with approximately 90 
million working years lost due to CHD morbidity and 1 million working years lost 
due to CHD mortality.2 Nevertheless, prognosis of CHD patients has been improv-
ing over the last decades.3 As a consequence, the prevalence of CHD is increasing 
rapidly, which is amplified by the aging of Western populations and increases in the 
number of people with known risk factors such as obesity.4,5
The clinical syndrome responsible for most CHD morbidity and mortality is the 
acute coronary syndrome (ACS). Patients with suspected ACS are commonly divid-
ed into non ST-segment elevation myocardial infarction (NSTEMI) and ST-segment 
elevation myocardial infarction (STEMI) based on electrocardiographic (ECG) find-
ings. The presence of persistent ST-segment elevation in two contiguous leads with 
reciprocal ST-depression on the ECG reflects transmural ischemia, which will lead 
to myocardial necrosis unless immediate reperfusion therapy is initiated. The main 
focus of this thesis is the STEMI population.
 
Pathophysiology of coronary heart disease
Atherosclerosis is the underlying pathophysiological process of the majority of 
CHD cases. It involves the formation of atheromatous plaques in the coronary and 
other medium to large-sized arteries throughout the body. Plaque formation is most 
likely initiated by irritant stimuli such as dyslipidemia, leading to expression of 
adhesion molecules on the endothelial surface and retention of low-density lipo- 
proteins in the vessel wall.6,7 Circulating leukocytes (mainly monocytes and lympho-
cytes) adhere to the “activated” endothelium and migrate into the vessel wall. The 
monocytes mature into macrophages in the intimal layer of the artery. These macro-
phages internalize the modified lipoproteins (thereby becoming foam cells), which 
results in an accumulation of lipids in the intima. Furthermore, macrophages and 
other leukocytes initiate an inflammatory response and cause tissue damage through 
the release of inflammatory cytokines, chemokines, proteases and oxygen radicals. 
Secreted growth factors stimulate both the migration of smooth muscle cells into 
the intima and the heightened synthesis of extracellular matrix such as collagen 
and elastin, promoting the formation of a collagenous fibrous cap that covers the 
plaque.6,7 As the lesion progresses, a necrotic core filled with cell debris, lipids, 
proteases and procoagulant material is formed inside the plaque. In this advanced 
stage, the plaque becomes prone to rupture due to thinning of the fibrous cap un-
der influence of proteases. When plaque rupture occurs, the procoagulant material 
from the necrotic core and the extracellular matrix come into contact with blood, 
thereby triggering the formation of a luminal thrombus.6,7 Alternatively, thrombus 
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formation may be triggered by denudation or erosion of the endothelial layer with-
out plaque rupture.6 When a localized or embolized thrombus impedes the coro-
nary blood flow towards a segment of the myocardium, ischemia and eventually 
myocardial necrosis occur. This gives rise to the clinical spectrum of ACS (unstable 
angina pectoris with or without myocardial infarction (MI)). The healing of plaque 
ruptures plays a role in the progressive narrowing of the coronary lumen in CHD, 
a process that can occur asymptomatically if coronary blood flow is not imped-
ed.8 The arterial wall may initially compensate for plaque progression by way of 
enlargement toward the adventitia (coined positive remodeling), thereby delaying 
the formation of a functionally significant stenosis.9 However, the capacity for the 
coronary artery to increase the blood supply to the myocardium becomes increas-
ingly limited as the narrowing of the coronary lumen progresses. This may result in 
myocardial ischemia during moments of increased demand (e.g. exercise, stress), 
creating the clinical entity of stable angina pectoris.
 
Risk factors
Well-established modifiable risk factors for cardiovascular disease include dys-
lipidemia, hypertension, diabetes mellitus and smoking, in addition to the strong 
unmodifiable risk factors age and gender.10 These traditional risk factors, along 
with abdominal obesity, lack of physical exercise, low consumption of fruit and 
vegetables, high consumption of alcohol and psychosocial factors account for an 
estimated 90% of the worldwide populations’ attributable risk of MI.11 Risk factor 
reductions explained half of the reduction in CHD mortality in the United States in 
the last 20 years, stressing the importance of identifying patients at risk for CHD.3 
European guidelines further acknowledge the value of primary prevention, and 
recommend screening of the general population for risk of cardiovascular disease 
using risk estimation systems such as ‘SCORE’.12,13 Recently, much research has 
been devoted to the role of biochemical markers in improving the early identifi-
cation of patients at risk for cardiovascular disease in the general population. In-
flammatory markers, cardiac troponins and natriuretic peptides have been stud-
ied extensively and contribute to risk stratification, although the added value over 
traditional risk factors remains uncertain.14-16
 
Diagnosis of myocardial infarction
The cornerstone of the diagnosis of MI is the detection of a rise and fall in bio-
markers of cardiac necrosis above the 99th percentile of the upper reference limit, 
in combination with other clinical signs and symptoms of myocardial ischemia or 
infarction (Table 1). However, the patient history and ECG findings remain the most 
important factors for determining the management strategy of patients with suspect-
ed MI, as biomarkers may still be undetectable in the early stages of MI. 
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Detection of a rise and/or fall of cardiac biomarker values (preferably cardiac troponin) 
with at least one value above the 99th percentile upper reference limit and with at least 
one of the following:
•      Symptoms of ischemia 
•      New or presumed new significant ST-segment changes or new left bundle 
        branch block 
•      Development of pathological Q waves in the ECG 
•      Imaging evidence of new loss of viable myocardium or new regional wall    
        motion abnormality 
•      Identification of an intracoronary thrombus by angiography or autopsy
Adapted from the third universal definition of myocardial infarction.17
STEMI is typically accompanied by prolonged chest pain in rest (>20 minutes in 
duration), located in the center of the chest and commonly described as a heavy, 
tight or burning sensation. Additional symptoms may include but are not limited to: 
radiation of the pain (to arm, neck, jaw, shoulder or abdomen), nausea/vomiting, 
diaphoresis, dyspnea, fatigue, fear of dying and collapse.18 Atypical symptomatol-
ogy is common, especially in women, diabetics and elderly patients, and may sig-
nificantly delay help-seeking behavior and timely diagnosis.19,20
The ECG is a vital tool for the rapid decision making in patients with suspected MI. 
In setting of STEMI, the ECG can be used to estimate the quantity of myocardium 
at risk and can in most cases identify the coronary culprit lesion.21,22 Furthermore, 
ECG monitoring is essential for the detection of potentially life-threatening ventric-
ular arrhythmias that may occur during the early stages of STEMI. In certain cases, 
interpretation of ST-segment changes may be limited due to the presence of bundle 
branch block or ventricular pacing, potentially delaying diagnosis of MI.23,24
Biomarkers
Currently, the most commonly used biomarkers for detection of myocardial necro-
sis are creatine kinase-MB (CK-MB) and cardiac troponins. Creatine kinase is an 
enzyme that catalyzes the transfer of high-energy phosphate from creatine phos-
phate to adenosine triphosphate, and is released rapidly during muscle damage. 
The creatine kinase system consists of different isoenzymes; CK-MM is present in 
large quantities in skeletal muscle and myocardium, while CK-MB is found pre-
dominantly in the myocardium, making it useful for the detection of myocardial 
necrosis.25 However, small amounts of CK-MB are also found in skeletal muscle, 
and the ratio of CK-MB to CK-MM in skeletal muscle is influenced by factors such 
as heavy exercise, reducing the specificity of CK-MB for myocardial damage.26 
Cardiac troponins are the current standard for the measurement of myocardial in-
jury. The contractile apparatus of the myofibril consists of myosin, actin, tropo- 
myosin and the troponin complex. The troponin complex has three sub-units; 
troponin-C, troponin-I and troponin-T. Although troponins are found in both skele-
tal and cardiac muscle, distinct cardiac isotypes exist for troponin-I and troponin-T, 
making these isotypes highly specific markers of myocardial injury.25 Continuous 
Table 1. Criteria for acute myocardial infarction
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improvements in troponin assays have led to greatly increased sensitivity for the 
detection of cardiac troponins, resulting in the adoption of the term high-sensitive 
cardiac troponin measurements. For optimal precision, assays should have a co- 
efficient of variation ≤10% at the 99th percentile upper reference limit of a healthy 
population. A rise and fall of troponin values is needed to distinguish acute from 
cardiac troponin elevations that are associated with structural heart disease.27
 
Treatment
The progress made in the treatment of MI in the last century has been impres-
sive, and several important developments deserve mention. One of the first major 
improvements in management was the introduction of coronary care units in the 
1970s. Coronary care units opened the possibility towards monitoring patients for 
hemodynamics and the occurrence of life-threatening arrhythmias, allowing prompt 
treatment when necessary.28 The beneficial concept of the coronary care unit was 
extended outside the hospital walls through the introduction of ambulances with 
defibrillation equipment, as it was recognized that many MI patients died before 
hospital admission due to fatal arrhythmias.29 The decrease in arrhythmia-related 
mortality increased the recognition of infarct size as the major determinant of mor-
bidity and mortality in patients with MI.30 Apart from initial success of beta-blockers 
in limiting infarct size, the real breakthrough came with the introduction of reper-
fusion therapy.31 The growing realization that coronary thrombus was present in 
the majority of patients with STEMI and the first successful lysis of coronary throm-
bus through infusion of streptokinase paved the way for the use of thrombolysis in 
STEMI patients.32,33
Thrombolysis
The GISSI trial was the first large multicenter trial to randomize patients with acute 
MI to treatment with intravenous streptokinase compared to conventional treat-
ment.34 This landmark trial showed that streptokinase reduced early mortality and 
was safe in acute MI patients. The ISIS-2 study confirmed the strength of intra- 
venous streptokinase in acute MI, and showed the effectiveness of the combina-
tion of streptokinase with aspirin in reducing mortality and re-infarction.35 These 
and other large trials led to the widespread adoption of thrombolysis in setting of 
MI. Genetic engineering subsequently produced several additional thrombolytic 
agents, such as tissue-plasminogen activator, which was found to be superior to 
previous thrombolytic regimens in combination with intravenous heparin.36  A large 
meta-analysis confirmed the value of the class of thrombolytic agents in acute MI, 
and revealed a strong association between the delay to treatment and benefit of 
thrombolysis.37 This gave rise to the notion of the golden hour, the first hour after 
onset of symptoms, during which the patient should ideally receive reperfusion 
therapy.38
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Despite the advantages and widespread availability of thrombolysis, several limita-
tions to this therapy were noted: thrombolysis failed to restore coronary artery pa-
tency in 20-45% of patients, and re-occlusion of the coronary artery occurred in up 
to 30% of patients after thrombolysis.39,40 Moreover, patients treated with thrombo- 
lysis showed a small but significant increase in intracranial hemorrhage.37
Primary angioplasty
Using a technique pioneered in peripheral arteries by Dotter and Judkins, Grüntzig 
et al. introduced the treatment of arteriosclerotic lesions in the coronary artery 
using catheter-mounted balloon dilatation (coronary angioplasty)41,42 (Figure 1). 
The potential of angioplasty in setting of MI was soon discovered, and multiple 
large trials were initiated to compare “primary” angioplasty with thrombolysis in 
MI patients.43 Several advantages of primary angioplasty were identified in these 
trials, among which higher rates of coronary patency, ability to reduce the residual 
coronary stenosis, lower rates of re-infarction and improvements in remaining left 
ventricular function compared to thrombolysis.44,45
Figure 1. Coronary angioplasty. A catheter with mounted balloon is introduced into the coronary artery 
and passed through the coronary stenotic segment. Pressure inflation of the balloon subsequently 
expands the stenotic lesion, restoring the patency of the coronary vessel. Source: National Heart, Lung, 
and Blood Institute, National Institutes of Health; U.S. Department of Health and Human Services.
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A large meta-analysis finally showed that also mortality was reduced with the use 
of primary angioplasty, in addition to reductions in stroke and re-infarction.46  How-
ever, management of MI using primary angioplasty is considerably more complex 
than thrombolysis, meaning that it can only be performed in specialized centers. 
As a consequence, approximately 30 minutes of additional delay until initiation of 
reperfusion therapy was added due to patient transfer times.47 Sophisticated net-
works of care were introduced to reduce the delay between onset of STEMI and 
reperfusion therapy.  Over the years, the optimization of MI care has led to gradual 
improvements in delay to treatment.48,49 Several important strategies contribute to 
minimizing this delay, including the following:
- Standardization of pre- and in-hospital care  and clear agreements 
 between regional health care providers regarding the referral of STEMI  
 patients (Figure 2).50 
- The use of pre-hospital ECG faxed from the ambulance to the operator on  
 call, to allow pre-hospital triage of STEMI patients.51 
- Transport of STEMI patients straight to PCI centers.52 
- Delivery of patients to the catheterization laboratory, bypassing the emer- 
 gency room.50,52  
- Around the clock service of intervention centers.51 
- Monitoring of pre- and in-hospital delays to quantify the delay and  
 identify bottlenecks.53,54 
Figure 2. Influence of MISSION! implementation on door-to-balloon times.  
The MISSION! protocol, implemented in the Leiden University Medical Center 
between 2004 and 2005, is an all-phases integrated STEMI care program aimed 
at maximizing the use of evidence based medicine to improve the care of 
STEMI patients. MISSION! focuses on rapid diagnosis, minimization of treat-
ment delay and aggressive reperfusion strategies, followed by active lifestyle 
improvement and structured medical therapy. Source: unpublished numbers.
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In quantifying delay, the time between symptom onset and reperfusion therapy 
(symptom-to-balloon time) is commonly referred to as the total ischemic time, as 
this is theoretically the time that the myocardium is deprived from coronary blood 
flow. Patient delay is the time between symptom onset and seeking of health care 
assistance, an interval that is potentially influenced by increased awareness of 
symptoms of MI through public campaigns.55 System delay starts at the moment 
of first medical contact, and can be divided into the overlapping time intervals of 
first ECG to reperfusion therapy (diagnosis-to-balloon time), and time from hospital 
arrival to reperfusion therapy (door-to-balloon time). Current guidelines recom-
mend a maximum delay of 90 minutes between first medical contact and PCI. If es-
timated delay to PCI is longer than 120 minutes, thrombolysis is recommended with 
subsequent transfer to a PCI center with angiographic follow-up within 24 hours.56
While primary angioplasty increasingly replaced thrombolysis as the standard 
therapy for MI, there were some remaining disadvantages associated with balloon 
angioplasty: acute vessel closure occurred in 5-8% of patients, causing ischemic 
complications frequently requiring management with emergency coronary artery 
bypass grafting.57 Also, restenosis of the treated coronary lesion occurred in up to 
40% of patients.58 Therefore, further optimization of primary angioplasty required 
an additional technological development. Mechanical scaffolding of the coronary 
artery using metallic stents proved effective in treating acute vessel closure, which 
led to widespread adoption of the coronary stent in clinical practice.59
Coronary stents
In landmark trials covering treatment of stable coronary artery disease, coronary 
stenting was shown to be superior to balloon angioplasty, resulting in higher rates 
of procedural success and less restenosis.60,61 However, the introduction of foreign 
material into the body was associated with a new complication; thrombotic occlu-
sion of the stent, or stent thrombosis (ST). This potentially catastrophic complication 
was found to occur in up to 1 in 5 patients.62 Nonetheless, it was soon discovered 
that improved stenting technique (avoiding stent underexpansion) and use of dual 
antiplatelet therapy (in the form of aspirin and a thienopyridin-derivate) could dras-
tically reduce the occurrence of ST, making coronary stenting safe for clinical prac-
tice.63,64 Concerns about the safety of stenting in the pro-thrombotic environment 
of MI remained, which prompted the initiation of dedicated trials in MI patients. 
Suryapranata et al. were the first to randomize patients with MI to routine coronary 
stenting or balloon angioplasty, and were quickly followed by larger trials, most no-
tably the CADILLAC and PAMI trials.65-67 These trials showed that coronary stenting 
in setting of MI was both safe and associated with improved angiographic outcomes 
compared to angioplasty alone, reducing the need for revascularization procedures 
due to reduced restenosis rates. Subsequently, a meta-analysis of 9 trials confirmed 
the benefit of primary coronary stenting over primary angioplasty in reducing target 
vessel revascularization as well as re-infarction in setting of MI.68
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Despite these improvements in outcome, a considerable proportion of patients 
still required re-intervention due to restenosis of the treated lesion. The mecha-
nism of restenosis after stenting differed from the restenosis occurring after angio- 
plasty, which was predominantly due to vessel recoil and negative remodeling.69 
The process involved in the re-narrowing of the in-stent lumen was coined neo- 
intimal hyperplasia. Commonly described as an excessive growth of scar tissue 
within the stent, this process is caused by the damaging effect of stent implantation 
to the vessel wall, leading to endothelial denudation, medial dissection, penetra-
tion of the lipid core and an inflammatory response to the stent struts, which results 
in the proliferation of smooth muscle cells on the luminal side of the stent.70-72 To 
battle this iatrogenic complication of stent implantation, drug-eluting stents (DES) 
were developed. 
Drug-eluting stents
DES are metallic stents which include a surface coating of polymer that gradually 
releases an antirestenotic drug which inhibits neo-intimal hyperplasia. The first DES 
that gained approval were the sirolimus-eluting stent (SES) (Cypher, Cordis, Bridge-
water, New Jersey, United States) and the paclitaxel-eluting stent (PES) (Taxus Ex-
press/Liberté, Boston Scientific, Natick, Massachusetts). SES are based on a 140μm 
stainless steel stent which releases sirolimus from a layer of polyethelyne co-vinyl 
acetate and poly-n-butyl methacrylate polymer. The antirestenotic drug sirolimus 
(rapamycin) is a macrolide antibiotic with immunosuppressant properties which 
was found to reduce neointimal proliferation through inhibition of lymphocyte and 
smooth muscle cell proliferation.73 Approximately 80 percent of the sirolimus is 
released within 28 days.74
PES are based on a 132 μm (Taxus Express) or 97 μm (Taxus Liberté) stainless steel 
stent which releases paclitaxel from a layer of poly(styrene-b-isobutylene-b-styrene) 
polymer. Paclitaxel is an antineoplastic agent that was initially isolated from bark of 
the Taxus tree and was found to inhibit smooth muscle cell migration and prolifera-
tion.75 Approximately 10% of the paclitaxel is released in the first 28 days.74
The pivotal trials that compared SES and PES with conventional bare-metal stents 
(BMS) found a considerable reduction in restenosis with the use of DES in patients 
with stable coronary artery disease.76-78 Importantly, no effect on mortality and re- 
infarction was observed.79 However, early trials excluded patients with acute MI, 
and therefore several dedicated trials were initiated to investigate the use of DES in 
this patient category. 
In setting of STEMI, use of SES was found to reduce medium term (1 to 2 year) rates 
of restenosis compared to BMS, while no differences in mortality, re-infarction and 
ST were observed.80-86 Similarly, PES were also found to reduce restenosis rates 
compared to BMS at medium term follow-up.85,87,88 In the larger trials, these results 
were sustained at long-term follow-up for both stent types.89-91 
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Although the beneficial effect of DES on restenosis became well established and 
no safety concerns were identified in individual trials, one meta-analysis did indi-
cate a heightened rate of very late ST and re-infarction after DES implantation in 
setting of STEMI.92 Furthermore, reports from real world data raised concerns on the 
long term safety of DES.93 This gave rise to extensive research on the safety of DES. 
The standardization of the definition of ST by the Academic Research Consortium 
greatly facilitated the comparison of ST rates (table 2).
Table 2. Definition of stent thrombosis
Adapted from the Academic Research Consortium on clinical endpoints in coronary stent trials.94
Several predictors of ST have been identified, among which patient factors (dia-
betes mellitus, renal insufficiency, peripheral artery disease, malignancy, reduced 
ejection fraction), lesion factors (bifurcation lesions, complex lesions, presence of 
dissection, sub-optimal reperfusion, late stent malapposition), stenting technique 
(undersizing of stent, long stented segments, small stent diameter), medication 
(premature discontinuation of dual antiplatelet therapy, periprocedural bivalirudin 
compared to glycoprotein IIb IIIa inhibitors), setting (acute MI) and other less com-
mon factors.95-98 
The predictors of ST show large overlap between BMS and DES. However, intra-
vascular ultrasound and pathological studies identified specific histological cor-
relates associated with late ST after DES implantation. Late stent malapposition 
was observed more frequently after SES implantation in setting of STEMI compared 
Classification
•      Definite ST: 
        Angiographic or pathological confirmation of thrombus in-stented area ± 5 mm  
        margin and presence of one of the following criteria within a 48-hour window: acute  
        onset of ischemic symptoms at rest, new ischemic ECG changes, typical rise and fall   
        in cardiac biomarkers.
•      Probable ST:
        Any unexplained death within 30 days after PCI or any MI that is related to 
        documented acute ischemia in the territory of the implanted stent without  
        angiographic confirmation of stent thrombosis and in the absence of any other 
        obvious cause.
•      Possible ST:
         Any unexplained death from 30 days after stent implantation until end of trial   
         follow-up.
Timing of stent thrombosis
•      Acute ST: 0 to 24 hours after stent implantation
•      Sub-acute ST: >24 hours to 30 days after stent implantation
•      Early ST: 0 to 30 days after stent implantation
•      Late ST: >30 days to 1 year after stent implantation
•      Very late ST: >1 year after stent implantation
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to BMS.82 Additionally, late ST was found to be strongly associated with delayed 
stent healing, which is more common after DES implantation due to inhibition of 
normal endothelial growth by the antirestenotic drug. Delayed healing is charac-
terized by reduced endothelial strut coverage and increased fibrin deposits.99,100 
Underlying plaque morphology influences this process: vessel healing after PCI for 
STEMI is more delayed compared to PCI in stable coronary lesions.101 Other local 
factors associated with late ST are strut penetration into the necrotic core and local 
hypersensitivity.100 Besides a reaction to the stent struts, the local hypersensitivity 
was shown to be due to the stent polymer, causing marked local inflammation. The 
tissue reaction to stent struts and polymer prompted the investigations of novel DES 
in attempt to improve the safety and efficacy of these first generation DES.102 
Second generation DES
The second generation DES included changes in platform, polymer and anti- 
restenotic drug. The stainless steel stent platforms were changed to cobalt- 
chromium, an alloy exhibiting superior radial strength.103 This allows thinner stent 
struts that may reduce thrombogenicity and improve vascular healing.104 The 
Endeavor zotarolimus-eluting stent (E-ZES) (Endeavor, Medtronic Vascular, Santa 
Rosa, California, United States) was the first second generation DES accepted for 
clinical appliance. The E-ZES is based on a 91 μm cobalt-chromium stent platform 
eluting zotarolimus, a sirolimus-analogue. The E-ZES applies a thin layer of bio- 
compatible phosphorylcholine polymer which has a fast elution pattern, releasing 
95% of its antirestenotic drug within 14 days.74
The everolimus-eluting stent (EES) (Xience V, Abbott Vascular, Santa Clara, Cali-
fornia, United States; Promus, Boston Scientific, Natick, Massachusetts, United 
States) is based on a thin 81 μm cobalt-chromium platform, eluting the sirolimus- 
analogue everolimus. The EES applies a layer of polyvinylidene fluoride co-hexafluoro- 
propylene and poly-n-butyl methacrylate polymer which releases 80% of the 
everolimus within 14 days.74
In animal studies, EES and BMS were associated with more complete endothelial-
ization at 14 days compared to PES, SES and E-ZES. At 28 days, this was also the 
case for E-ZES compared to the first generation DES.105 In clinical studies, E-ZES was 
associated with reduced restenosis rates compared to BMS, reduced re-infarction 
and very late ST rates compared to PES and long term reductions in mortality and 
MI with similar clinical efficacy compared to SES.106-109 EES were found to result in 
improved angiographic outcomes compared to BMS, reductions in repeat revascu-
larization procedures, MI and ST compared to PES and reduced rates of repeat re-
vascularization procedures and ST compared to SES.110-115 A large meta-analysis by 
Palmerini et al confirmed the excellent safety of EES, reducing rates of ST compared 
to BMS, PES, SES and E-ZES.116
So far, no dedicated trials for the use of E-ZES in STEMI have been performed. EES 
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have been compared with BMS in 1 dedicated STEMI trial. In this trial, EES re-
duced the need for repeat revascularization and the rates of ST compared to BMS 
at 1-year.117 Randomized comparisons of first and second generation DES in setting 
of STEMI have not been performed. Also, data are lacking on the optimal second 
generation DES in STEMI patients.
 
Adjunctive antithrombotic therapy
Current STEMI guidelines recommend that all STEMI patients should receive 
dual antiplatelet therapy in the form of acetylsalicylic acid (aspirin) and a P2Y12- 
receptor antagonist.118 Aspirin inhibits platelet aggregation through cyclo-oxy-
genase inhibition, and was shown to reduce the risk of mortality after MI with 
10 to 15% and the risk of re-infarction with 30%.119 P2Y12-receptor antagonists 
inhibit platelet aggregation through direct or indirect inhibition of the ADP- 
activated P2Y12-receptor expressed by thrombocytes. Clopidogrel has been the most 
commonly used drug for this purpose, and was found to reduce mortality and re- 
infarction without raising bleeding risk in MI patients.120 Recently, the more potent 
P2Y12-receptor antagonists prasugrel and ticagrelor were also approved for this 
purpose, following the large TRITON TIMI 38 and PLATO trials.121,122 In the STEMI 
arms of these trials, prasugrel was shown to reduce rates of cardiovascular death, 
re-infarction and ST compared to clopidogrel, while TIMI major bleeding after cor-
onary artery bypass grafting was increased.123 Ticagrelor reduced rates of all-cause 
mortality, re-infarction and ST, while a slight increase in stroke was observed com-
pared to clopidogrel.124 European guidelines currently recommend 9-12 months of 
dual antiplatelet therapy after STEMI, with a strict minimum duration of 6 months 
after DES implantation and 1 month after BMS implantation.118
The third group of platelet aggregation inhibitors that may be considered as an 
addition to the previously described dual antiplatelet therapy consists of the glyco- 
protein IIb/IIIa inhibitors. These drugs are antagonists of the glycoprotein IIb/IIIa 
receptor which is activated by fibrinogen and von Willebrand factor. Most evi-
dence exists for the use of acbiximab, which was shown to reduce mortality and 
reinfarction after primary PCI without increasing the risk of bleeding.125 
Additional mortality benefit may be achieved through the up-front administration of 
abciximab, a strategy performed routinely in the MISSION! protocol.126
In addition to antiplatelet therapy, STEMI patients should receive anticoagulation 
therapy around primary PCI. Traditionally, this purpose has been served by heparin, 
which indirectly inactivates thrombin and factor Xa through release of antithrom-
bin. The newer direct trombin inhibitor bivalirudin may be preferable to heparine, 
as bivalirudin monotherapy was found to be superior to the combination of heparin 
and a glycoprotein IIb/IIIa inhibitor. Bivalirudin therapy resulted in a reduction in 
mortality and major bleeding although an increase in early ST was observed.127 
Alternatively, the ‘low molecular weight heparin’ enoxaparin may be preferable to 
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heparin due to a beneficial effect on ischemic outcomes.128
 
Risk stratification
While guidelines recommend the routine use of risk scores such as GRACE in 
NSTEMI patients, there remains uncertainty regarding the role of risk scores in set-
ting of STEMI.118 The GRACE score uses age, heart rate, systolic blood pressure, 
serum creatinin, Killip class and presence or absence of cardiac arrest, ST-segment 
deviation and cardiac enzymes to estimate the in-hospital mortality of ACS pa-
tients.129 The TIMI risk score for STEMI differs slightly from GRACE by incorporating 
location of MI, history of diabetes/hypertension/angina, patient weight and time to 
treatment, although the strongest weighing physiological factors are similar.130 The 
CADILLAC and Zwolle risk scores focus specifically on the STEMI patient treated 
with primary PCI, and have the advantage that angiographic characteristics are tak-
en into account.131,132 
An alternative approach toward improving care and stratification of STEMI pa-
tients is through the identification of high-risk sub-populations. Ideally, this allows 
tailoring of care to suit the specific needs of these sub-populations. For instance, 
more potent antiplatelet therapy with prasugrel can reduce the heightened risk of 
ischemic events after ACS in diabetic patients.133 Also, newly identified or less 
common high-risk patient characteristics are often not included in conventional 
risk scores, thereby potentially underestimating the risk of adverse events in these 
patients. 
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Objective and outline of the thesis
This thesis can be divided into two distinct parts: the first part of this thesis aims to 
improve the risk stratification and care of STEMI patients, through the identification 
of high-risk sub-populations. The second part focuses on the optimization of treat-
ment of CHD through the use of second generation drug-eluting stents. 
Part 1: High-risk sub-populations
Previous studies have shown that women suffer higher mortality after ACS, due 
to higher age and comorbidity. However, conflicting results have been reported 
on the association between gender and prognosis in the STEMI population. Chapter 2 
investigates the influence of gender on ischemic times and outcomes after primary 
PCI for STEMI.
Out-of-hospital cardiac arrest is a common complication of STEMI which is asso-
ciated with a poor prognosis. Chapter 3 covers the angiographic determinants of 
out-of-hospital cardiac arrest and their association with prognosis after STEMI.
Simultaneous occurrence of cancer and CHD is increasingly frequent, and cancer 
patients are at a higher risk for cardiac complications due to side effects of cancer 
treatment and commonly present hypercoagulability. Chapter 4 investigates the in-
fluence of cancer on the prognosis after STEMI. 
As a result of aging populations in western countries, elderly patients form an 
increasingly large proportion of the STEMI population. However, the effects 
of primary PCI on the prognosis of the elderly remain poorly investigated. 
Chapter 5 studies the changes in care and prognosis of elderly patients suffering 
STEMI during a 10-year inclusion period.
Part 2: Treatment optimization
The potentially improved safety and efficacy of second generation DES may be 
especially useful in the high-risk setting of STEMI. However, limited studies 
have focused on the comparison of second generation DES in STEMI patients. 
Chapter 6 compares the long term outcome of EES and E-ZES in a real world obser-
vational cohort of STEMI patients. 
No previous trials have compared first and second generation DES in setting of 
STEMI. Therefore, a dedicated trial was initiated to compare the second generation 
EES with the first generation SES in patients with acute MI. Chapter 7 describes the 
results of the XAMI trial. 
The routine implantation of EES has potential advantages over first generation DES 
in clinical practice. Chapter 8 describes the APPENDIX-AMI trial, a randomized 
open label trial comparing EES and SES in all-comer patients.
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The clinical response to DES implantation may differ according to clinical presenta-
tion. Chapter 9 describes a pooled analysis of data from the XAMI and APPENDIX 
-AMI trials to investigate the performance of DES in patients presenting with and 
without STEMI during two-year follow-up. 
The final chapters describe a general summary, conclusions and future perspectives 
in English and in Dutch. 
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Previous studies investigating the influence of gender on ST-elevation myocardial 
infarction (STEMI) have reported conflicting results. The aim of this study was to 
assess the influence of gender on ischemic times and outcomes after ST-elevation 
myocardial infarction in patients treated with primary percutaneous coronary in-
tervention (PCI) in modern day practice. The present multicenter registry included 
consecutive patients with ST-elevation myocardial infarction treated with primary 
PCI at 3 hospitals. Adjusted mortality rates were calculated using Cox proportional- 
hazards analyses. In total, 3483 patients were included, of whom 868 women 
(25%). Women were older, had a higher risk factor burden and more frequently had 
histories of malignancy. Men more often had cardiac histories and peripheral vascu-
lar disease. Ischemic times were longer in women (median 192 min (IQR 141-286) 
vs. 175 min (128-279) in men, p=0.002). However, multivariable linear regression 
showed that this was due to age and co-morbidity. All-cause mortality was higher at 
7 days (6.0% in women vs. 3.0% in men, p<0.001) and 1 year (9.9% in women vs. 
6.6% in men, p=0.001). After adjustment, female gender predicted both 7 day all-
cause mortality (HR 1.61, 95% CI 1.06-2.46) and cardiac mortality (HR 1.58, 95% 
CI 1.03-2.42) but not 1-year mortality. Moreover, gender was an independent effect 
modifier for cardiogenic shock, leading to substantially worse outcome in women. 
In conclusion, ischemic times remain longer in women because of age and comor-
bidity. Female gender independently predicted early all-cause and cardiac mortality 
after primary PCI and a strong interaction between gender and cardiogenic shock 
was observed.
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Introduction
Coronary artery disease (CAD) is the leading cause of death in Western men and 
women.1 In 2003, the total cost of CAD in the European Union was an estimated 
45 billion euro, with approximately 1 million working years lost due to CAD mor- 
tality.2 To reduce the huge burden of CAD, research aimed at the optimal recogni-
tion and treatment of CAD in men and women is essential. Nonetheless, women are 
underrepresented in clinical trials of CAD.3 It is known that risk factors for CAD bear 
different weight among men and women and that women with anginal complaints 
more frequently show non-obstructive CAD on coronary angiography compared to 
men.4-7 Moreover, women have consistently shown higher mortality rates after acute 
coronary syndromes (ACS), due to higher age and more co-morbidities.8,9 How- 
ever, in the specific ST-elevation myocardial infarction (STEMI) population conflict-
ing results have been reported.8-14 Furthermore, previous studies lacked guideline 
recommended treatment with primary percutaneous coronary intervention (PCI) or 
excluded high risk patients commonly encountered in daily practice. Our goal was 
to investigate the influence of gender on ischemic times and outcomes after STEMI 
treated with primary PCI in modern day practice.
 
Methods
The present Dutch multicenter registry prospectively included consecutive patients 
treated with primary percutaneous coronary intervention (PCI) for STEMI in 3 ter-
tiary centers in the Netherlands. Two high-volume centers in the north of the Neth-
erlands, the Medical Center Alkmaar and the Medical Center Leeuwarden, provide 
24/7 cardiac care for an area of 450.000 and 650.000 inhabitants respectively. The 
Leiden University Medical Center serves an area of approximately 750.000 inhab-
itants.
Consecutive patients who underwent primary PCI for STEMI between January 2006 
and December 2009 were included in the analysis. Interventions included pass-
ing of guidewire through a thrombus, thrombosuction and/or percutaneous coro-
nary balloon angioplasty with or without placement of coronary stents. In case of 
out-of-hospital cardiac arrest, only patients with return of spontaneous circulation 
on moment of arrival at the catheterization laboratory were included. Furthermore, 
patients permanently living outside the Netherlands were excluded to make fol-
low-up through municipality records possible. STEMI was defined as symptoms 
of angina lasting >30 minutes along with typical electrocardiographical changes 
(ST-segment elevation ≥0.2 mV in ≥2 contiguous leads in V1 through V3 or ≥0.1 
mV in other leads or presumed new left bundle branch block). Pre-hospital proto-
cols included triage by 12-lead electrocardiogram in the field faxed to the operator 
on call and in-ambulance treatment with aspirin, intravenous heparin bolus and a 
loading dose of clopidogrel. Glycoprotein IIb/IIIa inhibitors were administered fre-
quently, using up-front administration in the Leiden University Medical Center and 
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periprocedural administration in the other hospitals. On arrival at the hospital, pa-
tients were transferred as soon as possible to the catheterization laboratory. Proce-
dures were performed according to current clinical guidelines. 
Patients treated in the Leiden University Medical Center were treated according to 
the institutional MISSION! protocol, a standardized prehospital, in-hospital and 
outpatient clinical framework for decision making and treatment.15 After hospital 
discharge, these patients were intensively monitored and managed at the outpatient 
clinic for 1 year, after which they were referred back to the general practitioner or 
referred to regular, generally regional, cardiological outpatient clinics.  At the other 
centers, local residents were managed in the outpatient clinics and patients referred 
from regional hospitals were referred back for further management after primary 
PCI by regional cardiologists. 
Hospitals prospectively included patients treated with primary PCI, registering 
baseline and procedural data. Definitions of variables were synchronized among 
centers. Cardiogenic shock was defined as systolic blood pressure <90 mmHg with 
signs of tissue hypoperfusion requiring treatment in form of resuscitation, inotropic 
agents or assistant devices. Symptom-to-balloon time was defined as the time be-
tween the onset of symptoms and balloon inflation. Diagnosis-to-balloon time was 
defined as the time between the first diagnostic ECG, mostly the ambulance triage 
ECG, and balloon inflation. Door-to-balloon time was the time between patient 
arrival at the tertiary hospital and balloon inflation. Close cooperation with regional 
emergency medical system providers supplied prehospital times. Vital status was 
obtained using municipality records. 
The 3 databases were pooled into a patient-level database, and stratification was 
done according to gender. Continuous variables are presented as mean with stan-
dard deviation or as medians with interquartile range and were compared using 
Student’s t-test for means and nonparametric tests for medians. Categorical vari-
ables are expressed as counts and percentages and were compared by means of 
Pearson’s χ² test. All statistical tests were 2-tailed and p-values <0.05 were con-
sidered statistically significant. Time to endpoint was analyzed using Kaplan-Meier 
plots and the log-rank test was applied to compare cumulative incidences of the 
endpoint between groups. Linear regression models were used to analyze variables 
predictive of log-transformed treatment delay. Univariable predictors of delay were 
added into multivariable linear regression models using a cut-off p-value of 0.10. To 
evaluate the effect of gender as an independent predictor of mortality, multivariable 
cox proportional hazards models were performed using a forward stepwise meth-
od. A cut-off p-value of <0.10 was applied to enter significant univariable predictors 
of outcome into the multivariable models. Gender was forced to stay in the mul-
tivariable models to allow calculation of adjusted hazard ratios for all outcomes.
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Results
During the inclusion period, 3483 consecutive STEMI patients were treated with 
primary PCI, of whom 868 were women (24.9%) and 2615 were men (75.1%). 
Baseline characteristics (Table 1) showed that women were on average older and 
had a higher risk factor burden with a higher prevalence of insulin-dependent 
diabetes mellitus and hypertension. Furthermore, women more often had histo-
ries of malignancy. In contrast, men had had previous myocardial infarctions more 
frequently and a larger proportion of men had undergone PCI or bypass surgery. 
Additionally, peripheral vascular disease was more common in men, and their me-
dian peak creatine kinase level was higher compared to women.








Age (yrs) 61.8 ± 11.9 67.6 ± 13.1 <0.001
Body mass index (kg/m2) 26.6 ± 3.7 26.3 ± 4.8 0.110
Risk factors
     Diabetes mellitus, non-insulin dependent 214 (8.3%) 80 (9.3%) 0.346
     Diabetes mellitus, insulin dependent 50 (1.9%) 42 (4.9%) <0.001
     Hypertension* 841 (32.5%) 394 (45.9%) <0.001
     Hypercholesterolemia† 608 (23.6%) 187 (21.8%) 0.282
     Family history of cardiovascular disease‡ 994 (40.2%) 335 (41.2%) 0.646
     Current smoker 1222 (47.8%) 344 (40.6%) 0.001
     Number of risk factors 1.52 ± 1.05 1.60 ± 1.10 0.036
Previous myocardial infarction 314 (12.1%) 61 (7.1%) <0.001
Previous PCI 238 (9.2%) 52 (6.0%) 0.004
Previous coronary artery bypass grafting 76 (2.9%) 9 (1.0%) 0.002
Previous peripheral vascular disease 136 (5.3%) 28 (3.3%) 0.016
Previous cerebrovascular disease 157 (6.1%) 59 (6.9%) 0.418
Previous malignancy 142 (5.5%) 68 (8.0%) 0.011
Previous renal insufficiency§ 86 (3.3%) 41 (4.8%) 0.053
Anemia on admission, moderate to severe|| 41 (1.6%) 14 (1.6%) 0.911
Out-of-hospital cardiac arrest 176 (6.7%) 48 (5.5%) 0.212
Cardiogenic shock 162 (6.2%) 65 (7.5%) 0.181
     Intra-aortic balloon pump placement 144 (4.4%) 35 (4.0%) 0.680
Creatine phosphokinase peak (U/l) 1420 (649-2715) 1170 (566-2335) <0.001
Symptom-to-balloon time (minutes) 175 (128-279) 192 (141-286) 0.002
Diagnosis-to-balloon time (minutes) 78 (64-99) 81 (66-101) 0.037
Door-to-balloon time (minutes) 46 (33-67) 46 (33-68) 0.405
* Blood pressure ≥140/90 mmHg or previous pharmacological treatment; † Total cholesterol ≥190 
mg/dl or previous pharmacological treatment; ‡ First degree family member suffering cardiovascular 
disease before the age of 60 years; § eGFR<60 ml/min/1.73m2; ||Admission hemoglobin <9.7 g/dl for 
women and <10.5 g/dl for men.
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Time between onset of symptoms and balloon inflation (ischemic time) was sig-
nificantly longer in women (Table 1). In addition, time between first diagnosis of 
STEMI and balloon inflation was marginally longer. Multivariable linear regression 
analysis of log transformed ischemic time revealed that age per 10 year increase 
(beta 0.03, 95% CI 0.01-0.05, p=0.001), history of diabetes mellitus (beta 0.10, 
95% CI 0.03-0.18, p=0.006) and history of renal insufficiency (beta 0.15, 95% CI 
0.02-0.27, p=0.020) were independent predictors of longer ischemic time, whereas 
gender was not (beta 0.03, 95% CI -0.03-0.08, p=0.295).








Coronary culprit vessel 0.049
    Left anterior descending 1026 (39.3%) 381 (43.9%) 0.016
    Left circumflex 435 (16.6%) 118 (13.6%) 0.033
    Right 1082 (41.4%) 352 (40.6%) 0.657
    Left main 36 (1.4%) 11 (1.3%) 0.807
    Bypass graft 34 (1.3%) 6 (0.7%) 0.144
Number of vessels narrowed >50% 0.152
     1 1204 (46.1%) 433 (49.9%)
     2 837 (32.0%) 257 (29.6%)
     3 571 (21.9%) 178 (20.5%)
Stenting 2503 (95.8%) 828 (95.4%) 0.616
     Drug-eluting stents 1806 (72.6%) 603 (73.6%) 0.584
     Bare-metal stents 688 (27.7%) 221 (27.0%) 0.701
Abciximab treatment 1964 (75.9%) 596 (69.2%) <0.001
Preprocedural TIMI flow grade* 0.078
      0 1809 (69.3%) 566/ (65.2%)
      1 274 (10.5%) 112 (12.9%)
      2 298 (11.4%) 100 (11.5%)
      3 229 (8.8%) 90 (10.4%)
Postprocedural TIMI flow grade ≥2 2558 (98.0%) 846 (97.6%) 0.488
Admission duration (days) 3.7 ± 6.2 4.0 ± 6.9 0.415
Discharge medication
          Aspirine / warfarin derivative 2438 (96.7%) 782 (96.0%) 0.305
          Clopidogrel 2472 (98.1%) 798 (97.9%) 0.745
          Beta-blocker 2277 (90.7%) 714 (88.0%) 0.029
          Ace-inhibitor / Angiotensin II antagonist 1791 (71.4%) 578 (71.3%) 0.938
          Statin 2345 (93.4%) 743 (91.6%) 0.093
* TIMI = Thrombolysis in myocardial infarction.
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Procedurally, a higher percentage of women presented with left anterior de-
scending artery as the culprit vessel, balanced by a lower percentage with the 
circumflex artery as the culprit vessel (Table 2). Abciximab treatment was more 
common in men and TIMI flow before and after procedure was similar between 
men and women. Beta-blocking agents were more frequently prescribed in men; 
other medications were balanced between the genders.
One-year survival status was known in 3479 patients. Both all-cause and cardiac 
mortality were more common in women compared to men during the entire fol-
low-up period (Table 3). Landmark analysis, with a cut-off point at 7 days (Figure 1), 
showed that this was due to higher early mortality, with similar prognoses for men 
and women after this period.









     Seven days 78 (3.0%) 52 (6.0%) <0.001
               Unadjusted HR (95% CI) 0.49 (0.35-0.70) 2.04 (1.43-2.89) <0.001
               Adjusted HR (95% CI) 0.62 (0.41-0.95) 1.61 (1.06-2.46) 0.027
     One year 173 (6.6%) 86 (9.9%) 0.001
               Unadjusted HR (95% CI) 0.65 (0.50-0.84) 1.54 (1.19-1.99) 0.001
               Adjusted HR (95% CI) 0.98 (0.73-1.32) 1.02 (0.76-1.37) 0.900
Cardiac mortality
     Seven days 77 (2.9%) 50 (5.8%) <0.001
               Unadjusted HR (95% CI) 0.50 (0.35-0.72) 1.98 (1.39-2.83) <0.001
               Adjusted HR (95% CI) 0.63 (0.41-0.97) 1.58 (1.03-2.42) 0.037
     One year 132 (5.1%) 75 (8.7%) <0.001
               Unadjusted HR (95% CI) 0.57 (0.43-0.76) 1.75 (1.32-2.32) <0.001
               Adjusted HR (95% CI) 0.79 (0.57-1.10) 1.26 (0.91-1.75) 0.168
HR were calculated using Cox proportional-hazards models. CI = confidence interval.
Figure 1. Landmark analysis of 1-year survival with 7-day cut-off.
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Figure 2. Independent multivariable predictors of 7-day all-cause mor-
tality. (CPK = creatine phosphokinase;  DM = diabetes mellitus; TIMI = 
thrombolysis in myocardial infarction. ).
Figure 3. Independent multivariable predictors of 1-year all-cause mortali-
ty. (LAD = left anterior descending artery; LM = left main artery; MI = myo-
cardial infarction; RCA = right coronary artery; RCX = ramus circumflex.).
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Multivariable Cox modeling showed that female gender predicted 7-day all-cause 
mortality (Figure 2) and 7-day cardiac mortality (Table 3). The association between 
ischemic time and 7 day mortality was investigated separately, resulting in a HR 
of 1.01 (95% CI 1.00-1.01) for every 10 minute increase in ischemic time. After 1 
year, gender no longer influenced all-cause (Figure 3) and cardiac mortality (Table 
3). The interaction of gender with predictors of all-cause mortality was investigated 
through multivariable modeling. After correction for confounders, female gender 
modified the effect of cardiogenic shock on 1-year mortality with an HR of 1.94 
(95% CI 1.04-3.62, p=0.038). For men with cardiogenic shock, an HR of 0.52 (95% 
CI 0.28-0.96) or an approximately 50% lower hazard of dying from the developed 
cardiogenic shock was observed during 1 year compared to women. Gender did 
not influence other predictors of all-cause mortality.
 
Discussion
The key findings of the present multicenter registry comparing men and women 
treated with primary PCI for STEMI are as follows: 1. Female gender independently 
predicted early all-cause and cardiac mortality. After this early period, prognoses 
were identical between men and women up to 1 year; 2. Ischemic times continue 
to be longer in women, explained by a higher prevalence of comorbidity and older 
age; 3. Women with cardiogenic shock had substantially worse outcomes com-
pared to men.
The influence of gender on CAD has long been a topic of debate.16 Traditional 
risk factors for CAD bear different weight between men and women and female- 
specific risk factors influence the development of CAD.4-6 Although women are 
more likely to present with atypical symptoms of ischemia, lower rates of obstruc-
tive CAD are observed.7,17,18 In contrast, women show longer delay to treatment in 
setting of STEMI, underlining the difficulties that exist regarding appropriate referral 
for coronary angiography.19 Moreover, women consistently show higher short term 
mortality after ACS.8,9 Although confounding factors were found responsible for 
this, focus on the STEMI population has produced conflicting results. In the present 
analysis, women were older than men and had a higher prevalence of risk factors, 
mirroring previous observations.20 After adjustment, female gender predicted short 
term mortality. The difference in outcome was due to particularly high mortality in 
the first days of admission. Similarly, Jneid et al.10 found that higher early mortal-
ity in women was due to the first day after infarction. Two other studies observed 
that female gender predicted short-term but not long-term mortality.11,12 Contradict-
ing this, Berger et al. reported that female gender predicted 30-day mortality but 
observed that this effect disappeared when only patients who underwent angio- 
graphy were selected.8 Also, a recent study found no effect of gender on survival, 
although a strong trend for higher mortality in women was observed.13 Moreover, 
a registry resembling our population found no effect of gender on early mortality.14 
Closer examination of these studies reveals that a substantial portion of patients 
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did not undergo reperfusion therapy,10,11 or that patients received thrombolysis 
only.8 Furthermore, high risk patients who would normally be encountered in daily 
practice were excluded because of longer ischemic times or transfer from referring 
hospitals.13,14 In contrast, the current analysis included patients from 3 centers in-
corporating modern systems of care with short time to treatment delays, full use of 
primary PCI and no exclusion based on delay or angiographic factors; following 
guideline recommended treatment and reflecting a population faced in daily prac-
tice.
Explanations for the higher early mortality in women remain speculative. It has been 
suggested that less aggressive treatment is applied in women.18 In the present study, 
women were treated less often with abciximab but this did not explain the mortality 
difference. Women have also been shown to suffer more bleeding complications 
during admission, events that are associated with mortality.13,21,22 However, female 
gender also predicted cardiac mortality in the current analysis, excluding bleeding 
as a cause. Besides this, longer ischemic times negatively influence prognosis of 
STEMI.23,24 In our population, ischemic times were longer in women because of 
older age and greater prevalence of diabetes mellitus and renal insufficiency. These 
factors have been previously linked to painless myocardial infarction, most likely 
explaining the longer delays in the current analysis.25 The observation that gender 
by itself did not predict but age and comorbidity did predict longer delay suggests 
that focus should be on recognition of STEMI in these subgroups in men and wom-
en. Because the association of ischemic time and mortality was small in this study, 
the delay failed to explain the mortality gap. Because the difference in outcome lay 
in the early days of hospital admission, the previous observation that more men die 
before reaching the hospital might explain the difference between men and women 
because of a sicker female population being admitted to the hospital.26 Therefore, 
prehospital mortality rates should be incorporated in future investigations.
The predictors of mortality established in the present study reflect those found in 
previous investigations.27-30 Strikingly, female gender was found to modify the ef-
fect of cardiogenic shock on mortality, causing higher mortality due to cardiogen-
ic shock in women compared to men. It has been noted that women developing 
cardiogenic shock have higher rates of ventricular septal rupture and severe mi-
tral regurgitation, possibly explaining the difference in outcome between men and 
women.31 Supporting this, Engström et al found that severe mitral regurgitation was 
more common in women with STEMIs and identified it as a predictor of mortality.32 
However, the clinical implications of these findings are unclear, and additional 
research is required to uncover the optimal treatment for these patients. The pres-
ent analysis had several limitations. The study was observational and thus shares 
the limitations of all observational analyses. Additionally, because left ventricular 
ejection fractions were not available for all patients, peak creatine phosphokinase 
during admission was used as a surrogate for infarction size, which may have un-
derestimated actual infarction size. There may have been other measured or unmea-
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sured confounding variables that, had they been adjusted for, might have modified 
the relation between gender and outcome. Finally, because our cohort only includ-
ed patients treated with primary PCI, it cannot be ruled out that a disproportionate 
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Background: Factors related to the occurrence of out-of-hospital cardiac arrest 
(OHCA) in ST-elevation myocardial infarction (STEMI) are still poorly understood. 
The current study sought to compare STEMI patients presenting with and without 
OHCA to identify angiographic factors related to OHCA.
Methods: This multicenter registry consisted of consecutive STEMI patients, includ-
ing OHCA patients with return-of-spontaneous circulation. Patients were treated 
with primary percutaneous coronary intervention (PCI) and therapeutic hypother-
mia when indicated. Outcome consisted of in-hospital neurological recovery, 
scored using the Cerebral Performance Categories (CPC) scale, and 1-year survival. 
Logistic regression was used to identify factors associated with OHCA and survival 
was displayed with Kaplan Meier curves and compared using log rank tests.
Results: In total, 224 patients presented with OHCA and 3259 without OHCA. 
Average age was 63.3 years and 75% of patients were male. OHCA occurred prior 
to ambulance arrival in 68% of patients and 48% required intubation. Culprit lesion 
was associated with OHCA: risk was highest for proximal left coronary lesions and 
lowest for right coronary lesions. Also, culprit lesion determined the risk of cardio-
genic shock and sub-optimal reperfusion after PCI, which were strongly related to 
survival after OHCA. Neurological recovery was acceptable (CPC≤2) in 77.1% of 
OHCA patients and did not differ between culprit lesions. 
Conclusions: In the present STEMI population, coronary culprit lesion was associ-
ated with the occurrence of OHCA. Moreover, culprit lesion influenced the risk of 
cardiogenic shock and success of reperfusion, both of which were related to prog-
nosis of OHCA patients.
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Introduction
Out-of-hospital cardiac arrest (OHCA) is a common and life threatening condi-
tion frequently caused by coronary artery disease.1 Historically, prognosis of OHCA 
has been poor.2 Revascularization techniques in OHCA have been under investiga-
tion for some time in an attempt to improve the prognosis of these patients. While 
thrombolysis during resuscitation failed to proof beneficial, coronary angiography 
with angioplasty showed promising results.3,4 Early or primary percutaneous cor-
onary intervention (PPCI) has been shown to improve survival after OHCA due to 
ST-elevation myocardial infarction (STEMI) and at present, PPCI is readily available 
in the Netherlands for STEMI patients suffering an OHCA due to extensive nation-
wide networks of care designed to minimize ischemic times.5-7 
Although PPCI for OHCA due to STEMI is commonly performed, factors associated 
with the occurrence of OHCA in setting of STEMI are still poorly understood. The 
current study sought to compare STEMI patients presenting with and without OHCA 
to identify angiographic factors related to the occurrence and prognosis of OHCA 




The current Dutch registry prospectively included STEMI patients treated in 3 
high-volume tertiary centers in the Netherlands. The design of this registry has been 
described previously.8 In short, all consecutive STEMI patients undergoing PPCI 
between January 2006 and December 2009 were included. STEMI was defined as 
symptoms of angina lasting longer than 30 minutes along with typical electrocar-
diographical changes (ST-segment elevation ≥0.2 mV in ≥2 contiguous leads in V1 
through V3 or ≥0.1 mV in other leads or presumed new left bundle branch block) or 
presumed new regional wall motion abnormalities on echocardiogram when these 
criteria were unavailable or inconclusive. In case of OHCA, only patients with re-
turn-of-spontaneous-circulation (ROSC) on arrival at the catheterization laboratory 
were included. Patients permanently living outside the Netherlands were excluded 
to make follow-up through municipality records possible.
Emergency medical services (EMS) were staffed with nurses trained in advanced 
cardiac life support. Patients were triaged in the field by 12-lead electrocardiogram 
faxed to the operator on call. In-ambulance medication included aspirin, intrave-
nous heparin bolus and loading dose of clopidogrel. Glycoprotein IIb/IIIa inhibitors 
were administered up-front in the Leiden University Medical Center and peripro-
cedurally in the other hospitals. Upon arrival at the hospital, unresponsive patients 
were admitted to the emergency department and following stabilization transferred 
directly to the catheterization laboratory. Stable patients were transferred directly 
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to the catheterization laboratory. Procedures were performed according to current 
clinical guidelines. Patients remaining unresponsive (Glasgow Coma Scale <8) after 
resuscitation were transferred to the intensive care unit, where TH (32-34°C) was 
induced for 24 hours using ice packs, cooling blankets and intravenous NaCl 0.9% 
of 4°C, if necessary. After this period, TH was ceased and as body temperature 
returned to normal values sedation was weaned. Patients remaining unresponsive 
(Glasgow Coma Scale motor response <5) 24 hours after reaching normothermia 
and weaning of sedation underwent sensory evoked potentials testing. Severe and 
permanent neurologic dysfunction was diagnosed if the N20 response was bilat-
erally absent. Patients with a positive N20 response remaining comatose after 72 
hours underwent neurological clinical examination and electro-encephalography 
after which further treatment strategy was decided. 
Patients treated in the Leiden University Medical Center were treated according to 
the institutional MISSION! protocol, a standardized pre-hospital, in-hospital and 
outpatient clinical framework for STEMI care.9 These patients were intensively mon-
itored at the outpatient clinic for 1 year, after which they were referred to the gen-
eral practitioner or regional cardiology clinic. In the other centers, local residents 
were managed at the outpatient clinics and patients referred from regional hospitals 
were referred back for further management by regional cardiologists.
Data collection
All hospitals prospectively registered patients. Close collaboration with regional 
EMS supplied pre-hospital times and resuscitation characteristics. Vital status was 
obtained using municipality records. In-hospital outcome was a composite of all-
cause mortality and neurological outcome. Neurological outcome was scored ret-
rospectively using the Cerebral Performance Categories (CPC) scale consisting of 5 
categories: 1. Conscious, good cerebral performance, able to work; 2. Conscious, 
moderate cerebral disability, able to work in a sheltered environment; 3. Conscious, 
severe cerebral disability, dependent on others; 4. Coma or vegetative state; 5. Brain 
death.10 Long term outcome consisted of 1-year all-cause mortality. Deaths were 
considered cardiac unless a clear non-cardiac cause could be identified. 
Statistical analyses
Continuous variables are presented as mean ± standard deviation or median (25th 
to 75th percentile) and were compared using Student’s t-test in case of mean and 
Mann-Whitney U test in case of median. Categorical variables are expressed as 
counts and percentages and were compared by means of Pearson’s χ² test. All statis-
tical tests were 2-tailed and a p-value <0.05 was considered statistically significant. 
Univariable logistic regression was performed to investigate the association of an-
giographic factors with OHCA and other prognostic factors. Cumulative incidences 
of endpoints were displayed visually using Kaplan-Meier plots and compared with 
log rank tests. Analyses were performed using IBM SPSS Statistics version 20.
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Results
Of the 3483 consecutive STEMI patients treated during the inclusion period, 224 
(6.4%) presented with OHCA and 3259 (93.6%) without cardiac arrest. Baseline 
characteristics (Table 1) showed that symptom-to-balloon time was shorter in pa-
tients presenting with OHCA. In contrast, door-to-balloon time was longer in OHCA 
patients compared to non-arrest patients. During angiography, patients presenting 
with OHCA more frequently showed left coronary artery culprit lesions compared 
to patients without arrest. Also, OHCA patients were more often in cardiogenic 
shock and were treated more commonly with intra-aortic balloon pumps. Throm-
bolysis-in-myocardial infarction flow pre- and post-procedure was comparable be-
tween the groups.






Age, years, mean ± standard deviation 62.5 ± 12.1 63.3 ± 12.5 0.365
Male sex 78.6 (176/224) 74.8 (2439/3259) 0.212
Diabetes mellitus 9.1 (20/219) 11.3 (366/3230) 0.318
Previous myocardial infarction 10.9 (24/221) 10.8 (351/3241) 0.989
Previous percutaneous coronary intervention 6.8 (15/221) 8.5 (275/3241) 0.378
Previous coronary artery bypass grafting 3.2 (7/221) 2.4 (78/3246) 0.477
Symptoms-to-balloon time, median minutes 150 (116-192) 181 (131-285) <0.001
Door-to-balloon time, median minutes 53 (36-79) 46 (33-66) 0.014
Culprit artery <0.001
    Left main 3.1 (7/224) 1.2 (40/3257) 0.017
    Left anterior descending 55.8 (125/224) 39.4 (1282/3257) <0.001
    Left circumflex 21.9 (49/224) 15.5 (504/3257) 0.011
    Right coronary artery 18.3 (41/224) 42.8 (1393/3257) <0.001
    Bypass graft 0.9 (2/224) 1.2 (38/3257) 0.710
Multivessel disease 50.9 (114/224) 53.1 (1729/3256) 0.522
Stenting 96.9 (217/224) 95.6 (3114/3257) 0.367
Cardiogenic shock during PCI 30.8 (69/224) 4.8 (158/3259) <0.001
    Intra-aortic balloon pump implantation 25.4 (57/224) 2.8 (92/3259) <0.001
TIMI flow ≤1 pre-procedure 79.9 (179/224) 79.3 (2582/3254) 0.841
TIMI flow 3 post-procedure 91.1 (204/224) 91.5 (2976/3254) 0.842
Values are percentage (n) or median (25th to 75th percentile). TIMI = Thrombolysis in myocardial 
infarction. *defined as systolic blood pressure lower than 90 mmHg with signs of tissue hypoperfusion 
requiring treatment in form of inotropic agents or assistant devices. 
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Table 2 shows the characteristics of the OHCA patients according to moment of 
arrest. Approximately two thirds of patients suffered a cardiac arrest before arrival 
of EMS. Most OHCAs were witnessed and delay in basic life support occurred 
in a quarter of patients with OHCA before EMS arrival. In most cases, the first 
observed rhythm was ventricular fibrillation or tachycardia. Intubation was per-
formed in 108 patients. Of these patients, 95.4% (103/108) survived PCI and 88.0% 
(95/108) underwent TH. The rest had no indication for TH due to return of con-
sciousness.  
Table 2. Characteristics and treatment of out-of-hospital cardiac arrest
OHCA witnessed by 
EMS (N=71)
OHCA not witnessed by 
EMS (N=153)
Delay in basic life support >5 minutes* 0.0 (0/71) 24.2 (37/153)
Bystander witnessed arrest 100 (71/71) 90.8 (139/153)
First observed rhythm
    Ventricular fibrillation / tachycardia 95.8 (68/71) 93.4 (142/152)
    Bradycardia 2.8 (2/71) 2.0 (3/152)
    Asystole / Pulseless electrical activity 1.4 (1/71) 4.6 (7/152)
Treatment performed
     Automatic external defibrillator 0.0 (0/71) 17.6 (27/153)
     Defibrillation 95.7 (3/70) 94.1 (143/152)
          Average number of shocks 1 (1-2) 2 (1-4)
     Chest compressions 51.4 (36/70) 88.2 (135/153)
     Intubation 10.0 (7/70) 66.0 (101/153)
          Therapeutic hypothermia† 100 (7/7) 87.1 (88/101)
Values are percentage (n) or median (25th to 75th percentile).  
*Based on history from bystanders; † The denominator is intubated patients.
Factors associated with OHCA
Angiographic culprit lesion was associated with risk of OHCA (Figure 1, Table 3). 
Lesions located in the left coronary artery (with the exception of diagonal branch 
lesions) were found to result in the highest risk of OHCA. In addition, proximally 
located left coronary artery lesions displayed a higher risk of OHCA compared to 
non-proximally located left coronary artery lesions: OR 1.43 (95% CI 1.05-1.95, 
p=0.025). Separately, proximal vs. non-proximal left anterior descending or left 
circumflex culprit lesions were not significantly associated with higher risk. Left 
main and proximal left anterior descending artery lesions were also associated with 
development of cardiogenic shock (Table 3, Figure 1). Moreover, culprit lesions in 
the left main and bypass grafts were associated with sub-optimal TIMI flow after PCI 
(Table 3).





















































































































































































































































































































































































































































































































































































































































































































































Figure 1. Culprit location and risk of out-of-hospital cardiac arrest and cardiogenic shock. Values are 
odds ratios. CarSh = cardiogenic shock; CX = circumflex artery; LAD = left anterior descending artery; 
OHCA = out-of-hospital cardiac arrest. 
Neurological recovery and outcome during 1-year follow-up
Discharge CPC was known in 218 OHCA patients (97.3%) (Figure 2). The majority 
of patients had acceptable CPC scores (CPC≤2 in 77.1%, n=168). Thirty-five pa-
tients were in CPC 5/dead, of which 21 patients were brain dead and 14 patients 
suffered cardiac death. Of the 107 patients with a proximal left coronary culprit 
lesion, 77 recovered (72.0%). This rate was slightly higher for the patients with a 
non-proximal left culprit lesion (84.1%, 58/69 patients recovered) and the patients 
with a right culprit lesion (80%, 32/40 patients recovered). Of the 2 patients with 
a bypass graft culprit lesion, one died due to neurological causes. The p-value for 


















Proximal left culprit lesions 






Non-proximal left culprit lesions 
Figure 2. In-hospital Cerebral Perfor-
mance Categories scale according 
to culprit lesion. CPC = cerebral 
performance categories scale. Other 
abbreviations as in figure 1.
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One-year survival status was known in 3479 patients. In-hospital mortality was 
higher in OHCA patients compared to patients without OHCA (16.5% vs. 3.1%, 
p<0.001). Also, 1-year mortality (19.2% vs. 6.6%, p<0.001) was higher, which was 
due to in-hospital mortality as post-discharge survival was similar between patients 
with and without OHCA (3.2% vs. 3.6%, p=0.774). Figure 3A and 3B show the as-
sociation between culprit location and mortality during follow-up in patients with 
and without OHCA. Figure 3C and 3D shows the association of cardiogenic shock 
and success of reperfusion with survival. OHCA patients with optimal TIMI flow 
after PCI had a better prognosis than OHCA patients with a sub-optimal TIMI flow 
after procedure, regardless of cardiogenic shock during PCI. In contrast, presence 
of cardiogenic shock was more important than success of reperfusion in patients 
without OHCA.









































































Figure 3. Survival in patients with and without OHCA according to A) and C) culprit lesion, B) and D) 
cardiogenic shock and TIMI flow after PCI.
Discussion
The present multicenter registry identified an association between angiographic 
culprit location and the occurrence of OHCA in STEMI patients: left proximal cor-
onary lesions were associated with the highest risk for OHCA and right coronary 
lesions with the lowest. Moreover, culprit location was associated with cardiogenic 




Attempts to improve the historically poor prognosis of OHCA led to investigation of 
revascularization techniques for OHCA patients.2 While thrombolysis during resus-
citation failed to prove beneficial, coronary angiography with angioplasty showed 
promise from early on.3,4 At present, extensive networks of care make PPCI read-
ily available for patients suffering an OHCA due to STEMI. In the current STEMI 
population, symptom-to-balloon times were strongly reduced in OHCA patients, a 
finding also observed by others, possibly reflecting the severity of symptoms leading 
to early initiation of professional care by either patient or bystanders.5,6 In con-
trast, the prolonged door-to-balloon times in OHCA patients were likely related to 
time needed for in-hospital patient stabilization. Patients presenting with OHCA 
were more frequently in cardiogenic shock on arrival, due to impaired coronary 
perfusion during cardiac arrest and culprit lesion location. Culprit location varied 
between OHCA and non-arrest patients and was found to be associated with oc-
currence of OHCA. Left coronary lesions resulted in the highest and right coronary 
artery lesions in the lowest risk for OHCA. Moreover, proximally located culprit 
lesions within the left coronary artery were associated with higher risk of OHCA 
compared to non-proximally located lesions. This is likely explained by the larger 
area of myocardium-at-risk in proximal left lesions, which was supported by the 
finding that left main and proximal left anterior descending artery culprits were also 
associated with cardiogenic shock.11 The lower percentage of right coronary artery 
culprit lesions is possibly explained by the commonly occurring vagal reaction in 
inferior MI, which may have a protective effect against VF.12 However, it cannot be 
completely ruled out that inferior MI may have caused more severe ischemia, pre-
venting ROSC and thus inclusion in this registry.
In-hospital and 1-year outcome rates stratified according to culprit lesion were 
similar in OHCA patients. Nevertheless, location of culprit lesions contributed in- 
directly to mortality due to the association with cardiogenic shock and sub-optimal 
reperfusion. Left main lesions were the highest risk lesions for STEMI patients, due 
to the strong association with OHCA, cardiogenic shock and sub-optimal reperfu-
sion, which is supported by other reports.13 Also, bypass graft culprit lesions were 
associated with reperfusion failure. The no-reflow phenomenon in setting of STEMI 
has multiple mechanisms, among which distal embolization and ischemic injury.14 
The occurrence of distal embolization is notorious in PCI of saphenous vein grafts 
and remains a challenge for operators.15 The importance of optimal reperfusion in 
OHCA patients was stressed by the lower survival rates for sub-optimally reper-
fused OHCA patients without cardiogenic shock during PCI compared to optimally 
reperfused OHCA patients with cardiogenic shock during PCI.  No-reflow possibly 
reflects the duration of ischemia prior to PCI in OHCA patients and the effect on 
prognosis may therefore also be explained by a prolonged resuscitation. In contrast, 
presence of cardiogenic shock was a stronger factor than failed reperfusion in pa-
tients without OHCA. This was likely explained by a smaller area of myocardium at 
risk in these patients due to the different distribution of culprit lesions.
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Using a combined treatment strategy of primary PCI and TH, 77% of the OHCA 
population was discharged with acceptable neurological outcome and 1-year sur-
vival was 81%. The combination of PPCI and TH was previously investigated in the 
PROCAT registry, where the investigators reported an overall in-hospital survival 
rate of 40%, rising to 54% in STEMI patients after successful PCI which predicted 
improved prognosis.7 Furthermore, the positive influence of both PCI and TH on 
long term survival was established in a cohort of OHCA patients, which included 
a large percentage of STEMI patients.16 Also, a recent smaller study focusing spe-
cifically on use of TH in STEMI complicated by OHCA reported a neurological 
recovery rate comparable to the rate observed in the population treated with TH in 
the current study, supporting the accuracy of our findings.17 
Limitations 
Our investigation represents one of the largest studies covering outcomes in OHCA 
patients due to STEMI. However, our study was observational and thus shares the 
limitations of all observational analyses. Because the registry only included STEMI 
patients with ROSC, no data was available on OHCA patients without ROSC or pa-
tients not referred for PPCI. Data covering these patients may have provided more 
insight into the full community experience. 
Conclusions
Location of angiographic culprit lesion was associated with the occurrence of 
OHCA in the current STEMI population. Moreover, angiographic culprit location 
predicted cardiogenic shock and success of reperfusion, both of which were asso-
ciated with the prognosis of OHCA patients.
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The simultaneous occurrence of cancer and coronary heart disease is increasing 
in the Western world. Nevertheless, the influence of cancer on ST-elevation myo- 
cardial infarction (STEMI) treated with primary percutaneous coronary interven-
tion (PCI) has not been investigated extensively. This multicenter registry included 
STEMI patients treated with primary PCI from 2006 to 2009. Patients were stratified 
according to history of cancer and primary focus lay on all-cause and cardiac mor- 
tality during 1-year follow-up. Adjusted effect sizes were calculated using Cox pro-
portional hazard models. In total, 208 patients had a history of cancer (diagnosed 
≤6 months ago in 20.7%, 6 months-3 years ago in 21.7% and >3 years ago in 
57.6%) and 3215 patients had no history of cancer. Chemotherapy had been admin-
istered previously to 23% of patients with cancer. Patients with cancer were older, 
more frequently women, and more commonly known with previous MI or anemia. 
Reperfusion rates were similar after PCI. Patients with cancer showed greater all-
cause (17.4% vs. 6.5% in other patients) and cardiac mortality at 1-year (10.7% 
vs. 5.4% in other patients), due to high early cardiac death (23.8%) in recently 
diagnosed cancer patients. After adjustment, a recent cancer diagnosis predicted 
cardiac mortality at 7-days (HR 3.34, 95% CI 1.57-7.08). The adverse prognosis 
was partly explained by anemia and occurrence of cardiogenic shock, whereas 
outcome was independent of cancer treatment. In conclusion, patients with cancer 
showed greater mortality after STEMI. A cancer diagnosis in the 6 months prior to 
primary PCI was strongly associated with early cardiac mortality.
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Introduction
Coronary heart disease (CHD) and cancer are the most common causes of death 
in the Western world, together responsible for 3.5 million deaths in Europe every 
year.1 Simultaneous occurrence of CHD and cancer is increasingly frequent be-
cause of high incidences and improving life expectancies for these patients. More-
over, frequently applied treatment methods for cancer have known cardiovascular 
side effects, which may predispose these patients to cardiac disease. Chemothera-
peutic regimens like anthracyclines and antimetabolites have cardiotoxic properties 
potentially leading to irreversible cardiomyopathy or cardiac ischemia.2 External 
radiation to the thorax is associated with cardiac sequelae including accelerated 
coronary artery disease, valvular disease, constrictive pericarditis and/or restrictive 
cardiomyopathy.3 In addition, cancer is commonly associated with a hypercoagu-
lable state,4 increasing the risk for venous and possibly arterial thrombosis.5,6 Re-
gardless of the numerous factors influencing development and prognosis of CHD 
in patients with cancer, there is little to no data covering the influence of cancer on 
outcome after myocardial infarction. 
The aim of the present multicenter study was to investigate the influence of cancer 
and cancer treatment on outcome after ST-elevation myocardial infarction (STEMI) 
treated with primary percutaneous coronary intervention (PCI). 
 
Methods
The current Dutch registry prospectively included STEMI patients treated in 3 ter-
tiary centers in the Netherlands. The design of this registry has been described pre-
viously.7 In short, all consecutive patients undergoing primary PCI for STEMI be-
tween January 2006 and December 2009 were included. Patients without return of 
spontaneous circulation after out-of-hospital cardiac arrest were excluded, as well 
as patients permanently living outside the Netherlands to allow follow-up through 
municipality records. Approval from local ethics committees was not required.
Protocols included field triage faxed to the operator on call and in-ambulance treat-
ment with aspirin, heparin and loading dose of clopidogrel. Glycoprotein IIb/IIIa 
inhibitors were administered up-front in one center and during procedure in the 
other centers. Patients treated in the Leiden University Medical Center were treat-
ed according to the institutional MISSION! protocol, a standardized prehospital, 
in-hospital and outpatient clinical framework for STEMI care.8 These patients were 
intensively monitored at the outpatient clinic for 1 year, after which they were re-
ferred to the general practitioner or regional cardiology clinic.  In the other cen-
ters, local residents were managed at the outpatient clinics and patients referred 




STEMI was defined as symptoms of angina lasting >30 minutes along with typical 
electrocardiographical changes (ST-segment elevation ≥0.2 mV in ≥2 contiguous 
leads in V1 through V3 or ≥0.1 mV in other leads or presumed new left bundle 
branch block) and a typical rise and fall of cardiac biomarkers. Patients with a 
history of non-melanoma skin cancer were included in the group without cancer. 
The cancer population was further subdivided according to time elapsed between 
diagnosis of cancer and primary PCI (diagnosed >3 years ago, 6 months to 3 years 
ago or ≤6 months ago). First moment of diagnosis was used, unless the patient had 
recently been diagnosed with progression of disease. For example, cancer diag-
nosed 5 years ago but identified to have metastasized in the 6 months prior to PCI 
was considered to be diagnosed in the last 6 months. However, metastasized dis-
ease identified 5 years ago was considered to be diagnosed more than 3 years ago.
Socioeconomic status was based on the average socioeconomic class of the pa-
tient’s residential address using income, access to employment and educational 
level. These scores are measured yearly by the ‘Netherlands Institute for Social 
Research’, an independent government agency.9 Vital status was obtained using 
municipality records. Hospital records and general practitioners provided causes of 
death. Deaths were considered cardiac unless a clear non-cardiac cause could be 
identified. 
Stratification was done according to history of cancer and subsequently according 
to time of diagnosis. Continuous variables are presented as mean with standard de-
viation or median with interquartile range and were compared using Student’s t-test 
or non-parametrical tests where appropriate. Categorical variables are expressed 
as counts and percentages and were compared by means of Pearson's χ2 test. All 
statistical tests were 2-tailed and a p-value <0.05 was considered statistically signif-
icant. Time to endpoint was analyzed using Kaplan-Meier plots and the log-rank test 
was applied to compare cumulative incidences of the endpoint between groups. To 
evaluate cancer as a predictor of mortality, multivariable Cox proportional hazard 
models were used. Univariable predictors of mortality were incorporated in the 
multivariable models using a forward stepwise approach with a cut-off p-value of 
<0.10. Second, a confounder model was created in order to investigate the theoreti-
cal causal pathway between cancer and mortality. The model included age, gender, 
socioeconomic status and smoking status. Confounders were chosen according to 
their relation with both the occurrence of cancer and mortality. Subsequently, ex-
planatory factors were added to the confounder model. Only those factors that 
could possibly be a consequence of the presence of cancer were added (previous 
MI, out-of-hospital cardiac arrest, anemia on admission, cardiogenic shock during 
PCI, TIMI flow after procedure, stent placement, treatment with abciximab, enzy-
matic infarct size, cancer treatment). Analyses were performed using SPSS version 
21 (IBM, Armonk, New York).
Cancer and ST-elevation MI
73
Results
During the inclusion period, 208 patients (6.0%) treated for STEMI had a history of 
cancer (hereafter referred to as patients with cancer) and 3215 patients (92.3%) had 
no known history of cancer. Cancer history was uncertain in 60 patients (1.7%). 
Baseline characteristics are shown in Table 1. 
Patients with cancer were on average older, more often women and more frequent-
ly suffered from hypertension compared to patients without a history of cancer. 
Patients with cancer were less frequently smokers but more commonly had a previous 
myocardial infarction. Furthermore, previous peripheral vascular disease, cerebro- 
vascular disease, renal insufficiency and anemia were more common in patients 
with a history of cancer. Also, the time interval between diagnosis and balloon 
inflation was significantly longer in patients with a history of cancer compared to 
patients without a history of cancer. 
Table 1. Baseline characteristics
Variable
History of cancer p-Value
Yes (N=208) No (N=3215)
Age (years ± standard deviation) 69.6 ± 11.0 62.8 ± 12.4 <0.001
Male gender 141 (67.8) 2427 (75.5) 0.013
Diabetes mellitus, non-insulin dependent 17 (8.3) 275 (8.6) 0.871
Diabetes mellitus, insulin-dependent 6 (2.9) 86 (2.7) 0.843
Hypertension* 88 (42.7) 1135 (35.4) 0.034
Hypercholesterolemia† 46 (22.4) 738 (23.1) 0.839
Current smoker 61 (31.0) 1487 (46.8 ) <0.001
Previous myocardial infarction 35 (17.0) 335 (10.4) 0.003
Previous percutaneous coronary intervention 21 (10.2) 267 (8.3) 0.345
Previous coronary artery bypass grafting 5 (2.4) 79 (2.5) 0.970
Prior peripheral vascular disease 18 (8.8) 146 (4.5) 0.006
Prior cerebrovascular disease 24 (11.7) 191 (5.9) 0.001
Prior renal insufficiency‡ 17 (8.3) 109 (3.4) <0.001
Anemia on admission § 53 (11.8) 152 (5.2) <0.001
Out of hospital cardiac arrest 18 (8.7) 203 (6.3) 0.183
Cardiogenic shock during PCI ǁ 18 (8.7) 196 (6.1) 0.140
Creatine phosphokinase peak (median U/l, IQR) 1360 (686-2790) 1365 (616/2611) 0.894
Symptom-to-balloon time (median minutes, IQR) 186 (136-259) 180 (130-284) 0.708
Diagnosis-to-balloon time (median minutes, IQR) 86 (68-107) 79 (65-99) 0.024
Door-to-balloon time (median minutes, IQR) 52 (37-77) 46 (33-67) 0.077
Values are expressed as counts (percentages). * Blood pressure ≥140/90 mmHg or previous pharmaco-
logical treatment; † Total cholesterol ≥190 mg/dl or previous pharmacological treatment; ‡ eGFR<60 
ml/min/1.73m2; § Admission hemoglobin <12 g/dl (<7.4 mmol/l) for women and <13 g/dl (<8.1 
mmol/l) for men. ǁ defined as systolic blood pressure lower than 90 mmHg with signs of tissue hy-
poperfusion requiring treatment in form of inotropic agents or assistant devices.
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History of cancer p-Value
Yes (N=208) No (N=3215)
Coronary culprit vessel 0.826
     Left anterior descending 91 (43.8) 1291 (40.2)
     Left circumflex 32 (15.4) 509 (15.8)
     Right 79 (38.0) 1337 (41.6)
     Left main 3 (1.4) 40 (1.2)
     Bypass graft 3 (1.4) 36 (1.1)
Number of vessels narrowed >50% 0.293
     1 87 (41.8) 1522 (47.4)
     2 71 (34.1) 1005 (31.3)
     3 50 (24.0) 685 (21.3)
Stenting 192 (92.3) 3082 (95.9) 0.014
     Drug-eluting stents 124 (60.8) 2263 (70.8) 0.002
     Bare-metal stents 67 (32.8) 812 (25.4) 0.019
Intra-aortic balloon pump use 14 (6.7) 124 (3.9) 0.041
TIMI flow pre-procedure 0.058
     Grade 0 132 (63.5) 2198 (68.5)
     Grade 1 26 (12.5) 356 (11.1)
     Grade 2 35 (16.8) 358 (11.1)
     Grade 3 15 (7.2) 299 (9.3)
TIMI flow post-procedure ≤2 21 (10.1) 270 (8.4) 0.384
Abciximab treatment 137 (67.2) 2397 (75.1) 0.012
Discharge medication
     Aspirine / Coumadin derivative 187 (98.4) 3097 (99.3) 0.202
     Clopidogrel 186 (97.9) 3058 (98.0) 0.885
     Beta-blocker 160 (84.2) 2812 (90.5) 0.005
     Ace-inhibitor / Angiotensin II antagonist 139 (73.2) 2220 (71.5) 0.622
     Statin 171 (90.0) 2897 (93.2) 0.095
Values are expressed as counts (percentages). TIMI = Thrombolysis in myocardial infarction. Other 
abbreviations as in table 1.
During PCI, cancer patients were less likely to receive coronary stents (Table 2). In 
case of stenting, the percentage of patients receiving bare-metal stents was high-
er in patients with a history of cancer although the majority of patients received 
drug-eluting stents. Additionally, patients with cancer were more frequently treated 
with intra-aortic balloon pumps. Finally, patients with cancer were less likely to 
receive abciximab treatment compared to patients without a history of cancer and 
were less frequently discharged on beta-blocker therapy.
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The characteristics of cancer history are shown in table 3. Exact moment of diag-
nosis was unknown in 5 patients. One year survival status was available in 99.8% 
of patients. Patients with cancer showed significantly greater all-cause mortali-
ty compared to patients without a history of cancer (in-hospital 9.1% vs. 3.4%, 
p<0.001; 7-day 9.7% vs. 3.1%, p<0.001; 1-year 17.4% vs. 6.5%, p<0.001, Figure 
1A). Moreover, cardiac mortality was greater in patients with cancer compared to 
patients without a history of cancer (in-hospital 8.7% vs. 3.4%, p<0.001; 7-day 
9.2% vs. 3.1%, p<0.001; 1-year 10.7% vs. 5.4%, p=0.002, Figure 1B). Stratification 
on moment of diagnosis showed that patients with cancer diagnosed  ≤6 months 
ago suffered the highest rates of all-cause (in-hospital 19.0%, 7-day 23.8%, 1-year 
50.0%, Figure 1C) and cardiac mortality (in-hospital 19.0%, 7-day 23.8%, 1-year 
28.9%, Figure 1D).
Figure 1: (A) Freedom from 1-year all-cause mortality according to history of cancer. (B): Freedom 
from 1-year cardiac mortality according to history of cancer. (C): Freedom from 1-year all-cause mor-
tality according to moment of cancer diagnosis. (D): Freedom from 1-year cardiac mortality according 
to moment of cancer diagnosis.  
*plogrank<0.001 for comparison between cancer diagnosis ≤6 months ago and other groups for both 
all-cause and cardiac mortality. Other comparisons were non-significant.
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Table 4 lists the association of cancer with cardiac mortality during follow-up. After 
multivariable adjustment, any history of cancer was found to predict cardiac mor-
tality at 7-days. Stratification on moment of diagnosis showed that this was driven 
by patients with a cancer diagnosis in the last 6 months, which strongly predicted 
early cardiac mortality. The explanatory analyses (table 5) showed that anemia at 
admission explained a major part of the effect size of recent cancer on cardiac mor-
tality. The rate of admission anemia was already high in the total cancer population 
(11.8% compared to 5.2% in the population without cancer), but in patients with 
recent cancer diagnosis the rate of anemia was even higher at 65.9%. 
Table 4. Cancer and cardiac mortality after STEMI
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           Cum. incidence = cumulative incidence of events based on Kaplan-Meier curve.  
           *Adjusted for age, gender, history of diabetes mellitus, history of peripheral vascular disease, previous  
           myocardial infarction, anemia, out-of-hospital cardiac arrest, cardiogenic shock during PCI, stenting,  
           thrombolysis-in-myocardial infarction flow <3 after procedure and enzymatic infarct size.  
           †Adjusted for age, history of diabetes mellitus, history of peripheral vascular disease, culprit lesion,  
           out-of-hospital cardiac arrest, cardiogenic shock during PCI, stenting, thrombolysis-in-myocardial  
           infarction flow <3 after procedure, enzymatic infarct size.
Table 5. Factors associated with the effect of cancer on 7-day cardiac mortality




Confounder model  





Confounder model + anemia - 3.40 
(1.52-7.57)
Confounder model + anemia, cardiogenic shock - 2.71  
(1.21-6.09)
Confounder model + anemia, cardiogenic shock, previous 
chemotherapy
- 3.44  
(1.43-8.26)
Abbreviations as in table 4.
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The other major contributing factor was cardiogenic shock during PCI, which oc-
curred in 16.7% of these patients. 
Individual corrections for the following variables were performed (the values of the 
variables are mentioned in parentheses, comparing patients with a recent cancer 
diagnosis to patients without a history of cancer): previous MI (19% vs. 10.4%), 
out-of-hospital cardiac arrest (9.5% vs. 6.3%), TIMI flow (TIMI 3 achieved in 92.7% 
vs. 91.6%), stenting (90.5% vs. 95.9%), treatment with abciximab (48.8% vs. 
75.1%) or enzymatic infarct size (median 1342 U/l (IQR 689 to 2854) vs. 1360 
U/l (IQR 686 to 2790)) did not provide any additional reduction in the effect size. 
Finally, previous treatment with chemotherapy was added to the confounder mod-
els, which had been administered in one third of patients with a recent cancer 
diagnosis. However, no association between chemotherapy and cardiac mortality 
was observed. Previous thoracic radiation was not added to the explanatory models 




The present multicenter study evaluated the influence of cancer on the prognosis of 
STEMI patients. Most notably, a cancer diagnosis in the 6 months prior to primary 
PCI was a strong predictor of early cardiac mortality. The adverse effect of cancer 
on prognosis after STEMI was partly explained by a high prevalence of anemia and 
the occurrence of cardiogenic shock, whereas outcome was independent of cancer 
treatment.
In the present population, patients with cancer were on average older and more 
often female. Previous myocardial infarctions were more frequent compared to pa-
tients without cancer because of higher average age, but also likely influenced by 
a greater risk of cardiac events.5 In contrast, patients with cancer were less likely to 
smoke. As expected, cancer patients showed higher all-cause mortality compared 
to patients without a history of cancer. Strikingly, also cardiac mortality was more 
common in cancer patients, due to high mortality in patients with a recent cancer 
diagnosis. A large part of the effect on mortality could be explained by anemia, 
which was very common after a recent cancer diagnosis. Factors contributing to 
cancer-related anemia include impaired erythropoiesis, hemolysis, chemotherapy, 
nutritional deficiencies and interaction between tumor and immune system.10 Ane-
mia is known to predict cardiovascular death and heart failure in STEMI patients, 
due to the increased myocardial oxygen demand associated with the increased 
stroke volume and tachycardia required to maintain adequate systemic oxygen 
delivery.11 Additionally, presence of cardiogenic shock explained part of the ad-
verse outcome. The higher rate of previous infarctions in patients with cancer most 
likely contributed to the increased rate of cardiogenic shock. Also, patients with 
cancer were less likely to receive coronary stenting during primary PCI. Whether 
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this reflects a more conservative approach or was intended to shorten the need for 
dual antiplatelet therapy is unclear. The higher rate of implanted bare-metal stents 
supports the latter theory. Moreover, the higher rate of intra-aortic balloon pump 
implantation suggests that in general they were not withheld from aggressive treat-
ment. As final TIMI flow was similar to patients without cancer, failed reperfusion 
did not appear to contribute to the development of cardiogenic shock. Further-
more, correction for stenting, abciximab treatment, TIMI flow and infarct size did 
not change the effect of recently diagnosed cancer on cardiac death, suggesting that 
the higher mortality rate was unrelated to the procedure and infarct size.
Contrary to expectations, no association between adverse outcome and chemother-
apy or radiation was observed, and therefore a cancer-specific effect on prognosis 
after STEMI was suspected. The observed cancer types in these patients support 
this, as they have all been associated with risk of CHD.5 Cancer is commonly asso-
ciated with a hypercoagulable state due to reduced fibrinolysis and expression of 
procoagulant factors by tumors.4,12 The most characterized factors are cancer pro-
coagulant and tissue factor. Tissue factor has been related to increased myocardial 
ischemia-reperfusion injury in animal studies as well as mortality and reinfarction 
in patients with acute myocardial infarction.13-16 Moreover, cancer is a known pre-
dictor of stent thrombosis.17 
Recently diagnosed patients with cancer represent a challenge for the operator per-
forming primary PCI. Antithrombotic treatment and vascular access increase the 
risk of bleeding which may worsen the anemia present in many of these patients, 
increasing the risk of heart failure. At the same time, antithrombotic treatment is 
essential to avoid ischemic complications associated with hypercoagulability. An-
other complicating factor is the frequent need for surgical procedures, potentially 
causing cessation of antiplatelet therapy and increased risk of stent thrombosis.18 It 
might be preferable to use balloon angioplasty without stents to limit the duration of 
dual antiplatelet therapy. If stents need to be used, those with fast endothelialization 
rates, i.e. bare-metal or everolimus-eluting stents, should likely be preferred to min-
imize the risk of stent thrombosis.19 Also, coronary artery bypass grafting may have 
advantages over stenting.  However, these suggestions remain speculative without 
definitive randomized data.
To our knowledge, this multicenter registry was the first cohort to systematically 
investigate the association between cancer and prognosis after STEMI. The wide 
range of patients included across 3 regions in the Netherlands supports the gen-
eralizability of the findings. However, the observational design limits conclusions 
of causality, and findings should be considered hypothesis-generating. Additional 
research is needed to fully clarify the mechanism behind the adverse prognosis. 
Furthermore, the number of cancer patients was relatively small and the enzymatic 
correction for infarct size may have underestimated the actual infarct size. Also, it 
was not possible to measure whether all individual cancer patients received the 
same treatment as patients without cancer. However, there were no signs of lim-
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itations in the care applied to the cancer population. Finally, follow-up data on 
re-infarction and stent thrombosis after PCI may have provided more insight into the 
mechanisms of death but were not available.
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Background: Elderly patients constitute a growing part of the population presenting 
with ST-elevation myocardial infarction (STEMI).  The use of primary percutaneous 
coronary intervention (PCI) in this high-risk population remains poorly investigated.
Methods: Using the SCAAR registry, we identified consecutive elderly STEMI 
patients (aged≥80 years) undergoing primary PCI during a 10-year period. Temporal 
trends in care and 1-year prognosis were investigated and long term outcome was 
compared to a control group of PCI treated patients aged 70-79 years. Relative 
survival was calculated by dividing the observed survival rate with the expected 
survival rate of the general population. Adjusted endpoints were calculated using 
Cox regression.
Results: In total, 4876 elderly STEMI patients were included. During the study 
period, average age and presence of comorbidity increased, as well as the use of 
antithrombotic therapy. Procedural success remained constant. One-year mortality 
was exclusively reduced between the most recent versus the earliest cohort, while 
the risk of re-infarction, heart failure, stroke and bleeding remained similar. The risk 
of death was higher for elderly patients early after PCI, after which the prognosis 
was slightly better compared to the general population. Long term risk of adverse 
events increased markedly with age.
Conclusions: The prognosis of patients over 80 years of age treated with PCI for 
STEMI was relatively unchanged during the study period, despite changes in patient 
characteristics and treatment. Advanced age increased the risk of adverse events, 
but survivors of the early phase after primary PCI had a slightly improved prognosis 
compared to the general population. 
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Introduction
The average age of patients presenting with an acute coronary syndrome is rising 
as a consequence of the aging populations in the Western world.1-2 The increasing 
burden of elderly patients on health care resources stresses the need for research 
focused specifically on this part of the population. Nevertheless, elderly patients 
are underrepresented in clinical trials.3 It is known that elderly patients presenting 
with ST-elevation myocardial infarction (STEMI) are less likely to receive revascular-
ization compared to younger patients and that average delay to treatment is longer 
when referred for revascularization.4-5 Over the recent years, the use of primary 
percutaneous coronary intervention (PCI) and other evidence-based treatments in 
elderly patients have been increasing and improvements in outcome have been re-
ported.6-8 However, most studies focused exclusively on survival and little is known 
about the long term results of primary PCI in these patients.
In the present population-based cohort study we sought to investigate temporal 
changes in presentation, treatment and prognosis of octogenarians and nona- 
genarians treated with PCI for STEMI over a 10 year period.
Methods
Objectives and endpoints
Our objective was to investigate temporal trends in patient and treatment charac-
teristics, as well as changes in 1-year all-cause mortality, re-infarction, heart failure 
admissions, stroke and bleeding over a 10 year period in patients over 80 years of 
age.  Long term outcome rates of the elderly population (stratified according to ages 
80-89 and >90 years) were compared to a control group of patients aged 70-79 
years. Additionally, survival of the elderly population was compared to the general 
population and driving factors of safety endpoints, i.e. stroke and bleeding, were 
investigated. 
Patient selection
All consecutive patients over 80 years of age undergoing primary PCI for STEMI 
in Sweden between January 1st 2001 and December 31st 2010 were identified 
through the national comprehensive Swedish Coronary Angiography and Angio-
plasty Registry (SCAAR). Analyses were based on first recorded invasive coronary 
procedure during the inclusion period to avoid duplicate entries. In addition, a 
control group of patients aged 70-79 years was identified using identical criteria. 
Primary PCI was defined as any use of a guidewire for more than diagnostic pur-
poses in patients with STEMI or a new left bundle branch block and suspicion of 




SCAAR is a Swedish nationwide registry for angiography and PCI and is a part of 
the SWEDEHEART registry, which also enrolls patients hospitalized in coronary 
care units and those undergoing cardiac surgery in the country.9 Data in SCAAR 
are collected prospectively and are audited and monitored as previously descri- 
bed.10 Vital status and date of death were obtained from the Swedish National 
Population Register until December 31st 2010. Information on previous medical 
history and patient follow-up were obtained from the National Inpatient Register, 
which holds information on discharge diagnoses of all hospitalizations in Sweden 
according to ICD (International Classification of Diseases) code.11 In-hospital major 
bleeding was obtained from SCAAR and was defined as any bleeding associated 
with a hemoglobin drop of ≥5 g/dl or intracranial bleeding. 
Merging of SCAAR with the national databases was performed by the Epidemiologic 
Center of the Swedish National Board of Health and Welfare using Swedish per-
sonal identification numbers. The merging was approved by the ethics committee 
of Uppsala University and the study complied with the Declaration of Helsinki. The 
SCAAR registry is sponsored by the Swedish Health Authorities and is independent 
of commercial funding.
Statistical analyses
Elderly patients were divided into cohorts according to year of PCI; 2001-2004, 
2005-2006, 2007-2008 and 2009-2010. Patient grouping was based on compa-
rability of group size and a median follow-up of 1 year. The years 2001 to 2004 
were grouped together due to the relatively smaller numbers of patients treated in 
those years. Categorical variables are presented as frequency values and propor-
tions. Continuous variables are presented as mean ± standard deviation or median 
and interquartile range where appropriate. Cox proportional hazards analyses were 
used to adjust for confounders. The log minus log test was evaluated to test the pro-
portional hazard assumption. The multivariable models that corrected for patient 
characteristics incorporated the following variables: age, gender, diabetes mellitus, 
hypertension, hyperlipidemia, smoking, prior myocardial infarction, prior coronary 
artery bypass grafting, peripheral vascular disease, previous kidney failure, previ-
ous stroke, cancer in the last 3 years, number of vessel disease and hospital of PCI. 
Subsequently, multivariable correction was performed for treatment characteristics, 
adding the following variables to the patient characteristics model: stenting tech-
nique and type, aspirin use before/during PCI, P2Y12 receptor inhibitor use before/
during PCI, glycoprotein IIb/IIIa inhibitor use before/during PCI and thrombolysis 
prior to PCI. Effect sizes were reported as hazard ratios (HR) with 95% confidence 
interval (CI). 
Long term cumulative incidences of outcome were compared using Kaplan Meier 
curves and log rank tests. To investigate an excess of mortality in the elderly STEMI 
population after primary PCI, interval specific relative survival rates were calculat-
ed using intervals 0-0.05, 0.05-0.2, 0.2-0.5, 0.5-1, 1-2, 2-3 and 3-4 years. Relative 
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survival was measured as the absolute survival rate of the elderly STEMI population 
divided by the expected survival rate in the year of intervention from the general 
population with identical gender and age. Age, gender and intervention year mor-
tality estimates of the general population were obtained from life tables of Statistics 
Sweden. Finally, forward stepwise Cox proportional hazard models were performed 
to identify factors associated with stroke and bleeding at 1-year, with a p-value for 
inclusion of <0.05. Calculations were performed using SPSS version 20 (IBM cor-
poration, Armonk, NY, USA). STATA 12 (Statacorp LP, College Station, TX, USA) was 
used for the relative survival analysis.















Age, mean years ± SD 83.1 ± 2.7 83.7 ± 3.1 84.0 ± 3.2 84.0 ± 3.3 <0.001
Age ≥90 years 23 (2.8) 61 (5.0) 92 (6.4) 98 (6.9) <0.001
Male gender 449 (55.2) 641 (52.5) 720 (50.5) 716 (50.7) 0.130
Diabetes mellitus 114 (14.3) 170 (13.9) 187 (13.1) 205 (14.5) 0.813
Hypertension 291 (36.1) 514 (42.1) 628 (44.0) 746 (52.8) <0.001
Hyperlipidemia 91 (11.7) 138 (11.3) 192 (13.5) 243 (17.2) <0.001
Current smoker 53 (6.6) 76 (6.2) 94 (6.6) 102 (7.2) 0.775
History of
   Myocardial infarction 189 (23.4) 222 (18.2) 190 (13.3) 189 (13.4) <0.001
   Coronary artery bypass grafting 17 (2.1) 28 (2.3) 37 (2.6) 41 (2.9) 0.010
   Peripheral vascular disease 38 (4.7) 51 (4.2) 53 (3.7) 60 (4.2) 0.737
   Stroke 99 (12.2) 182 (14.9) 184 (12.9) 180 (12.7) 0.241
   Kidney failure 9 (1.1) 17 (1.4) 29 (2.0) 42 (3.0) 0.006
   Cancer in the last 3 years 31 (3.8) 45 (3.7) 47 (3.3) 70 (5.0) 0.131


































During the study period, 5471 patients over 80 years of age underwent primary 
PCI for STEMI. After exclusion of duplicate procedures, a total of 4876 patients 
remained. Baseline characteristics are shown in Table 1. Within this group, the aver-
age age increased gradually over time and so did the proportion of patients of very 
advanced age. The ratio of male to female patients was the same during the study 
period. Hypertension, hyperlipidemia, prior coronary artery bypass grafting and a 
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history of kidney failure were more common over time, while the percentage of pa-
tients with prior myocardial infarctions declined. A reduction in time from symptom 
onset to PCI was observed between the earliest and the later cohorts. Additionally, 
presence of cardiogenic shock decreased over time.
Procedural characteristics showed a pronounced increase in the use of the radial 
approach during PCI (Table 2). The total rate of stenting was stable over time, al-
though stent type varied. Procedural success was similar over the years and was 
over 90% for all cohorts. The use of antithrombotic therapy increased while glyco-
protein IIb/IIIa inhibitor treatment was common in the earlier years but gradually 
decreased and bivalirudin use increased. 
















   Femoral access 610 (94.3) 1056 (86.4) 1103 (77.3) 820 (58.1)
   Radial access 37 (5.7) 163 (13.3) 320 (22.4) 588 (41.6)
Angiographic findings <0.001
   Single vessel disease 274 (37.4) 393 (32.8) 533 (37.4) 512 (36.3)
   Dual vessel disease 192 (26.2) 346 (28.9) 403 (28.2) 405 (28.7)
   Triple vessel disease 185 (25.2) 341 (28.4) 369 (25.9) 343 (24.3)
   Left main disease 80 (10.9) 109 (9.1) 104 (7.3) 114 (8.1)
Treatment technique <0.001
   Balloon angioplasty 80 (9.9) 116 (9.5) 175 (12.3) 169 (12.0)
   Bare-metal stenting 650 (80.0) 816 (66.7) 1175 (82.5) 1106 (78.4)
   Drug-eluting stenting 82 (10.1) 290 (23.8) 74 (5.2) 135 (9.6)
Stent length, mean mm ± SD 17.1 ± 6.1 18.0 ± 6.2 17.6 ± 5.8 17.8 ± 5.8 0.003
Stent diameter, mean mm ± SD 3.1 ± 0.5 3.0 ± 0.5 3.0 ± 0.5 3.0 ± 0.5 0.041
Procedural success 725 (92.6) 1110 (91.0) 1303 (91.5) 1287 (91.4) 0.651
Medication
   Any anti-thrombotic treatment 
   before PCI
505 (62.7) 1054 (87.5) 1227 (86.2) 1235 (87.7) <0.001
   Aspirin before PCI 482 (59.4) 1015 (83.2) 1152 (80.9) 1167 (82.9) <0.001
   P2Y12 inhibitor before PCI 192 (23.8) 636 (52.3) 956 (67.1) 1030 (73.2) <0.001
   GPIIb/IIIa inhibitor  before PCI 42 (5.2) 113 (9.3) 108 (7.6) 42 (3.0) <0.001
   GPIIb/IIIa inhibitor during PCI 400 (49.3) 657 (53.8) 570 (40.0) 334 (23.7) <0.001
   Bivalirudin during PCI - 166 (15.7) 485 (34.1) 779 (55.3) <0.001
   Thrombolysis before PCI 95 (11.8) 43 (3.6) 17 (1.2) 17 (1.2) <0.001
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     Any event 213 (26.4) 308 (25.2) 346 (24.3) 302 (23.1)
     Age-adjusted, HR (95% CI) 1.25 (1.04-1.49) 1.12 (0.96-1.32) 1.05 (0.90-1.22) Reference
     Comorbidity-adjusted, HR (95% CI)* 1.12 (0.93-1.36) 1.11 (0.95-1.31) 1.09 (0.93-1.27) ”
     Treatment-adjusted, HR (95% CI)† 1.00 (0.81-1.23) 1.12 (0.94-1.33) 1.06 (0.90-1.24) ”
Myocardial infarction
     Any event 102 (15.4) 149 (14.8) 182 (15.1) 145 (13.4)
     Age-adjusted, HR (95% CI) 1.13 (0.87-1.45) 1.06 (0.85-1.34) 1.09 (0.88-1.36) Reference
     Comorbidity-adjusted, HR (95% CI)* 1.12 (0.85-1.47) 1.04 (0.83-1.32) 1.12 (0.90-1.40) ”
     Treatment-adjusted, HR (95% CI)† 1.08 (0.81-1.45) 1.12 (0.88-1.44) 1.14 (0.91-1.42) ”
Heart failure admission
     Any event 141 (21.6) 203 (20.3) 255 (21.2) 190 (18.2)
     Age-adjusted, HR (95% CI) 1.20 (0.97-1.50) 1.11 (0.91-1.36) 1.17 (0.97-1.41) Reference
     Comorbidity-adjusted, HR (95% CI)* 1.14 (0.90-1.45) 1.12 (0.91-1.37) 1.20 (0.99-1.45) ”
     Treatment-adjusted, HR (95% CI)† 1.15 (0.89-1.47) 1.15 (0.93-1.42) 1.21 (1.00-1.47) ”
Stroke
     Any event 27 (4.2) 50 (5.1) 65 (5.5) 40 (4.5)
     Age-adjusted, HR (95% CI) 1.02 (0.62-1.66) 1.21 (0.79-1.83) 1.30 (0.88-1.93) Reference
     Comorbidity-adjusted, HR (95% CI)* 1.17 (0.70-1.96) 1.27 (0.83-1.94) 1.38 (0.93-2.06) ”
     Treatment-adjusted, HR (95% CI)† 1.18 (0.69-2.03) 1.35 (0.86-2.11) 1.40 (0.94-2.10) ”
Bleeding, post-discharge
     Any event 30 (4.7) 58 (5.9) 59 (5.0) 51 (5.2)
     Age-adjusted, HR (95% CI) 0.91 (0.58-1.43) 1.14 (0.78-1.65) 0.96 (0.66-1.40) Reference
     Comorbidity-adjusted, HR (95% CI)* 0.95 (0.59-1.53) 1.16 (0.79-1.70) 0.98 (0.67-1.44) ”
     Treatment-adjusted, HR (95% CI)† 0.88 (0.53-1.46) 1.18 (0.78-1.78) 1.01 (0.69-1.48) ”
* Adjusted for: Age, gender, DM, hypertension, hyperlipidemia, smoking, prior MI, prior CABG, pe-
ripheral vascular disease, previous kidney failure, previous stroke, cancer, number of vessel disease, 
hospital.
† Adjusted for characteristics under * and stenting technique and type, aspirin before/under PCI, P2Y12 
before/under PCI, GPI before/under PCI, thrombolysis.
In the beginning of the study period, slightly more than 10% of patients received 
thrombolysis prior to PCI, compared to marginal numbers of patients in later years.
Temporal trends in outcome
Stratification of outcome according to year of treatment in general showed sim-
ilar rates of 1-year mortality (Table 3). The only statistically significant difference 
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in mortality was observed between the earliest and the most recent cohorts, 
which was eliminated after correction for comorbidity and treatment factors. Re- 
infarction and heart failure admissions did not change over time. Additionally, 
post-discharge stroke and bleeding rates remained stable. In-hospital major bleed-
ing was rare (1.5% in 2001-2004, 0.7% in 2005-2006, 0.1% in 2007-2008 and 
0.1% in 2009-2010) and adjusted in-hospital bleeding rates were not calculated 
due to the low number of events.
Long term results
Long term outcome was stratified according to age: 4593 patients were aged 80-
89 years (mean 83.3 ± 2.6 years) and 274 patients were older than 90 years (mean 
91.3 ± 1.7 years). The control group consisted of 8169 PCI treated patients aged 
70-79 years (mean 74.4 ± 2.8 years).  An approximate doubling of mortality risk per 
decade increase in age was observed (Figure 1). Mortality early after PCI explained 
a major part of the differences between the age groups, although curves continued 
to diverge during follow-up. 
Relative survival analyses showed a lower survival of elderly STEMI patients com-
pared to the general population in the first few months after PCI (Figure 2). After 
this early period, survival was slightly higher compared to the general population 
up to 3-years.
Compared to patients aged 70-79 years, the risks of a new myocardial infarction or 
heart failure were higher for patients over 80 years of age during follow-up (Figure 
3A and 3B). Moreover, stroke rates were higher in patients over 80 years compared 
to those aged 70-79 years, with an early peak in stroke in the population above 90 
years (Figure 4A). During the first year after PCI, stroke rates were 2.8%, 4.8% and 
6.9% for patients aged 70-79 years, 80-89 years and more than 90 years, respec-
tively. In the patients aged 80 years and above, a previous history of stroke was the 
sole predictor of another stroke during the first year of follow-up (HR 2.38, 95% CI 
1.69-3.35). 
Bleeding was more common in patients over 80 years of age (Figure 4B). During the 
first year after PCI, bleeding rates were 3.9%, 5.3% and 4.6% for patients aged 70-
79 years, 80-89 years and more than 90 years, respectively. Multivariable analyses 
showed that male gender (HR 1.70, 95% CI 1.27-2.29); a history of peripheral vas-
cular disease (HR 2.11, 95% CI 1.22-3.64) and cancer in the last 3 years (HR 1.99, 
95% CI 1.17-3.38) were associated with bleeding during the first year of follow-up 
in patients aged 80 years or higher. 
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Figure 2. Relative survival of the elderly STEMI 
population (≥80 years) compared to the general 
population during 3-year follow-up. 
Figure 3: (A) Myocardial infarction and (B) heart failure during long term follow-up.
Figure 4: (A) Stroke and (B) bleeding during long term follow-up.




Our main findings were that patients with STEMI over the age of 80 years treated 
with primary PCI during the 10-year inclusion period of the present population- 
based cohort study generally showed a similar prognosis over time, despite changes 
in patient and treatment characteristics. Importantly, elderly STEMI patients showed 
a similar and even slightly improved long term survival after the early phase from 
PCI compared to the general population. Nonetheless, the long term risk of adverse 
events increased with age, stressing the importance of appropriate risk stratification 
in older patients. 
Elderly patients constitute a growing part of the population presenting with STEMI 
and the use of invasive and antithrombotic therapy is increasing in these patients.2,6 
However, the impact of these developments on the prognosis remains unclear. In 
the present study, the average age in the group of patients over 80 years of age rose 
gradually over time and the proportion of nonagenarians more than doubled. The 
increase in age was associated with higher comorbidity, although a sharp decline 
in prior myocardial infarctions was seen. The 1-year prognosis of elderly patients 
suffering an STEMI was relatively unchanged, with the exception of a significant 
difference in mortality between the earliest and the most recent cohorts. Thus, the 
temporal improvements in mortality were smaller than other reports.4,6,8 However, 
the survival benefit reported in these previous studies was largely driven by the in-
creased appliance of PCI, whereas the population in our study consisted exclusively 
of invasively treated patients. 
During the study period, the occurrence of cardiogenic shock was observed to de-
crease, which may have been related to both decreases in prior myocardial infarc-
tions and improving symptom to PCI times. The overall use of antithrombotic med-
ication during and after PCI increased, and adjunctive treatment shifted gradually 
from glycoprotein IIb/IIIa inhibitor use to bivalirudin. The shift toward bivalirudin, 
increased radial access and decreased use of thrombolysis could probably explain 
the decrease in in-hospital major bleedings.12,13 Interestingly, the rates of radial 
approach were markedly higher compared to other reports, suggesting a high level 
of comfort with radial access among Swedish operators.14 Bleeding and stroke rates 
after discharge did not change over times. Whether this indicates a relatively sim-
ilar dual antiplatelet strategy over the years is unclear, as data on dual antiplatelet 
therapy compliance were not available.
During long term follow-up, a strong association between advanced age and the 
occurrence of adverse events was observed.  However, the relative survival analysis 
indicated that long term prognosis was comparable and even slightly improved in 
patients over 80 years of age compared to the expected survival rate of the general 
population (based on age, gender and year of birth), although survival was reduced 
in the first few months after primary PCI. Survival rates in our investigation were 
similar to a recent Danish study, but our study showed a slightly higher mortality of 
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nonagenarians.15 The higher rates of a new myocardial infarction and heart failure 
in old patients are generally explained by more extensive coronary artery disease 
and comorbidity with age.16,17 
Stroke rates diverged early after PCI and remained increased in patients over 80 
years of age compared to patients 70-79 years of age during long term follow-up. 
The early peak in stroke in nonagenarians suggested a possible procedure related 
association. Patients with a previous stroke were found to be at risk a new stroke, 
an observation that may help to tailor therapy in these patients.18 Bleeding during 
long term follow-up was doubled in patients aged 80-89 years compared to those 
aged 70-79 years. Reassuringly, bleedings were rare in patients during the first year 
after PCI. Risk factors of bleeding in elderly patients with STEMI during the first year 
after PCI included a history of peripheral vascular disease, potentially explained by 
the increased use of anticoagulants in these patients, and concomitant cancer.19 The 
etiology of bleeding in cancer patients is multifactorial, including abnormalities in 
platelet number and function due to cancer treatment, need for invasive procedures 
and use of anticoagulants for prevention of deep venous thromboembolism.20 Male 
gender also predicted bleeding events, which contrasts with the commonly report-
ed observation that women have a higher risk of bleeding after PCI.21 The higher 
bleeding risk possibly reflected a generally worse state of health of male patients in 
the elderly population.22 
Limitations
The current study was observational and thus shares the limitations of all observa-
tional analyses. Nevertheless, registry studies remain important to study clinical 
outcomes and practices in populations underrepresented in clinical trials. The cur-
rent study only included elderly patients treated with PCI, which limits the gen-
eralizability of our results to invasively treated patients. Additionally, in-hospital 
bleeding was not based on ICD codes. Although in-hospital registration may have 
varied during the observation period, registration rates generally improved over 
time and therefore the higher rates of bleeding in the earlier cohorts are unlikely to 
be influenced by this. Furthermore, 1-year follow-up was not available for patients 
treated in 2010, potentially influencing the comparison between the cohorts. How-
ever, a sensitivity analysis showed similar findings after exclusion of patients treated 
in the year 2010.
Conclusions
In this large population-based study of elderly patients with STEMI, we found a gen-
erally unchanged prognosis over a 10-year time period, despite changes in patient 
characteristics and medical treatment. Although higher age was associated with 
increased risk of adverse events, elderly patients surviving the early phase after pri-
mary PCI showed a similar and even slightly improved relative survival compared 
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the general population, supporting the use of primary PCI in these high-risk patients.
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Aims: The optimal drug-eluting stent (DES) in ST-elevation myocardial infarction 
(STEMI) patients remains unclear. We sought to compare the long term performance 
of everolimus-eluting stents (EES) and Endeavor zotarolimus-eluting stents (E-ZES) 
in STEMI.
Methods and results: The current analysis of a prospective registry included con-
secutive patients treated with EES or E-ZES for STEMI. Adjustment for measured 
confounders was done using Cox regression. In total, 931 patients met the inclusion 
criteria (412 EES and 519 E-ZES). Baseline characteristics were balanced, apart from 
a lower rate of renal insufficiency in EES. Median follow-up duration was 2.4 years 
(IQR 1.6-3.1). Mortality outcomes were similar. Up to three year follow-up, the 
composite endpoint of cardiac death, target vessel-related myocardial infarction 
and target lesion revascularization (TLR) was lower in EES; 9.7% vs. 13.7% in E-ZES 
(HR 0.64, 95% CI 0.42-0.99), primarily driven by reduced TLR rates; 3.4% in EES 
vs. 7.3% in E-ZES (HR 0.46, 95% CI 0.23-0.92). Definite stent thrombosis rates 
were low and similar between groups (1.1% in EES vs. 1.9% in E-ZES, p=0.190).
Conclusion: Use of EES led to lower rates of the composite endpoint, driven by 
reduced TLR. This suggests that EES are more efficacious than Endeavor ZES in 
STEMI. Definite ST rates were low and the strategy of second generation DES im-
plantation and upfront GPIIb/IIIa inhibitors administration appears to be safe in 
STEMI.
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Introduction
Second generation everolimus-eluting stents (EES) have shown superior results in 
stable coronary lesions and all-comer patients compared to both bare-metal and 
first generation paclitaxel-eluting stents (PES).1-5 Comparison of Endeavor zotaro-
limus-eluting stents (E-ZES) with bare-metal and PES showed improved outcome 
after E-ZES implantation in stable coronary lesions.6-9 Results of these trials have led 
to widespread use of second generation stents in current clinical practice. Use of 
drug-eluting stents (DES) in setting of ST-elevation myocardial infarction (STEMI) is 
however still under investigation. Trials comparing DES in STEMI mainly focused 
on comparison of bare-metal and first generation DES.10 Therefore, limited data 
exist with regard to the performance of different types of second generation DES 
in patients presenting with STEMI. The current study sought to investigate the long 




The prospective MISSION! registry included all patients treated with primary per-
cutaneous coronary intervention (PCI) for STEMI in a high-volume tertiary center.11 
For the current retrospective analysis, consecutive patients treated between the 1st 
of January 2007 and the 1st of October 2010 were eligible for inclusion. Patient 
selection was done according to procedural stent type. All patients treated with 
either EES (Promus, Boston Scientific, Natick, Massachusetts) or E-ZES (Endeavor, 
Medtronic Vascular, Santa Rosa, California) were included in the current analysis. 
E-ZES were implanted in the Leiden University Medical Center from early 2006 
and EES were implanted from the beginning of 2007, therefore both stent types 
were used during the entire inclusion period. Stent choice was left to the discre-
tion of the operator. Patients treated with both stents simultaneously as well as 
patients treated with other types of drug-eluting or bare-metal stents (BMS) were 
excluded. Patients were treated and followed according to the institutional STEMI 
protocol (MISSION!), implemented at Leiden University Medical Center since Feb-
ruary 2004.11 Patients follow a standardized pre-hospital, in-hospital and outpatient 
clinical framework for decision making and treatment. The pre-hospital protocol 
included field triage by 12-lead electrocardiogram (ECG) faxed to the operator on 
call and in-ambulance treatment with loading dose of clopidogrel, aspirin, heparin 
and intravenous glycoprotein IIb/IIIa inhibitors. Upon arrival at the hospital, pa-
tients were transferred directly to the catheterization laboratory or coronary care 
unit to wait for arrival of the intervention team. Procedures were performed accord-
ing to current clinical guidelines. If tolerated, patients received beta-blockers, ACE- 
inhibitors and statins within 24 hours. Additionally, patients were prescribed dual 
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antiplatelet therapy, consisting of aspirin 100 mg daily for life and clopidogrel 75 
mg daily for 12 months. Patients with an indication for a coumadin were subscribed 
warfarin instead of aspirin.
Following hospital discharge, patients were intensively monitored and managed in 
the outpatient clinic for one year, after which they were referred back to the gener-
al practitioner or referred to a regular, generally regional, cardiological outpatient 
clinic.  Vital status was gathered through municipality records. Follow-up data were 
adjudicated and prospectively collected in the electronic patient file (EPD Vision 
version 8.7.0.1.) by independent clinicians; data from patients participating in the 
out-patient program were gathered by out-patient chart review and follow-up data 
of patients not participating in the out-patient program were gathered by telephone 
interviews. 
Definitions
STEMI was defined as symptoms of angina lasting longer than 30 minutes along 
with electrocardiogram demonstrating STEMI (ST-segment elevation ≥0.2 mV in ≥2 
contiguous leads in V1 through V3 or ≥0.1 mV in other leads or presumed new left 
bundle branch block). Recurrent myocardial infarction was defined as symptoms of 
angina lasting longer than 30 minutes in addition to troponin levels above the ULN 
(upper limit of normal) or a 25% re-rise of troponin levels in case of re-infarction 
after index procedure. Peri-procedural infarction was defined as an elevation of 
troponins 3 times above ULN for PCI and 5 times above ULN for coronary artery 
bypass grafting (CABG). Target vessel revascularization (TVR) was defined as any 
repeat percutaneous intervention or surgical bypass of any segment of the target 
vessel. Target lesion revascularization (TLR) was defined as any repeat PCI or by-
pass surgery of the target lesion including the 5 mm proximal or distal region of the 
stented area. Stent thrombosis (ST) was defined according to Academic Research 
Consortium (ARC) definitions.12 Furthermore, ARC suggested composite endpoints 
were defined. The device-oriented endpoint was a composite of cardiac death, MI 
not clearly related to a non-target vessel and target lesion revascularization (TLR). 
The patient-oriented endpoint consisted of all-cause mortality, any myocardial in-
farction and any repeat revascularization procedure. 
Statistical analyses
Continuous variables are presented as means with standard deviations (SD) and 
were compared using Student’s t-test. Categorical variables are expressed as 
counts and percentages and were compared by means of Pearson's χ² test. Time 
to endpoint was analyzed using Kaplan-Meier plots and the log-rank test was ap-
plied to compare the cumulative incidences of the endpoints between groups. 
All statistical tests were 2-tailed and a p-value ≤0.05 was considered statistically 
significant. Crude and adjusted hazard ratios (HR) with 95% confidence in-
tervals (CI) were calculated using cox proportional hazard regression models. 
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Univariable predictors of outcome were entered into multivariable models using a 
cut-off p-value <0.10. In case of limited number of events, selection of variables 
was based on effect size.
Figure 1. Inclusion and follow-up chart.
Results
During the inclusion period a total of 1199 patients were treated with primary PCI. 
Of these patients 931 met the inclusion criteria of this study: 412 patients received 
at least one EES and 519 patients at least one E-ZES (figure 1). Median follow-up 
duration was 2.3 years (IQR 1.6-3.0) for EES patients and 2.4 years (IQR 1.6-3.2) for 
E-ZES patients. Baseline characteristics (table 1) showed that patients treated with 
E-ZES more frequently had a history of renal insufficiency. Furthermore, patients 
treated with EES were more frequently discharged with beta-blockers compared 
to E-ZES patients (table 2). Other baseline and procedural characteristics were 
balanced.
Table 3 presents clinical outcomes up to three years. During the first year, the pa-
tient-oriented endpoint was balanced between the groups. The device-oriented 
composite endpoint occurred in 4.7% of EES patients and in 8.7% of E-ZES pa-
tients (HR 0.56 in multivariable analysis, 95% CI 0.32-0.97). This was driven by 
both lower rates of target vessel-related MI (HR 0.27, 95% CI 0.08-0.93) and TLR 
(HR 0.21, 95% CI 0.06-0.72). In addition, the individual rate of TVR was lower in 
patients treated with EES compared to E-ZES patients (HR 0.53, 95% CI 0.29-0.98) 











Age, years 61.0 ± 12.4 61.9 ± 12.4 0.292
Male 309 (75.0) 378 (72.8) 0.455
Insulin dependent diabetes mellitus 18 (4.4) 18 (3.5) 0.484
Non-insulin dependent diabetes mellitus 35 (8.5) 49 (9.5) 0.607
Hypertension 164 (40.3) 198 (38.6) 0.600
Hypercholesterolemia 86 (21.2) 104 (20.4) 0.758
Family history of cardiovascular disease 169 (41.8) 214 (42.1) 0.929
Current smoker 185 (45.7) 230 (45.0) 0.840
Previous MI 42 (10.2) 50 (9.7) 0.791
Previous PCI 34 (8.3) 42 (8.1) 0.928
Previous CABG 14 (3.4) 14 (2.7) 0.538
History of peripheral vascular disease 17 (4.1) 25 (4.8) 0.605
History of cerebrovascular disease 16 (3.9) 24 (4.7) 0.567
History of malignancy 21 (5.1) 40 (7.7) 0.107
History of renal insufficiency* 7 (1.7) 24 (4.6) 0.013
Symptom to balloon inflation 0.348
     0-6 hours 246 (86.0) 328 (85.6)
     6-12 hours 28 (9.8) 44 (11.5)
    12-24 hours 8 (2.8) 10 (2.6)
    >24 hours 4 (1.4) 1 (0.3)
Diagnosis to balloon inflation, minutes (IQR) 78 (66-98) 80 (67-98) 0.660
Door to balloon inflation, minutes (IQR) 41 (30-63) 40 (32-56) 0.601
Out-of-hospital cardiac arrest 19 (4.6) 34 (6.6) 0.205
Cardiogenic shock 13 (3.2) 21 (4.0) 0.472
* Defined as eGFR<60 ml/min/1.73m2. Data are expressed as mean ± standard deviation,  
n (%) or median (interquartile range [IQR]).  
The rate of the device-oriented endpoint remained significantly lower up to three 
years follow-up (figure 2A), with 9.7% of EES patients versus 13.7% of E-ZES pa-
tients reaching the endpoint (HR 0.64, 95% CI 0.42-0.99). This was mainly driven 
by TLR (figure 2B), which showed rates of 3.4% in EES patients versus 7.3% in E-ZES 
patients (HR 0.46, 95% CI 0.23-0.92). 
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    Left main stem 4 (1.0) 7 (1.3)
    Left anterior descending 179 (43.4) 229 (44.1)
    Left circumflex 70 (17.0) 78 (15.0)
    Right coronary artery 154 (37.4) 200 (38.5)
    Bypass graft 5 (1.2) 5 (1.0)
Pre-dilation 363 (88.1) 470 (90.6) 0.226
Post-dilatation 154 (37.5) 180 (34.7) 0.379
Glycoprotein IIb/IIIa inhibitors 397 (97.3) 501 (96.5) 0.503
Number of vessel disease* 0.944
   1 163 (39.6) 211 (40.7)
   2 151 (36.7) 187 (36.0)
   3 98 (23.8) 121 (23.3)
Pre-procedure TIMI (grade) 0.881
  0 251 (61.1) 309 (59.5)
  1 72 (17.5) 88 (17.0)
  2 53 (12.9) 76 (14.6)
  3 35 (8.5) 46 (8.9)
Post-procedure TIMI 2 or more 406 (98.8) 511 (98.6) 0.857
Stent length culprit vessel, mean ± SD 28 ± 13 29 ± 14 0.792
Stent diameter culprit vessel, mean ± SD 3.3 ± 0.4 3.2 ± 0.4 0.136
Number of stents in culprit, mean ± SD 1.6 ± 0.8 1.6 ± 0.9 0.552
Discharge medication
     Aspirin 397 (99.0) 502 (99.2) 0.741
     Clopidogrel 399 (99.5) 505 (99.8) 0.433
     ACE-inhibitor 393 (98.0) 492 (97.2) 0.453
     Statin 396 (98.8) 499 (98.6) 0.858
     Beta-blocker 387 (96.5) 470 (92.9) 0.018
Data are expressed as mean ± standard deviation or n (%). * >50% visual stenosis. 
TIMI = thrombolysis in myocardial infarction; other abbreviations as in Table 1.
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The patient-oriented composite endpoint (figure 2C) and cardiac mortality (fig-
ure 2D) did not differ during long term follow-up. Moreover, definite ST (figure 3) 
showed comparable rates. ST occurred sub-acutely (24 hours to 30 days after PCI) 
in 6 cases, of which 1 in EES and 5 times in E-ZES. Late ST (30 days to 1 year after 
PCI) occurred in 2 E-ZES patients and very late ST (later than 1 year) occurred in 2 
EES patients and 1 E-ZES patient. Dual antiplatelet therapy compliance was similar 
between the groups, showing a 99% rate for aspirin/coumadin adherence and 98% 
for clopidogrel adherence at one year. Of the patients suffering from late ST, 2 were 
using aspirin and one was using both aspirin and clopidogrel at time of ST.















    All-cause mortality 17 (4.1) 27 (5.2) 0.84 (0.46-1.53) 0.567 -
        Cardiac mortality 14 (3.6) 26 (5.0) 0.73 (0.39-1.37) 0.325 -
    Myocardial infarction, any 6 (1.5) 17 (3.4) 0.44 (0.17-1.12) 0.084 0.44 (0.17-1.10) 0.080
        Target vessel-related MI 3 (0.8) 12 (2.4) 0.27 (0.08-0.93) 0.038 0.27 (0.08-0.93) 0.037
    Revascularization, any 44 (11.1) 74 (14.8) 0.73 (0.51-1.07) 0.105 -
        Target vessel revascularization 15 (3.8) 37 (7.4) 0.50 (0.27-0.91) 0.022 0.53 (0.29-0.98) 0.041
        Target lesion revascularization 3 (0.8) 17 (3.4) 0.22 (0.06-0.75) 0.015 0.21 (0.06-0.72) 0.013
    Definite stent thrombosis 1 (0.3) 8 (1.6) 0.16 (0.02-1.25) 0.080 0.16 (0.02-1.28) 0.084
    All-cause mortality, any MI, any 
revascularization
60 (14.7) 98 (19.0) 0.77 (0.56-1.06) 0.108 -
    Cardiac death, target vessel 
related MI, TLR
19 (4.7) 45 (8.7) 0.55 (0.33-0.94) 0.028 0.56 (0.32-0.97) 0.037
Up to 3 years
    All-cause mortality 28 (7.6) 39 (8.7) 0.85 (0.52-1.39) 0.512 -
        Cardiac mortality 20 (5.6) 29 (5.7) 0.92 (0.52-1.61) 0.761 -
    Myocardial infarction, any 20 (7.0) 29 (6.7) 0.86 (0.49-1.52) 0.605 -
        Target vessel-related MI 8 (2.7) 19 (4.3) 0.52 (0.23-1.20) 0.124 -
    Revascularization, any 74 (21.5) 108 
24.5)
0.84 (0.63-1.13) 0.247 -
        Target vessel revascularization 32 (9.9) 56 (12.9) 0.70 (0.45-1.08) 0.108 -
        Target lesion revascularization 11 (3.4) 31 (7.3) 0.44 (0.22-0.87) 0.019 0.46 (0.23-0.92) 0.027
    Definite stent thrombosis 3 (1.1) 9 (1.9) 0.42 (0.11-1.54) 0.190 -
    All-cause mortality, any MI, any 
revascularization
99 (27.3) 144 
(31.4)
0.84 (0.65-1.09) 0.193 -
    Cardiac death, target vessel-re-
lated MI,  TLR
34 (9.7) 64 (13.7) 0.66 (0.44-0.99) 0.049 0.64 (0.42-0.99) 0.046
Data are n (%). Percentages are cumulative incidences of events from Kaplan Meier analysis. Hazard 
ratios were calculated using cox proportional hazard models. 
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Discussion
The major finding of this observational investigation, comparing long term out-
comes of EES and Endeavor ZES in an unselected STEMI population up to three 
year follow-up, was that EES implantation was independently associated with lower 
rates of the device-related endpoint of cardiac mortality, target vessel-related MI 
and TLR compared to E-ZES. This was driven by lower rates of TLR in EES patients. 
Furthermore, definite ST rates were low and the strategy of second generation DES 
implantation and upfront GPIIb/IIIa inhibitors administration appears to be safe in 
STEMI.
Figure 2: (A) Device-oriented endpoint (composite of cardiac death, target vessel-related MI and target lesion 
revascularization) up to three year follow-up. (B) Target lesion revascularization up to three year follow-up.  
(C) Patient-oriented endpoint (composite of all-cause mortality, any myocardial infarction and any revascular-
ization procedure) up to three year follow-up. (D)  Cardiac mortality up to three year follow-up. Hazard ratios 
are calculated using crude cox proportional hazards analyses with E-ZES as reference group. 
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Myocardial infarction has long been con-
sidered an off-label indication for DES. 
While first generation DES have been 
shown to reduce revascularization rates 
in STEMI patients compared to BMS, the 
benefit is offset by a higher risk of very 
late ST.13,14 Stenting in acute coronary 
syndromes was found to be an indepen-
dent predictor of ST after DES implan-
tation.15 Delayed endothelialization, 
thrombotic burden, stent underexpansion 
and stent malapposition have been iden-
tified as mechanisms for the higher rate 
of ST after DES implantation in patients 
Figure 3. Definite stent thrombosis.
with acute coronary syndromes.16-18 Moreover, evaluation of patient adherence to 
dual antiplatelet therapy is complicated by the acute setting of myocardial infarc-
tion. Second generation stents have been developed to reduce the incidence of ST 
while attempting to improve the efficacy of DES. In this study, we compared the 
second generation EES and E-ZES. The EES is a thin strut (81 µm), cobalt-chromium, 
Multi-Link™ stent with a biocompatible polymer eluting everolimus, a sirolimus- 
analogue. Eighty percent of the everolimus is eluted in the first 28 days. EES showed 
faster endothelialization compared to first generation stents in pre-clinical studies.19 
The Endeavor ZES is based on a cobalt-chromium Driver™ platform, consisting of 
91 µm struts covered by a biomimetic phosphorylcholine polymer releasing the 
sirolimus-analogue zotarolimus. The Endeavor stent releases 95% of its inhibitory 
drug within 28 days, which is the fastest elution of all stents currently in use. 
In the current study, patients treated with EES showed lower rates of the composite 
endpoint of cardiac mortality, target vessel-related MI and TLR compared to E-ZES 
patients up to three year follow-up. The difference was driven by lower rates of TLR 
in EES patients. This observation is in line with previous studies demonstrating an 
association of EES with lower late luminal loss (average 0.14 mm, compared to 
0.6mm in E-ZES) which is a strong surrogate endpoint for TLR.20,21 This indicates that 
EES have a higher potential for suppressing neointimal growth. It underlines that 
more aggressive inhibition of intimal hyperplasia is not directly related to a higher 
risk of ST but that other factors like stent design, polymer properties and release 
characteristics of the drug also play a role. 
Recently, Hannan et al. performed a propensity score matched comparison of EES 
and E-ZES and found a reduced rate of repeat revascularizations for EES patients 
during two year follow-up,22 reflecting the current results. Ten percent of patients 
included in their registry were treated for MI within 24 hours, however exact di-
agnosis was not mentioned. Trials or registries focusing on use of EES or E-ZES in 
STEMI patients specifically are limited. The Evaluation of Xience-V stent in Acute 
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Myocardial Infarction (EXAMINATION) trial randomized MI patients to EES or BMS 
and reported lower rates of TVR, TLR and definite ST in the EES group after 1 year.23 
A comparison of EES and SES was made in The XienceV Stent vs. Cypher Stent 
in Primary PCI for Acute Myocardial Infarction (XAMI) trial, which included 96% 
STEMI patients, and suggested superior MACE rates in EES compared to SES up to 
1 year follow-up, although the trial was not powered for this.24  Additionally, Kedhi 
et al.,25 comparing EES with PES in the indication of STEMI in a post-hoc analysis, 
observed superior outcomes of EES up to two years of follow-up. Rates of mortality, 
MI and revascularizations were relatively low compared to the current study. This is 
most likely due to a higher risk population in the current analysis, since no patients 
were excluded on account of clinical or angiographic characteristics. In contrast, 
the HORIZONS-AMI trial reported markedly higher rates of definite ST after PES 
implantation (4.2% at 3 years) despite inclusion of lower risk patients, indicating 
that there might be improved safety with use of second generation stents in STEMI.26
The ST rates found in the E-ZES group of this study were somewhere in between the 
results of PES and EES. E-ZES have previously been compared with SES in the setting 
of STEMI by Kim et al.27 Up to one year follow-up, E-ZES showed a similar inci-
dence of ST (1.0% vs. 1.8%). Additional studies found no differences in outcome 
between PES, SES and E-ZES in STEMI patients up to 18 months follow-up.28-31 In 
these studies, the E-ZES groups showed variable ST rates ranging from zero to 2.9 
percent. Longer term data on the performance of E-ZES in STEMI are lacking. 
Recent results from the RESOLUTE all-comers trial showed non-inferiority of the 
Resolute ZES (R-ZES, characterized by a new biocompatible polymer with a more 
gradual release of zotarolimus) compared to EES. The 2 year definite ST rate was 
2.0% in the R-ZES compared to 1.0% in EES.32 In contrast, the recent TWENTE 
trial found a trend toward a reduction in definite/probable ST after 1 year in pa-
tients treated with R-ZES compared to EES.33 These results suggest that improved 
safety and efficacy outcomes of the R-ZES compared to E-ZES are possibly due to 
improvements in polymer and elution pattern. However this remains speculation 
without definitive randomized clinical data. In this study a trend between lower 1 
year ST rates in EES was seen, due to differences in the incidence of ST in the early 
period after stent implantation. From previous studies it is known that acute ST is 
related to procedure related factors like dissection, undersizing of stent, TIMI flow 
less than 3 after procedure and lack of glycoprotein IIb/IIIa inhibitors.34 However, 
no acute ST were observed in our population. Sub-acute ST, which occurred in 6 
instances, is related to a variability of factors, among which diabetes mellitus, left 
ventricular function under 40%, complex lesions and acuteness of PCI.35 The role 
of procedure related factors is smaller in sub-acute ST, suggesting that the higher 
early rate of ST in E-ZES might be due to differences in stent design. However, long 
term rates of ST were similar in our population, supporting adequate safety of both 





The current observational cohort included the entire range of STEMI patients en-
countered in daily practice. Optimal care consisted of low diagnosis- and door-to-
balloon times, up-front glycoprotein IIb/IIIa inhibitors and an intensive outpatient 
management program. There are however several limitations to the current study 
design. Because the Endeavor ZES is no longer clinically in use, the Resolute ZES 
might have been a better comparator for EES. Furthermore, results must be inter-
preted with caution due to the non-randomized, observational nature of the study. 
Although a wide range of baseline and angiographic characteristics were balanced 
between the groups, bias could have occurred during the selection of the patients. 
Multivariable Cox proportional hazards analyses were performed to correct for con-
founders but unmeasured characteristics may have influenced comparison of the 
groups. Propensity score matching may have provided more adequate correction 
for confounding but was not possible due to limitations in population size. The 
study was underpowered to detect differences in rare events like ST. Additionally, 
the adjudication of repeat MI events was not performed according to the latest trial 
protocols and this may have led to underestimation of MI events though there is 
no reason to suspect that this favored any of the stent types. Moreover, this was a 
single center investigation and there were no predefined endpoints which may have 
increased chances of type 2 error, therefore results of this analysis should be con-
sidered hypothesis-generating. Whether the advantage of EES in setting of STEMI 
remains when compared to the newer generation R-ZES is yet to be explored. Large 
randomized trials with long term follow-up and sufficient power are necessary to 
decide which newer generation stent is most suitable for STEMI patients.
Conclusions
The current retrospective investigation of EES and Endeavor ZES in setting of STEMI 
found lower rates of the device-oriented endpoint in EES patients compared to 
E-ZES patients, driven by lower rates of TLR. This suggests that EES is more effica-
cious than E-ZES in setting of ST-elevation myocardial infarction up to three years 
follow-up. Furthermore, definite ST rates were low and the strategy of second gen-
eration DES implantation and upfront GPIIb/IIIa inhibitors administration appears 
to be safe in STEMI.
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Objectives: The goal of this study was to compare the efficacy and safety of second 
generation everolimus-eluting stents (EES) with first generation sirolimus-eluting 
stents (SES) in primary percutaneous coronary intervention (PCI) for acute myocar-
dial infarction (AMI).
Background: Drug-eluting stents (DES) in AMI are still feared for possible late and 
very late stent thrombosis (ST). Newer generation DES, with more hemocompati-
ble polymers and improved healing, may show promise to combine the increased 
efficacy of DES with improved safety. However, no randomized trials in AMI are 
available.
Methods: A total of 625 patients with AMI were randomized 2:1, EES or SES, in the 
XAMI trial (Xience vs Cypher in AMI).  Primary endpoint was major adverse cardiac 
events (MACE) at 1 year consisting of cardiac death, non-fatal AMI or any target 
vessel revascularization (TVR). The study was powered for non-inferiority of EES. 
Secondary endpoints contain ST rates and MACE rate up to 3 years.
Results: The MACE rate was 4.0% for EES and 7.7% for SES, absolute difference - 
3.7% [95% CI: - 8.28;-0.03], p = 0.048, RR 0.52, [95% CI: 0.27;1,00]. One year 
cardiac mortality was low at 1.5% (EES) vs 2.7% (SES) (p=0.36) and one year inci-
dence of definite and/or probable ST 1.2% (EES) vs 2.7% (SES) (p=0.21).
Conclusions: In this all-comer randomized multi-center AMI trial, second genera-
tion EES was non-inferior to SES and superiority for MACE was suggested. ST rate 
in EES at one year was low, but long-term follow-up and larger studies will have to 
show whether very late ST rates will also be improved in newer DES.
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Introduction
The efficacy and safety of drug-eluting stents (DES) in the treatment of coronary 
artery disease is well established. Restenosis rates have dramatically decreased for 
both on-label and off-label indications.1-3 Despite these results the concern for in-
creased (late) stent thrombosis is still present.3-5 This may be due to delayed vascular 
healing after DES implantation,6,7 probably as a result of drug and/or polymer reac-
tion. Late coronary endothelial dysfunction after DES stenting has previously been 
reported.8 Because acute myocardial infarction (AMI) presents the highest possible 
thrombotic coronary lesions, DES implantation during primary percutaneous coro-
nary intervention (PCI) for AMI is still not advocated by many interventional cardi-
ologists. However, even in this challenging population the use of DES has increased 
over the last few years and several randomized studies and large cohort studies 
show efficacy and safety.9-12 
Newer anti-proliferative drugs and more biocompatible polymers have shown 
promise in reducing further the rate of (late) stent thrombosis in stable patients.13,14 
However, no randomized data is available on the efficacy and safety of newer gen-
eration DES in AMI patients.
In our center, Cypher (Cordis, Bridgewater, New Jersey), the sirolimus-eluting Cypher 
stent (SES) has been the default stent since 2004 in PCI for all indications including 
acute coronary syndromes. With the emergence of a second generation “limus” 
DES stent (Xience V [Abbott Vascular, Santa Clara, California], an everolimus- 
eluting stent [EES]), a multi-center randomized trial was designed to compare both 
stents in AMI patients (XAMI : Xience vs Cypher in AMI).
Methods
Study design and patient population
Between February 2008 and December 2009 consecutive patients presenting with 
ST-elevation myocardial infarction (STEMI) treated with primary PCI and fulfilling 
the inclusion criteria were included in three large interventional centres in the Neth-
erlands. To be included, patients had to have ST-elevation myocardial infarction and 
be eligible for primary PCI.  Patients with Non-ST elevation myocardial infarction 
(NSTEMI) with emergency indication for PCI at admission were also allowed. Ex-
clusion criteria were as follows: stent thrombosis of previous stent or chronic total 
occlusion as target lesion, known allergy or intolerance to sirolimus, everolimus, 
aspirin or clopidogrel, intubated patient after extensive resuscitation or shock pa-
tients for whom no informed consent could be obtained, estimated life expectancy 
< 1 year or stent size required to treat lesion > 3,5 mm (maximum diameter of SES). 
The study was approved by the institutional ethics committee at each participating 
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center, and written informed consent was obtained from all patients.
Randomization and blinding
Patients were randomized 2:1 to EES or SES by sealed envelope, directly after diag- 
nostic angiography and assessment of feasibility for stenting. Operators were not 
blinded to the allocated stent. An independent Data Safety Monitoring Board 
(DSMB) evaluated the study safety after 30 day inclusion of 300 patients, blinded 
to the allocated stent type. At one year, all events were evaluated and adjudicated 
by an independent Clinical Event Committee (CEC), again blinded to treatment 
assignment.
Procedure
All patients were pretreated with i.v. aspirin, heparin 5000 IE bolus and received 
clopidogrel with a loading dose of preferably 600 mg. Interventions were performed 
according to local practice in three high volume centres by high volume opera-
tors. GP IIb/IIIa receptor blocker use, thrombus aspiration and balloon predilatation 
were left up to the operator. Aspirin was recommended for life and clopidogrel for 
a minimum of one year. The study has a planned follow-up of 3 years.
Study Endpoints and Definitions
The primary endpoint was major adverse cardiac events (MACE) at 12 months con-
sisting of any event during follow-up in hierarchical order: cardiac death, non-fatal 
re-infarction or any target vessel revascularization (TVR). The secondary endpoints 
were (sub)-acute stent thrombosis (SAT) at 30 days and late stent thrombosis (LST) 
at 1, 2 and 3 year, MACE at 30 days and 2 and 3 years and all-cause mortality at 1, 
2 and 3 year. Reinfarction was defined by recurrent symptoms and/or new electro-
cardiographic changes, with re-elevation of the creatine kinase (CK) of > 1.5 times 
the previous value with elevation of CK-MB, if within 48 h, or > 3 times the upper 
normal limit, if after 48 h from the index AMI. More than 5 times the upper limit 
of normal CK was required for the diagnosis of AMI after bypass surgery. TVR was 
defined as any repeat percutaneous intervention or by-pass grafting of the target 
vessel and Target Lesion Revascularization (TLR) as any repeat percutaneous inter-
vention or by-pass grafting of the target lesion or the 5 mm proximal or distal to the 
initial stent. Definite and probable stent thrombosis was defined according to the 
Academic Research Consortium criteria (ARC).15
Statistical analysis
Data collection, handling and statistical analyses were performed by an indepen-
dent Core Lab, Diagram b.v., Zwolle, The Netherlands. This trial was based on the 
notion that the performance of EES would not be inferior to SES in relation to the 
primary outcome, MACE at 1 year, with the use of a pre-specified non-inferiority 
margin and a 95% confidence interval. We calculated that a sample size of 600 
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patients (2:1 randomisation) would give a power of 80% (Farrington and Manning 
method). This sample size took into account an expected one year MACE rate of 8% 
and a non-inferiority margin of 6%, and a two sided risk of 0.05. Sample size was 
increased to 625 patients (after the pilot phase without any unblinding of data) to 
compensate for a small pilot phase of 80 patients, randomized 1:1, to maintain ad-
equate power of the trial. Study outcomes were assessed by both intention-to-treat 
and per-protocol analyses. The intention-to-treat population included all patients 
who were randomized. These results are reported in this paper. The per-protocol 
population included all patients who fulfilled the inclusion and exclusion criteria 
and in which the randomized stent was placed. A second per-protocol analysis also 
excluded the included NSTEMI patients in the trial to check consistency of the trial 
results in true STEMI patients. Data are reported as percentages for discrete vari-
ables. Continuous variables are reported as mean with standard deviation or medi-
an with 25th and 75th percentiles. Categorical variables were compared with the 
chi-square test or Fisher's exact test. Continuous variables were compared with the 
nonparametric Mann Whitney U test. Kaplan-Meier survival estimates were used 
to compare time to the first occurrence of MACE, with pair-wise differences tested 
using the log rank test.
Results
Patients and baseline characteristics
A total of 625 consecutive patients with AMI were included in three large referral 
interventional clinics in The Netherlands. Four percent of patients were included 
with NSTEMI, treated with emergency PCI at presentation. All other patients pre-
sented with STEMI. Baseline characteristics are shown in Table 1. Seven percent of 
patients presented with Killip class > 1. Diabetes was present in 10 % of patients. In 
the Netherlands, a dedicated infrastructure is present to directly refer AMI patients 
to the catheterization suite of an interventional center without any interference of a 
local hospital, general practitioner or even the emergency department. First medical 
contact is typically at the patient’s home and median time from this first contact to 
balloon inflation was only 75 minutes in this study. At diagnosis, the ambulance 
personnel immediately administer both high dose acetylsalicylic acid and heparin 
intravenously and in some regions clopidogrel orally. 
Procedure
Angiographic and procedural characteristics are shown in table 2. More than 50% 
of  patients had TIMI 0 flow at presentation and single vessel disease. Compared 
with previous AMI studies, a high percentage of radial access of >50% was used. 
High dose clopidogrel loading was administered in most patients; there was also a 
high percentage of Glycoprotein IIb/IIIa receptor blocker use and thrombus aspi-
ration catheter use. No significant differences were seen in all parameters except 
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Male gender - no. (%) 295   (73.0) 167    (75.1) 0.57
Age (mean)  – yr ± SD 61.2 ± 11.3 62.0 ± 11.4 0.39
Killip class I  - no. (%) 377   (93.3) 206    (92.8) 0.79
STEMI  - no. (%) 387   (95.8) 213    (96.4) 0.72
NSTEMI  - no. (%) 17    (4.2) 8     (3.6) 0.72
History
Previous Q wave MI - no. (%) 6     (1.5) 7     (3.2) 0.24
Previous non Q wave MI - no. (%) 17     (4.2) 7     (3.2) 0.52
Previous PCI  - no. (%) 17     (4.2) 6     (2.8) 0.34
Previous CABG - no. (%) 1     (0.2) 4      1.8) 0.06
Previous stroke - no. (%) 10     (2.5) 12     (5.4) 0.06
Risk factors
Smoking  - no. (%) 220    (54.5) 122    (55.2) 0.86
Diabetes Mellitus - no. (%) 36      (8.9) 25    (11.3) 0.33
Hypertension  - no. (%) 119    (29.5) 66    (29.9) 0.92
Family history  - no. (%)  172    (42.6) 99    (44.8) 0.59
Renal failure  - no. (%) 4       (1.0) 4     (1.8) 0.46
Time (median in minutes)
symptoms to first medical contact 94 (60 – 180) 97.5 (60 – 186) 0.92
First medical contact to balloon 75 (60 – 103) 75    (61 – 100) 0.58
Infact size (peak in U/l; mean ± SD)
CPK 1831 ± 1816 1923 ± 1994 0.93
CPK-MB 205 ±   180 216 ±   219 0.96
Pre hospital anticoagulation/antithrombotics
Aspirin  -  (%) 85.3 83.1 0.47
Unfractionated heparin  - (%) 74.6 71.7 0.43
Clopidogrel loading -  (%) 37.3 34.2 0.45
GP 2b/3a blocker iv - (%) 5.2 6.8 0.41
Access site (%) 0.27
  Radial 52.0 56.6
  Femoral 48 43.4
IABP  (%) 1.5 1.4 1.00
CABG:Coronary artery bypass grafting; CPK:Creatinin phosphokinase; EES: Everolimus-eluting 
stent; GP:Glycoprotein; MI:Myocardial infarction; NSTEMI:Non-ST-elevation myocardial infarc-
tion;  PCI:Percutaneous coronary intervention;  SES: Sirolimus-eluting stent; STEMI: ST-elevation 
myocardial infarction.
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Target vessel (%) 0.43
  RCA 42.3 36.7
  LAD 38.6 43.0
  RCX 18.8 19.5
  Left main 0 0.5
  Graft 0.2 0.5
Lesion type (%) 0.44
  A 1.2 0
  B1 31.4 32.6
  B2 34.7 34.9
  C 32.7 32.6
Heavy calcification  (%) 5.7 11.0 0.02
Severe tortuosity  (%) 11.2 9.5 0.52
Ostial lesion  (%) 3.5 5.4 0.24
Bifurcation  (%) 11.4 15.8 0.12
Visible Thrombus (%) 85.1 86.4 0.67
TIMI flow   (%) 0.74
  0 54.5 57.2
  1 6.7 5.0
  2 17.8 15.8
  3 21.0 22.1
Extend of coronary artery disease  (%) 0.54
  One vessel 54.2 49.8
  Two vessels 32.7 36.7
  Three vessels 13.1 13.6
Clopidogrel 300 mg loading (%) 3.2 2.3 0.62
Clopidogrel 600 mg loading (%) 96.0 97.2 0.46
Overall GP2b/3a blocker  (%) 74.5 77.8 0.36
Thrombus aspiration  (%) 61.9 63.8 0.64
Stent placement (%) 99.5 99.5 1.00
TIMI flow 0-2  (%) 5.0 6.3 0.47
Total stent length target segment  (mm) 25.1 ± 13.5 27.9 ± 17.0 0.09
Max stent diameter target segment  (mm) 3.1 ± 0.4 3.1 ± 0.4 0.54
Additional treatment other vessel than target   (%) 5.2 5.9 0.72
Number of stents per patient 1.3 ± 0.6 1.4 ± 0.7 0.45
GP:Glycoprotein; IABP:Intra-aortic balloon pump; TIMI:Thrombolysis in myocardial infarction.
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for more heavy calcification in the SES group. Medication at discharge is shown in 
table 3.







  ASA 98.5 98.2 0.75
  Clopidogrel 98.5 98.6 1.00
  Beta blocker 83.7 81.9 0.57
  Ace inhibitor 45.8 47.1 0.76
  AT II Blocker 5.2 5.9 0.72
  Statin 90.6 90.0 0.82
  Diuretics 8.9 14.5 0.03
  Insulin 3.5 3.6 0.92
  Oral antidiabetic 5.7 6.8 0.58
  Calcium antagonist 4.0 5.9 0.28
  Anticoagulation 2.5 6.8 0.01
  Nitrate 4.5 2.3 0.16
  Spironolacton 2.2 5.4 0.03
  Digoxin 0 0.5 0.35
*: in case of in-hospital mortality, medication was checked at time of death. ASA: acetylsalicylic  
acid; AT: Angiotensin.
30 day outcome
One patient was excluded because of withdrawal of informed consent. Results can 
be seen in table 4. Mortality was low and consisted entirely of cardiac mortality. 
Acute stent thrombosis was seen in 1 patient of each group and definite and/or 
probable stent thrombosis at 30 day was low at 1.3%. Subacute stent thrombosis 
was higher with SES though not statistically significant.
1 Year outcome
At 1 year, 1 additional patient withdrew informed consent and was excluded. This 
withdrawal resulted in a clinical follow-up at 1 year of 99.7%. One year results 
are listed in table 4. The primary endpoint of MACE, consisting of cardiac death, 
non-fatal MI or any TVR at 1 year was 4.0 % for EES and 7.7% for SES. The non- 
inferiority criterion for EES was met with an absolute difference of -3.7% (95% CI: 
-8.28; -0.03). MACE rate was significantly reduced for EES with a p-value of 0.048 
and a relative risk (RR) of 0.52 (95% CI: 0.27; 1.00). Diverging of the MACE-free 
survival curves can be seen in figure 1. The cardiac death rate was 1.9 % for the 
total group. Individual endpoints of all-cause mortality, cardiac death, AMI and TVR 
all showed a consistently slightly higher event rate in the SES group, but this was 
not statistically significant.
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30 day follow-up - no. (%)
Death 10   (1.6) 4    (1.0) 6   (2.7) 0.18
Cardiac death 10   (1.6) 4    (1.0) 6   (2.7) 0.18
Non fatal MI 1   (0.2) 0 1   (0.5) 0.35
TVR 7   (1.1) 5    (1.2) 2   (0.9) 1.00
TLR 2   (0.3) 1    (0.2) 1   (0.5) 1.00
Stent thrombosis (definite, probable) 8   (1.3) 3    (0.7) 5   (2.3) 0.14
   Acute 2   (0.3) 1    (0.2) 1   (0.5) 1.00
   Sub acute 6   (1.0) 2    (0.5) 4   (1.8) 0.19
One Year follow-up- no. (%) (n=623) † (n=402) (n=221)
MACE  ‡ 33   (5.3) 16    (4.0) 17   (7.7) § 0.048
Death 15   (2.4) 8   (2.0) 7   (3.2) 0.36
Cardiac death 12   (1.9) 6   (1.5) 6   (2.7) 0.36
Non fatal MI 5   (0.8) 2   (0.5) 3   (1.4) 0.35
TVR 19   (3.0) 10   (2.5) 9   (4.1) 0.27
TLR 7   (1.1) 5   (1.2) 2   (0.9) 1.00
Stent thrombosis (definite, probable) 11   (1.8) 5   (1.2) 6   (2.7) 0.21
   Late ( 30-365 days) 3   (0.5) 2   (0.5) 1   (0.5) 1.00
*: One patient is excluded, withdrawal informed consent. †: In total by 1 year two patients 
excluded because of withdrawal of consent ‡:  MACE is primary endpoint: Cardiac Death, 
Non fatal MI, any TVR §:Non-inferiority criterion was met, absolute difference -3.7%  
(95% CI: -8.28; -0.03); p value: 0.048 with RR 0.52 (95% CI: 0.27; 1.00).
Figure 1. Kaplan-Meier estimates of MACE-free survival at one year of 
infarct patients randomized to EES and SES.
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The overall one year definite and/or probable stent thrombosis rate was 1.8%. The 
difference between EES (1.2%) and SES (2.7%) could be attributed to an early dif-
ference at 30 days. Late stent thrombosis rate beyond 30 day and up to 1 year was 
identical and 0.5% in each group. At 1 year, 94% of patients were still using clopi-
dogrel, together with ASA or with oral anticoagulants. No significant difference 
between both groups was seen (data not shown).
Additional “per-protocol analysis”, including NSTEMI patients, confirmed robust-
ness of the outcome of the primary endpoint, with a MACE rate of 3.3% (EES) vs 
7.8% (SES), p= 0.01; RR 0.43 (95% CI: 0.21; 0.86). Per protocol analysis, excluding 
the 4% NSTEMI patients which were included in the trial, also revealed a clear 
benefit of the EES with a MACE rate of 3.5 % vs 7.6 % for SES, p= 0.027, RR 0.46 
(95 % CI: 0.22; 0.93).
Discussion
In this randomized trial, the first generation drug-eluting stent, the SES Cypher stent 
was compared with the second generation EES Xience V stent in patients with AMI. 
The results show very low MACE rates and low percentages of stent thrombosis 
at one year in these very thrombotic lesions. Superiority of the EES was shown 
for the primary endpoint and MACE-free survival curves are still diverging at one 
year follow-up. Robustness of outcome was confirmed with additional per-protocol 
analysis.
Study Population
The current study represents a medium mortality risk all-comer AMI population. 
This is illustrated by the mean peak infarction enzyme levels and comparable to 
other trials.12,16 Diabetes was present in only 10 % of patients, which is almost 
identical to findings from several other Dutch AMI trials.16,17 Patient characteristics 
were comparable to other AMI trials like the large HORIZONS-AMI trial12 and the 
PASSION trial,16 and higher risk than the Typhoon trial,10 in which sirolimus-eluting 
stents were compared to BMS in AMI patients. In this study, mortality was low and 
quite similar to our study, but extensive exclusion criteria made this a low mortality 
risk population. 
Event Rates
All-cause mortality and cardiac mortality rates at 1 year were very low in both arms 
of our study. This may also reflect the progress over the last few years in patient 
treatment. Pre-medication with aspirin and heparin at the patient’s home and direct 
referral to interventional centers leading to a short “ first contact to balloon” times 
will undoubtedly have an effect on final infarct size and mortality. The use of radial 
access in over 50 % of cases impacts the risk of bleeding and the morbidity and 
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mortality related to bleeding complications.18,19 The benefit of thrombus aspiration 
was demonstrated in the TAPAS study.17 Thrombus aspiration was used in almost 
63% of cases in the XAMI trial. For comparison, in the HORIZONS-AMI study 
thrombus aspiration was used in only 11 % of patients. Using these contemporary 
interventional techniques, DES was associated with a low re-intervention rate at 1 
year. Overall TLR rate in this trial was only 1.1 % at 1 year. In-stent restenosis, as 
seen in BMS in 20% to 23% of patients in TYPHOON and HORIZONS-AMI, may 
not be benign20 and reintervention for in–stent restenosis is also associated with 
complication risks.
The entire cohort of patients in our trial was not treated for STEMI. The inclusion cri-
teria allowed NSTEMI patients to be randomized under strict conditions of indica-
tion for emergency PCI at presentation. The pathophysiology of these very unstable 
lesions will barely differ and frequently also reflect a totally thrombotic occluded 
vessel in NSTEMI. In our trial only 4% of patients with NSTEMI were included and 
will not preclude comparison of our event rates with other STEMI trials.  Per proto-
col analysis, excluding the 4% NSTEMI patients, confirmed this hypothesis, show-
ing a clear benefit for EES in MACE rate at 1 year, with a p-value of 0.027.
Stent Thrombosis
The event rate was accompanied by a low rate of definite and/or probable stent 
thrombosis. The rate for sirolimus-eluting stent was 2.7 % and for everolimus-elut-
ing stent even only 1.2 %. In comparison, rates were 3.1 % for paclitaxel-eluting 
stents in the largest randomized AMI trial with DES so far, the HORIZONS-AMI. 
In that trial the bare metal stent thrombosis rate (definite or probable) was 3.4 %. 
Pre-randomization heparin and a 600 mg clopidogrel loading dose were indepen-
dent predictors of reduced acute and subacute stent thrombosis in HORIZONS-AMI, 
respectively.21 In the XAMI trial a very high percentage of patients received both. 
The difference in stent thrombosis rates at 30 days was mainly responsible for the 
difference at one year. Though the influence of procedural and patient character-
istics cannot be excluded, it has been suggested that the newer polymer coatings 
used in second generation DES, like the EES, may have anti-inflammatory proper-
ties and may be partly responsible for reduction in early stent thrombosis. Emerg-
ing data on delayed healing6,7 and late endothelial dysfunction after stenting with 
SES,8,22 possibly involved in (very late) stent thrombosis, has hampered the use of 
DES, especially in patients with acute coronary syndromes as their highly thrombot-
ic lesions are more prone to stent thrombosis. Despite this, randomized trials and 
large risk-adjusted retrospective studies have shown superiority of first generation 
DES over bare metal stents (BMS) up to several years follow-up.23,24 Next to a signif-
icant decrease in re-interventions, some studies also indicate decreased mortality,23 
although randomized trials have not confirmed this. Despite the promising low per-
centage of stent thrombosis, long-term follow-up will have to demonstrate safety, as 
continuing rates of late stent thrombosis have been reported in first generation DES 
during the first few years.5,25 Data on improved vascular healing and endotheliali-
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zation of second generation DES7,26 provide some incentive for the hypothesis that 
in these newer generation DES incremental rates of (very) late stent thrombosis may 
be ameliorated, even in this highly thrombotic subset of patients. Recently, 2 year 
follow-up data of large randomized all-comer trials including 20-30 % of AMI pa-
tients were presented. Very few additional stent thromboses were seen between one 
and two year in the EES stent arms,27-29 as well as in a (not separately randomized) 
subgroup analysis of AMI patients.30 The XAMI trial will conduct a follow-up up to 
3 years to investigate the incidence of very late ST.
Study Limitations
Despite the fact that this was an all-comer trial and infarct enzymes do not reflect 
a low-risk population, clinically unstable shock patients were less likely to be en-
rolled and only 7% of patients were in Killip class > 1. The low MACE rate cannot 
be extended to the general total AMI population, but patient characteristics were 
very comparable to most other reported clinical AMI trials comparing DES and 
BMS as discussed previously. The lesions in the SES group were more calcified and 
despite comparable peak enzymes in both groups, medication at discharge shows 
a higher percentage of diuretics and oral anticoagulation use in the SES patients. 
A small imbalance between groups with lower ejection fraction in the SES group 
at presentation cannot be excluded, but quantified data on left ventricular func-
tion at presentation or follow-up were not collected. The primary objective of the 
XAMI trial was to demonstrate non-inferiority of the EES for MACE. The trial was not 
powered for superiority, but at one year follow-up a marginally significant better 
outcome was seen for EES. According to several statistical papers,31,32 superiority 
may be claimed in this case, but a definite verdict is questionable. As MACE curves 
diverge at one year, longer follow-up may answer this question in the coming years. 
The trial is not powered to detect significant differences in adverse events like stent 
thrombosis, which has a low incidence. Very large trials are necessary to be ad-
equately powered for these events. However, our trial has a planned follow-up 
of three years and continuing trends towards differences in incidence of very late 
stent thrombosis may be seen at longer follow-up. The cardiologists performing the 
primary PCI were not blinded to the allocated stent type. This would also not be 
ethical as each stent type has its own typical behaviour and handling. Despite the 
higher profile of the sirolimus-eluting stent, only once the operator had to cross over 
from the SES to EES to cross the lesion. Four times the EES was crossed over to a 
non-study stent.  However, analysis of MACE was performed on “intention to treat” 
basis and performed by a blinded independent CEC.
 
Conclusions
In this contemporary all-comer randomized multi-center AMI  trial, low MACE rates 
were seen at 1 year with the use of DES in primary PCI in AMI. Although not pow-
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ered for superiority, the second generation everolimus-eluting DES displayed a sig-
nificantly lower MACE rate than the first generation sirolimus-eluting stent, at least 
proving non-inferiority and even suggesting superiority. Stent thrombosis rate in EES 
was very low, but long-term follow-up and larger scale studies will have to show 
whether the reported continuing stent thrombosis rates beyond one year as shown 
in first generation DES will also be improved in EES.
Acknowledgements
Prof H. Boersma PhD, Thoraxcenter, Erasmus University Rotterdam, The Nether-
lands, is especially appreciated as chairman of the DSMB and for his statistical 
advise.  Data collection, handling and statistical analyses were performed by 
an independent Core Lab, Diagram b.v., Zwolle, The Netherlands, with special 





1. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in 
patients with coronary artery disease. N Engl J Med 2004;350:221-31.
2. Caixeta A, Leon MB, Lansky AJ, et al. 5-Year Clinical outcomes after sirolimus-eluting 
stent implantation. J Am Coll Cardiol 2009;54:894–902.
3. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting 
stents with bare-metal stents. N Engl J Med 2007;356:1030-9.
4. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term 
outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 
2007;356:1009–1019.
5. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis 
of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice. Lancet 
2007;369:667–678.
6. Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-
eluting stents. Angioscopic findings. J Am Coll Cardiol 2006;47:2108 –11.
7. Joner M, Nakazawa G, Finn AV, et al.  Endothelial cell recovery between comparator 
polymer-based drug-eluting stents J Am Coll Cardiol 2008;52:333–42.
8. Hofma SH, van der Giessen WJ, van Dalen BM, et al. Indication of long-term 
endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 
2006;27:166-170;Epub 2005 Oct 25.
9. Lemos PA, Saia, F, Hofma SH, et al. Short- and long-term clinical benefit of sirolimus-
eluting stents compared to conventional bare stents for patients with acute myocardial 
infarction. J Am Coll Cardiol 2004;43:704-8. 
10. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute 
myocardial infarction. N Engl J Med 2006;355:1093-104.
11. Violini R, Musto C, De Felice F, et al. Maintenance of long-term clinical benefit with 
sirolimus-eluting stents in patients with ST-elevation myocardial infarction. 3 Year 
results of the SESAMI trial. J Am Coll Cardiol 2010;55:810-814.
12. Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal 
stents in acute myocardial infarction. N Engl J Med 2009;360:1946-59.
13. Kedhi E, Sheik Joesoef K, McFadden E, et al. Second-generation everolimus-eluting 
and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. 
Lancet 2010; 375: 201–09.
14. Stone GW, Rizvi A, Newman W, et al. Everolimus-Eluting versus paclitaxel-eluting 
stents in coronary artery disease. N Engl J Med 2010;362:1663-74.
15. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a 
case for standardized definitions. Circulation 2007;115:2344-51.  
16. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in 
primary percutaneous coronary intervention. N Engl J Med 2006;355:1105-13.
17. Vlaar PJ, Svilaas T,van der Horst IC, et al. Cardiac death and re-infarction after 1 
year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute 
myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet 2008; 371: 
1915–20.
18. Arzamendi D, Quoc H, Tanquay JF, et al. Effect on bleeding, time to revascularization, 
and one-Year clinical outcomes of the radial approach during primary PCI in patients 
with STEMI. Am J Cardiol 2010;106:148-154.
19. Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography 
and intervention in patients with acute coronary syndromes (RIVAL). Lancet 2011; 
377:1409–20. 
EES vs. SES in acute MI: XAMI trial
133
20. Chen MS, John JM, Chew DP, et al. Bare metal stent restenosis is not a benign clinical 
entity. Am Heart J 2006;151:1260-64.
21. Dangas GD, Caixeta A, Mehran R, et al. Frequency and predictors of stent thrombosis 
after percutaneous coronary intervention in acute myocardial infarction. Circulation 
2011;123:1745-56.
22. Obata J, Kitta Y,Takano H, et al. Sirolimus-eluting stent implantation aggravates 
endothelial vasomotor dysfunction in the infarct-related coronary artery in patients 
with acute myocardial infarction. J Am Coll Cardiol 2007;50:1305–9.
23. Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents for acute 
myocardial infarction. N Engl J Med 2008;359:1330-42.
24. Brar SS, Leon MB, Stone GW, et al. Use of Drug-eluting stents in acute myocardial 
infarction. A systematic review and meta-analysis. J Am Coll Cardiol 2009;53:1677–
89.
25. Räber L, Windecker S. Primary percutaneous coronary intervention and risk of stent 
thrombosis. A look beyond the HORIZON. Editorial, Circulation 2011;123:1709-12.
26. Hamilos MI, Ostojic M, Beleslin B, et al. Differential effects of drug-eluting 
stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol 
2008;51:2123–9.
27. Silber S, Windecker S, Vranckx P, et al.Unrestricted randomised use of two new 
generation drug-eluting coronary stents: 2-year patient-related versus stent-related 
outcomes from the RESOLUTE All Comers trial. Lancet 2011;377: 1241–47.
28. Räber L, Jüni P, Nüesch E, et al. Long-term comparison of everolimus-eluting 
and sirolimus-eluting stents for coronary revascularization. J Am Coll Cardiol 
2011;57:2143–51.
29. Smits PC, Kedhi E, Royaards K, et al. Two year follow-up of a randomized controlled 
trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in 
daily practice. J Am Coll Cardiol 2011;58:11-8.
30. Kedhi E. COMPARE-AMI: Everolimus-eluting and paclitaxel-eluting stents for  
treatment of ST-elevation myocardial infarction: Two-year clinical outcome. 
Paper presented at: Transcatheter Cardiovascular Therapeutics; September, 2010; 
Washington, DC.
31. Snapinn SM. Non-inferiority trials; Commentary. Curr Control Trials Cardiovasc Med 
2000;1:19-21.
32. EMEA. Points to consider on switching between superiority and non-inferiority.  
London, 27July 2000. http://www.tga.gov.au/pdf/euguide/ewp048299en.pdf

CHAPTER 8
Two-year results of an open-label  
randomized comparison of everolimus- 
eluting stents and sirolimus-eluting stents
M.A. Velders,  
S.H. Hofma,  
J. Brouwer,  
C.J. de Vries,  
M. Queré,  
A.J. van Boven.




Background: Second generation drug-eluting stents were developed to improve the 
safety and efficacy of first generation stents. So far, limited long term randomized 
data exist comparing the second generation everolimus-eluting stents (EES) with first 
generation sirolimus-eluting stents (SES).
Methods: A prospective, open-label, randomized, single center trial comparing EES 
and SES in all-comer patients. The primary endpoint was a composite of cardiac 
mortality, myocardial infarction and target vessel revascularization. Secondary end-
points included individual components of the composite, along with target lesion 
revascularization and stent thrombosis.
Results: In total, 977 patients were randomized, of which 498 patients to EES and 
479 to SES. Average age was 65.2 ± 11.2 years and 71.6% of the population was 
male. Fifty percent of patients were treated for acute coronary syndrome, more 
often for ST-elevation myocardial infarctions in EES patients (13.7% vs. 9.2% in 
SES). In contrast, SES patients more often had prior interventions and showed more 
calcified lesions. Two-year follow-up was available in 98% of patients. The primary 
endpoint occurred in 10.7% of EES patients compared to 10.6% of SES patients (HR 
1.00, 95% CI 0.68-1.48). Additionally, secondary endpoints were similar between 
groups. The rate of stent thrombosis was low for both stent types.
Conclusion: In this all-comer population, there were no differences in endpoints 
between EES and SES during two-year follow-up. Stent thrombosis rates were low, 
supporting the safety of drug-eluting stent appliance in clinical practice.
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Introduction
First generation drug-eluting stents (DES) have reduced the need for revasculariza-
tion procedures compared to bare-metal stents.1 However, introduction of DES did 
not lead to reductions in mortality and re-infarctions but instead was associated 
with a higher incidence of late stent thrombosis (ST).2,3 In order to improve the 
safety and efficacy of DES, second generation stents were developed. Everolimus- 
eluting stents (EES) have shown superior outcomes compared to first generation 
paclitaxel-eluting stents in a wide range of coronary lesions.4,5 Data is starting to 
accumulate for the comparison of EES with first generation and previous golden 
standard sirolimus-eluting stent (SES) but randomized data with long term follow-up 
are limited.6,7
 Our goal was to compare the safety and efficacy of the second generation EES with 
first generation SES in all-comer patients undergoing percutaneous coronary inter-
vention (PCI) during two year follow-up.
Methods
The APPENDIX-AMI trial was a single center, prospective, open-label, randomized 
clinical superiority trial (NTR3170, http://www.trialregister.nl/trialreg/admin/rct-
view.asp?TC=3170) comparing EES (Xience V [Abbott Vascular, Santa Clara, Cali-
fornia]) and SES (Cypher [Cordis, Bridgewater, New Jersey])  in patients treated with 
PCI for any indication. APPENDIX-AMI was a sub-study of the XAMI trial,8 and was 
designed to evaluate the superiority of EES over SES in all-comer patients up to two 
year follow-up. The protocol for this trial and supporting CONSORT checklist are 
available as supporting information; see Checklist S1 and Protocol S1. Inclusion 
ran between 18 September 2007 and 27 May 2010 in the Medical Center Leeu-
warden, the Netherlands. Patients had to be eligible for coronary revascularization 
by PCI and willing to sign informed consent to be entered in the trial. Exclusion 
criteria were: minor patients, intravenous drug or alcohol abusers, patients unable 
to give informed consent, patients with a known allergy for everolimus or sirolimus, 
patients with known intolerance or contra-indications for acetylsalicylic acid or 
clopidogrel and finally patients in whom stent implantation was not deemed tech-
nically possible. Also, patients included in XAMI were not eligible for inclusion in 
APPENDIX-AMI. Patients were randomized in a 1:1 fashion to EES or SES directly 
after angiography using sealed envelopes by research nurses. The randomization 
sequence was based on date of birth, resulting in different stent allocation between 
uneven and even dates. Operators were not blinded to the allocated stent.
In the power analysis performed for the XAMI trial, a primary endpoint rate of 8 
% in both stent groups at 1-year follow-up was assumed. An absolute difference in 
the primary endpoint between the two stents of 6 % at 1 year was accepted, which 
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required in total 600 patients when assuming a power of 80%, an alpha of 0.05 and 
2:1 randomization to EES versus SES (Farr. & Mann testing method). The population 
size of 2000 in APPENDIX-AMI was deduced from the power analysis of the XAMI 
study and was estimated to be able to show a relevant difference in the rate of the 
primary endpoint between the groups. Inclusion was stopped before reaching 2000 
patients after exceeding the planned inclusion period due to a slower than antici-
pated inclusion. 
Ethics statement
The study protocol was approved by the local ethics committee of the Medical 
Center Leeuwarden and the trial was conducted according to the principles of the 
Declaration of Helsinki. All patients gave oral consent before enrollment and 
written informed consent after procedure. Note: APPENDIX-AMI was primarily 
registered as a sub-study under XAMI (NTR1123, http://www.trialregister.nl/trialreg/
admin/rctview.asp?TC=1123). Because enrollment for APPENDIX-AMI started ear-
lier than for XAMI, the start of the inclusion period pre-dated the registration of the 
XAMI study by 1 month.
Procedure
Patients were pretreated with loading doses of aspirin and clopidogrel, in addition to 
intravenous heparin bolus of 5.000 IE in case of acute myocardial infarction. Inter- 
ventions were performed according to local practice by high-volume operators. The 
use of glycoprotein IIb/IIIa inhibitors, thrombus aspiration and balloon pre-dilata-
tion were left up to the discretion of the operator. Aspirin was recommended for life 
and clopidogrel for a minimum of 1 year. 
Follow-up
Protocol-defined follow-up was performed after thirty days, one year and two years 
by either questionnaires or phone contact. Follow-up was gathered by research 
nurses in a blinded fashion. Final event adjudication was performed between phy-
sicians on a consensus-basis in an unblinded fashion. No routine angiographic fol-
low-up was scheduled. Information about in-hospital outcome was obtained from 
the institutional clinical database and by review of hospital records of those dis-
charged to referring hospitals. Patient data were collected on case report forms and 
entered into an online database. Follow-up was planned for three years. 
Study endpoints and definitions
The primary endpoint was a composite of cardiac death, myocardial infarction (MI) 
and target vessel revascularization (TVR). MI was defined as a rise of creatine ki-
nase (CK) more than 3 times the upper limit of normal along with a rise in CK-MB 
with recurrent symptoms and/or new electrocardiographic changes. In acute cor-
onary syndrome patients, re-infarction within 48 hours after index procedure was 
EES vs. SES: APPENDIX-AMI trial
139
defined as a re-elevation of CK of >1.5 times the previous value with elevation of 
CK-MB, along with recurrent symptoms and/or new electrocardiographic changes. 
MI around CABG required a CK rise of >5 times the upper limit or normal. TVR 
was defined as any repeat percutaneous or surgical intervention on any segment of 
the target vessel. Secondary endpoints included the individual components of the 
primary endpoint (cardiac mortality, MI or TVR), in addition to all-cause mortality, 
target lesion revascularization (TLR) and definite or probable ST. TLR was defined 
as any repeat intervention or bypass grafting of the target lesion previously treated 
with stenting along with the 5 mm proximal or distal vessel. ST was defined in ac-
cordance with the Academic Research Consortium definitions.9 
Statistical analyses
Study outcomes were analyzed using both intention-to-treat and per-protocol prin-
ciple. Continuous variables are presented as means with standard deviations or 
medians with interquartile range (IQR) and were compared using Student’s t-test. 
Categorical variables are expressed as counts and percentages and were compared 
by means of Pearson's χ² test. All statistical tests were 2-tailed and a p-value <0.05 
was considered statistically significant. Time-to-event analyses were performed us-
ing Kaplan Meier curves and survival curves were compared using log-rank tests. 
Finally, cox proportional hazards analyses were performed to calculate unadjusted 
and adjusted effect sizes. Adjustment for misbalance between the arms was done 
through multivariable models which included clinical characteristics that signifi-
cantly differed at baseline. In case of limited events, the clinical characteristics 
with the strongest effect size were entered into the multivariable models to avoid 
over-adjustment. 
Results
In total, 977 patients were included in the intention-to-treat analysis; 498 patients 
were randomized to EES and 479 patients to SES. The study flowchart is shown in 
Figure 1. Baseline characteristics (Table 1) showed that the average age was 65.2 ± 
11.2 years and 71.6% of the population was male. Patients in the EES arm less com-
monly suffered a history of hypertension and also less frequently had undergone 
previous PCI or coronary artery bypass grafting compared to SES patients. Further-
more, indication for PCI was more commonly ST-elevation myocardial infarction in 
EES patients, balanced by a higher percentage of PCI for stable angina in patients 
included in the SES arm. Angiographic and procedural characteristics are shown in 
Table 2. EES patients showed a lower percentage of heavily calcified coronary le-
sions compared to SES patients. Also, the vascular access site differed significantly, 
with slightly more radial access in the EES arm. Finally, EES patients were treated 




Figure 1. Study flowchart.







Age, years 65.3 ± 11.3 65.0 ± 11.2 0.688
Male 353 (70.9) 347 (72.4) 0.589
Risk factors
    Insulin dependent diabetes mellitus 22 (4.6) 29 (6.3) 0.248
    Non-insulin dependent diabetes mellitus 28 (5.8) 41 (8.9) 0.072
    Hypertension 208 (42.8) 238 (51.0) 0.012
    Hypercholesterolemia 249 (53.7) 251 (54.9) 0.701
    Family history of cardiovascular disease 263 (55.3) 256 (55.9) 0.843
    Current smoker 133 (27.4) 107 (23.2) 0.137
Previous myocardial infarction 109 (22.1) 108 (22.7) 0.829
Previous percutaneous coronary intervention 83 (16.8) 108 (22.5) 0.023
Previous coronary artery bypass grafting 50 (10.1) 72 (15.0) 0.019
Renal insufficiency 53 (11.6) 45 (10.3) 0.542
Indication for percutaneous coronary intervention
     Stable angina 251 (50.4) 275 (57.4) 0.028
     Non ST-segment elevation myocardial infarction or 
unstable angina
179 (35.9) 160 (33.4) 0.404
     ST-segment elevation myocardial infarction 68 (13.7) 44 (9.2) 0.028
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Target vessel location 0.109
    Left main artery 26 (5.3) 15 (3.2)
    Left anterior descending artery 214 (43.4) 184 (38.7)
    Left circumflex artery 106 (21.5) 131 (27.5)
    Right artery 145 (29.4) 144 (30.3)
    Bypass graft 2 (0.4) 2 (0.4)
Lesion type 0.251
    A 24 (4.9) 35 (7.4)
    B1 192 (39.1) 173 (36.5)
    B2 176 (35.8) 158 (33.3)
    C 99 (20.2) 108 (22.8)
Heavy calcification 65 (13.2) 89 (18.7) 0.019
Chronic total occlusion 18 (3.7) 25 (5.3) 0.229
Bifurcation lesion 116 (23.7) 100 (21.1) 0.338
Visible thrombus 89 (18.1) 72 (15.2) 0.221
Thrombus aspiration 11 (2.3) 7 (1.5) 0.379
Extent of coronary artery disease 0.688
   1-vessel 227 (45.7) 208 (43.4)
   2-vessel 171 (34.4) 166 (34.7)
   3-vessel 99 (19.9) 105 (21.9)
Access site 0.019
    Radial 302 (61.1) 255 (53.7)
    Femoral 192 (38.9) 220 (46.3)
Rotablation 8 (1.6) 4 (0.8) 0.271
Glycoprotein IIb/IIIa blocker 143 (29.2) 106 (22.3) 0.015
Total stent length  (mm) 28.1 ± 19.2 28.1 ± 15.8 0.942
Max stent diameter (mm) 3.1 ± 0.6 3.1 ± 0.5 0.199
Multivessel intervention 95 (19.3) 94 (19.7) 0.851
Number of stents/patients 1.50 ± 0.76 1.47 ± 0.76 0.477
Clinical outcomes at two years (Table 3, Figure 2) were balanced between patients 
treated with EES and SES, resulting in a HR of 1.00 (95% CI 0.68-1.48) for the pri-
mary endpoint rate. This did not change after adjustment for potential misbalance 
between the two groups: EES showed a HR of 1.02 (95% CI 0.68-1.53) compared 
to SES for the primary endpoint rate.  Furthermore, per-protocol analysis showed 
identical results: implantation of EES resulted in a HR of 0.99 (95% 0.81-1.20) for 
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the primary endpoint compared to SES. 
During follow-up, use of dual antiplatelet was similar between the groups. Aspirin 
(or coumadin when indicated) was used for at least 1 year in 97.8% of EES and 
99.3% of SES patients (p=0.053), while 97.7% of EES and 97.8% of SES patients 
used aspirin for at least 2 years (p=0.943). Clopidogrel was used for at least 1 year in 
97.3% of EES and 97.3% of SES patients (p=0.977), while 12.6% of EES and 11.0% 
of SES patients used clopidogrel at the 2-year follow-up moment (p=0.445).













































    Early (0 to 30 days) 0 (0.0) 1 (0.2) 0.308
    Late (30 days to 12 months) 0 (0.0) 1 (0.2) 0.308
    Very late (>12 months) 2 (0.4) 2 (0.4) 0.971




Percentages are cumulative incidences of events based on survival tables.  
*Cardiac mortality, myocardial infarction and target vessel revascularization 
CI = confidence interval; HR = hazard ratio.
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Figure 2. Two-year clinical outcomes. Primary endpoint = composite of cardiac mortality, MI and 
target vessel revascularization.
Discussion
In the present open-label, randomized clinical trial, the primary endpoint was com-
parable between EES and SES during 2-year follow-up. Moreover, secondary end-
points were balanced and definite ST was low in both groups, supporting the safety 
of DES appliance in clinical practice.
The heightened occurrence of late ST in first generation DES compared to bare- 
metal stents led to the development of next generation stents in attempt to improve 
the safety and efficacy of DES.2,3 The COMPARE and SPIRIT trials established the su-
periority of EES over first generation paclitaxel-eluting stents.4,5 Major trials compar-
ing EES with SES, the previous golden standard DES, are on-going but so far mostly 
limited to 1-year follow-up. The current trial compared EES and SES in an all-comer 
population, which included a high percentage of acute coronary syndromes and 
complex lesions such as bifurcations and chronic total occlusions. No differences 
in the primary and secondary endpoints between the 2 limus-based stents were 
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observed during 2-year follow-up.
The findings of this single-center trial are in accordance with the results of the SORT 
OUT IV (Scandinavian Organization for Randomized Trials with Clinical Outcome 
IV) Trial.6 The Danish investigators found no differences in clinical endpoints during 
2-year follow-up, with the exception of a lower rate of definite ST in EES patients. 
ST rates found in SORT OUT IV mirror our results, albeit that the current study was 
underpowered to detect a difference in ST rates. The largest follow-up available to 
date exists in the ISAR-TEST-4 (Intracoronary Stenting and Angiographic Results: 
Test Efficacy of 3-Limus-Eluting Stents-4) trial, showing no differences in outcome 
up to 3 years.7 As both arms of the permanent polymer part of the trial consisted of 
approximately 650 patients, this trial was most likely also underpowered to detect 
differences in ST. Consistent among all previous trials was the similar efficacy of 
both stent types.  The RESET (Randomized Evaluation of Sirolimus-Eluting Versus 
Everolimus-Eluting Stent Trial) and the EXCELLENT (Efficacy of Xience/Promus Ver-
sus Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Inter-
vention) trials further support this by showing comparable rates of late luminal loss 
in these stents during 1-year follow-up.10,11 The comparable efficacy is explained by 
the chemically similar antirestenotic drugs with a virtually identical elution pattern 
applied in these stents, albeit that the total dose is lower in the EES. The characteris-
tics that set EES apart from SES are the slim 81μm struts covered with biocompatible 
fluoropolymer. Compared to the 140 μm struts with polyethylene-co vinyl acetate 
+ poly n-butyl methacrylate polymer used in SES, endothelialization is faster after 
EES implantation. This possibly explains the slight safety benefit of EES over SES as 
incomplete endothelialization of strut surface is a substrate for stent thrombosis.12 
The important influence of polymer on ST was further emphasized in the LEADERS 
(Limus Eluted from A Durable versus ERodable Stent coating) trial, which showed 
an improvement of (very) late ST rates after implantation of stents with a biode-
gradable polymer compared to conventional SES.13 The question whether the final 
solution of long term safety issues will be provided by complete disappearance of 
the stent structure is currently under investigation in the ABSORB II trial.14 
Additional studies focused on comparison of EES with second generation Resolute 
zotarolimus-eluting stents. In both the RESOLUTE All Comers trial and the TWENTE 
trial, no differences in outcome between EES and zotarolimus-eluting stents were 
observed.15,16 Importantly, both stents showed low rates of ST during follow-up, 
supporting the safety of DES appliance in clinical practice. 
Limitations
There are several limitations that apply to the current study. The randomization 
sequence was based on date of birth, which may have been the cause of the partial 
misbalance between the groups, theoretically influencing the outcomes. However, 
adjustment for baseline differences using cox proportional hazards analyses result-
ed in only marginal changes in the effect sizes for the individual endpoints, sug-
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gesting that the misbalance between the arms was of little influence. Furthermore, 
the required population size was deduced from the power analysis of the primary 
study, the XAMI trial. An independent power analysis may have been more accu-
rate. Moreover, the final number of patients was not reached due to inclusion that 
was slower than anticipated and therefore, the trial was underpowered to discrim-
inate between rare events such as ST. Operators were not blinded to the allocated 
stent and event adjudication was performed in an unblinded fashion. This reduced 
the objectivity of the results although the adjudication on consensus basis makes 
it unlikely that one of the stent types would have been favored. Finally, SES are no 
longer in clinical use. However, monitoring clinical outcomes of current and previ-
ously used stents is necessary to provide further evidence for existing devices and 
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Background: Everolimus-eluting stents (EES) were superior to sirolimus-eluting 
stents (SES) in a dedicated myocardial infarction trial, a finding that was not ob-
served in trials with low percentages of ST-elevation myocardial infarction (STEMI). 
Therefore, this study sought to investigate the influence of clinical presentation on 
outcome after EES and SES implantation. 
Methods: A pooled population of 1602 randomized patients was formed from XAMI 
(acute MI trial) and APPENDIX-AMI (all-comer trial). Primary outcome was cardiac 
mortality, MI and target vessel revascularization at 2-years. Secondary endpoints 
included definite/probable stent thrombosis (ST). Adjustment was done using cox 
regression.
Results: In total, 902 EES and 700 SES patients were included, of which 44% STEMI 
patients (EES 455;SES 257) and 56% without STEMI (EES 447;SES 443). In the 
pooled population, EES and SES showed similar outcomes during follow-up. More-
over, no differences in the endpoints were observed after stratification according 
to presentation. Although a trend toward reduced early definite/probable ST was 
observed in EES compared to SES in STEMI patients, long term ST rates were low 
and comparable.
Conclusions: EES and SES showed similar outcome during two-year follow-up, re-
gardless of clinical presentation. Long term safety was excellent for both devices, 
despite wide inclusion criteria and a large sub-population of STEMI patients.
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Introduction
Drug-eluting stents (DES) were designed to reduce the in-stent neointimal hyper-
plasia that commonly occurred in bare-metal stents (BMS). Indeed, first generation 
DES (i.e. paclixatel-eluting stents (PES) and sirolimus-eluting stents (SES)) reduced 
the need for revascularization procedures compared to BMS but were associated 
with higher rates of late stent thrombosis (ST), especially in complex patients such 
as those presenting with myocardial infarction (MI).1-3
Delayed arterial healing and stent malapposition were found to play a role in the 
higher ST rates after DES implantation in setting of MI.4-5 Second generation DES 
were designed to be safer and more effective through changes in stent alloy, strut con-
figuration, polymer and anti-restenotic drugs. So far, second generation everolimus- 
eluting stents (EES) have shown superior results to PES in a wide range of indica-
tions.6 Compared to SES, EES have mostly shown comparable outcomes but im-
provements in ST rates have been observed.7-10 In contrast, one dedicated trial of 
predominantly ST-segment elevation myocardial infarction (STEMI) patients showed 
superiority of EES over SES during short term follow-up.11 Long term randomized 
data are scarce, especially in setting of STEMI. 
This study sought to investigate the influence of clinical presentation on outcome of 
EES and SES during two-year follow-up. 
Methods
Patient-level data from the randomized XAMI and APPENDIX-AMI trials were 
pooled to form the patient population. The design and results of these trials have 
been published previously.11,12 In short, XAMI (NTR1123, http://www.trialregister.
nl/trialreg/admin/ctview.asp?TC=1123) was a multicenter, clinical non-inferiority 
trial randomizing 625 acute MI patients to EES (Xience V [Abbott Vascular, Santa 
Clara, California]) or SES (Cypher [Cordis, Bridgewater, New Jersey]) in a 2:1 ratio. 
To be enrolled, patients had to have STEMI or non-STEMI with an emergency indi-
cation for percutaneous coronary intervention (PCI). Exclusion criteria were: chron-
ic total occlusion as target lesion; known allergy to sirolimus, everolimus, aspirin or 
clopidogrel; inability to obtain informed consent; life expectancy <1 year or stent 
size required to treat lesion >3.5 mm. 
APPENDIX-AMI (NTR3170, http://www.trialregister.nl/trialreg/admin/rctview.as-
p?TC=3170) was a single center open-label trial randomizing 977 all-comer pa-
tients to EES and SES (ratio 1:1). The trial included all patients eligible for coronary 
revascularization by PCI for any indication. Exclusion criteria were: minor patients; 
intravenous drug or alcohol abusers; patients unable or unwilling to give informed 
consent; known allergy for everolimus or sirolimus; known intolerance or con-
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tra-indications for acetylsalicylic acid or clopidogrel and anatomy in which stent 
implantation was not deemed technically possible. 
Patients were pretreated with loading doses of aspirin and clopidogrel, in addition 
to intravenous heparin bolus of 5.000 IE in case of acute MI. Interventions were 
performed according to local practice by high-volume operators. Use of glycopro-
tein IIb/IIIa inhibitors, thrombus aspiration and balloon pre-dilatation were left up 
to the discretion of the operator. Aspirin was recommended for life and clopidogrel 
for a minimum of 1 year. Protocol-defined follow-up was performed after thirty 
days, one year and two years by questionnaires and phone contact. Follow-up was 
gathered by research nurses in a blinded fashion. Event adjudication was performed 
by a blinded clinical event committee in XAMI. In APPENDIX-AMI, event adjudi-
cation was performed between physicians on a consensus-basis in an unblinded 
fashion. The study protocols were approved by the local ethics committees of the 
participating centers and the trials were conducted according to the principles of 
the Declaration of Helsinki. All patients gave oral consent before enrollment and 
written informed consent after procedure.
Definitions
The primary endpoint was a composite of cardiac death, MI and target vessel re-
vascularization (TVR). MI was defined as a rise of creatine kinase (CK) more than 3 
times the upper limit of normal along with a rise in CK-MB with recurrent symptoms 
and/or new electrocardiographic changes. In acute coronary syndrome patients, 
re-infarction within 48 hours after index procedure was defined as a re-elevation of 
CK of >1.5 times the previous value with elevation of CK-MB, along with recurrent 
symptoms and/or new electrocardiographic changes. MI around coronary artery 
bypass grafting required a CK rise of >5 times the upper limit or normal. TVR was 
defined as any repeat percutaneous or surgical intervention on any segment of the 
target vessel. Other secondary endpoints included the individual components of the 
composite endpoint, target lesion revascularization (TLR) and definite or probable 
ST. TLR was defined as any repeat intervention or bypass grafting of the target lesion 
previously treated with stenting along with the 5 mm proximal or distal vessel. ST 
was defined in accordance with the Academic Research Consortium definitions.13 
Statistical analyses
Comparisons were made according to randomized treatment and presentation with 
or without STEMI. Continuous variables are presented as means with standard de-
viations or medians with interquartile range (IQR) and were compared using Stu-
dent’s t-test. Categorical variables are expressed as counts and percentages and 
were compared by means of Pearson's χ² test. All statistical tests were 2-tailed and a 
p-value <0.05 was considered statistically significant. Time-to-event analyses were 
performed using Kaplan Meier curves, which were compared using log-rank tests. 
To adjust for unbalanced baseline characteristics, cox proportional hazards analy-
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ses were performed. The proportional hazards assumption was investigated visually. 
Adjusted effect sizes were calculated for primary and secondary endpoints with a 
p-value less than 0.10 as judged by log rank test. Adjustment was performed for 
characteristics significantly differing between groups (p<0.05), which were incor-
porated in the multivariable models. Analyses were repeated with a variable stating 
the trial the patient originated from, to evaluate the influence of individual trials on 
the results.
To avoid dropping of events due to missing baseline information, multiple imputa-
tion was performed for the baseline variables that were included in the multivari-
able models: presence of heavy calcification was unknown in 4 patients (3 EES and 
1 SES) and total stent length was unknown in 4 patients (3 EES and 1 SES). Reasons 
for missing data were unknown and assumed to be random. Total stent length was 
log transformed to meet the assumption for normal distribution. Missing data values 
were imputed for heavy calcification and total stent length using the following pre-
dictors: age, gender, cardiac risk factors, cardiac history, renal insufficiency, indica-
tion for PCI, target lesion, lesion type, number of vessel disease, heavy calcification, 
total stent length, max stent diameter, number of stents per patient. Twenty imputed 
datasets were created and cox proportional hazards analyses were performed on 
the pooled datasets.14 Analyses were performed using IBM SPSS version 21.
Results
In total, 1602 patients were randomized in the XAMI and APPENDIX-AMI trials, 
of which 902 to EES and 700 to SES.  Two year follow-up data was available for 
1575 patients (98.3%). The presenting diagnosis was stable angina in 526 patients 
(32.8%), unstable angina or non-STEMI in 364 patients (22.7%) and STEMI in 712 
patients (44.4%). After pooling of the 2 trials, the primary endpoint occurred in 
8.8% of EES patients vs. 10.2% of SES patients during 2-year follow-up in the over-
all population, HR 0.86 (95% CI 0.62-1.18), p=0.347. Secondary endpoints were 
also balanced between the groups.
Stratification on presenting diagnosis
STEMI patients were younger than patients without STEMI and more likely to 
smoke but had lower rates of comorbidity and other risk factors (Table 1). Cor-
onary thrombus was more common in STEMI, but rates of heavy calcifica-
tion, bifurcations and multivessel disease were lower. Stent length and number 
of stents used were also lower in STEMI, but stent diameter was slightly larger. 
Finally, glycoprotein IIb/IIIa inhibitor use was more common in STEMI while TIMI 3 
flow after procedure was less often achieved. During 2 year follow-up, STEMI pa-
tients showed lower rates of the primary endpoint (7.2% vs. 11.2%, p=0.007) and 
TLR (1.4% vs. 4.1%, p=0.001) compared to patients without STEMI.
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Age, years 61.8 ± 11.4 62.4 ± 11.5 0.501 65.2 ± 11.3 65.1 ± 11.1 0.868
Male 329 (72.3%) 194 (75.5%) 0.356 319 (71.4%) 319 (72.0%) 0.831
Diabetes mellitus 41 (9.1%) 26 (10.2%) 0.612 73 (16.9%) 80 (18.6%) 0.492
Hypertension* 136 (30.1%) 81 (31.8%) 0.643 191(43.6%) 223 (51.5%) 0.020
Hypercholesterolemia† 124 (27.8%) 60 (23.8%) 0.250 242 (57.5%) 246 (57.9%) 0.906
Current smoker 232 (51.3%) 135 (53.1%) 0.642 121 (27.6%) 94 (21.9%) 0.051
Prior myocardial infarction 32 (7.0%) 19(7.4%) 0.858 100 (22.6%) 102 (23.2%) 0.844
Prior PCI 19 (4.2%) 9 (3.5%) 0.653 81 (18.2%) 105 (23.7%) 0.046
Prior CABG 4 (0.9%) 5 (1.9%) 0.221 47 (10.5%) 71 (16.0%) 0.016
Prior renal insufficiency 8 (1.8%) 6 (2.4%) 0.596 49 (11.8%) 43 (10.6%) 0.598
Presenting diagnosis 0.072
    Stable angina 0 (0.0%) 0 (0.0%) - 251 (56.2%) 275 (62.1%)
    Unstable angina or  
    Non-STEMI
0 (0.0%) 0 (0.0%) - 196 (43.8%) 168 (37.9%)
    STEMI 455 (100%) 257(100%) - 0 (0.0%) 0 (0.0%) -














Data are expressed as mean ± SD, as number (percentage), or as median (interquartile range). CABG = 
Coronary artery bypass grafting. * Blood pressure 140/90 mm Hg or previous pharmacologic treatment. 
† Total cholesterol 190 mg/dl or previous pharmacologic treatment.
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Target coronary lesion 0.651 0.108
    Left main artery 0 (0.0%) 1 (0.4%) 26 (5.9%) 15 (3.4%)
    Left anterior 
    descending artery
175 (38.5%) 104 (40.5%) 195 (44.0%) 175 (39.8%)
    Left circumflex artery 86 (18.9%) 50 (19.5%) 96 (21.7%) 124 (28.2%)
    Right coronary artery 192 (42.3%) 101 (39.3%) 124 (28.0%) 124 (28.2%)
    Bypass graft 1 (0.2%) 1 (0.4%) 2 (0.5%) 2 (0.5%)
Multivessel disease 206 (45.3%) 130 (50.6%) 0.173 249 (55.8%) 252 (56.9%) 0.751
Bifurcation intervention 55 (12.1%) 37 (14.4%) 0.390 107 (24.4%) 98 (22.4%) 0.496
Heavy calcification 26 (5.8%) 28 (10.9%) 0.013 62 (14.0%) 85 (19.4%) 0.032
Lesion type B2/C 300 (66.7%) 171 (67.6%) 0.803 245 (55.4%) 241 (55.0%) 0.903
Visible thrombus 383 (84.5%) 223 (87.1%) 0.352 49 (11.1%) 39 (8.9%) 0.276
Thrombosuction 250 (54.9%) 142 (55.3%) 0.937 11 (2.5%) 6 (1.4%) 0.222
Total stent length (mm) 25.3 ± 14.7 27.7 ± 16.5 0.046 28.2 ±18.9 28.2 ±16.0 0.986
Max stent diameter 
(mm)
3.1 ± 0.4 3.1 ± 0.3 0.676 3.1 ± 0.6 3.1 ± 0.5 0.436
No. of stents/patients 1.4 ± 0.7 1.4 ± 0.7 0.396 1.5 ± 0.7 1.5 ± 0.8 0.475
Glycoprotein IIb/IIIa 
inhibitor treatment
346 (76.0%) 196 (76.3%) 0.947 98 (22.3%) 82 (18.7%) 0.181
Postprocedural TIMI 
flow grade 3
431 (94.9%) 238 (92.6%) 0.206 428 (98.2%) 420 (97.0%) 0.262




In the STEMI population, EES patients less frequently showed heavily calcified le-
sions and total stent length was shorter compared to SES (Table 2). During two-year 
follow-up, randomization to EES resulted in a similar primary endpoint rate (un- 
adjusted HR 0.63, 95% CI 0.36-1.09, p=0.097, adjusted HR 0.66, 95% CI 0.38-
1.15, p=0.141) compared to SES (Table 3, Figure 1). A trend was observed for a re-
duction in early definite/probable ST in EES. However, long term ST rates were low 
and similar (Figure 2). At 1-year, aspirin (or coumadin) compliance was 94.8% in 
EES versus 91.5% in SES (p=0.092). Thienopyridine compliance was 95.6% in EES 
versus 91.8% in SES (p=0.040). Two patients were not on dual antiplatelet therapy 
at the time of ST, 1 EES and 1 SES patient, both suffering probable ST.














Primary composite endpoint* 27 (6.0) 24 (9.3) 0.099 51 (11.7) 46 (10.6) 0.624
Mortality
    All-cause 15 (3.3) 14 (5.4) 0.173 25 (5.7) 19 (4.4) 0.370
    Cardiac 10 (2.2) 8 (3.1) 0.470 16 (3.7) 10 (2.3) 0.242
Myocardial infarction 6 (1.3) 5 (1.9) 0.527 6 (1.4) 8 (1.9) 0.578
Target vessel revascularization 15 (3.3) 13 (5.1) 0.258 33 (7.6) 32 (7.4) 0.928
Target lesion revascularization 7 (1.6) 3 (1.2) 0.674 19 (4.4) 17 (3.9) 0.755
Stent thrombosis
    Definite 3 (0.7) 0 (0.0) 0.190 3 (0.7) 4 (0.9) 0.695
    Definite/probable 6 (1.3) 7 (2.7) 0.186 4 (0.9) 5 (1.2) 0.727
        Early 3 (0.7) 6 (2.3) 0.057 1 (0.2) 2 (0.5) 0.558
        Late 2 (0.4) 1 (0.4) 0.913 0 (0.0) 1 (0.2) 0.315
        Very late 1 (0.2) 0 (0.0) 0.449 3 (0.7) 2 (0.5) 0.661
Values are expressed as number (percentage). *Cardiac mortality, myocardial infarction and target  
vessel revascularization.
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In the population without STEMI, EES patients showed lower rates of hypertension, 
prior PCI, bypass grafting and heavy calcification compared to SES patients (Table 1, 
Table 2). At 2-years, EES and SES showed similar rates of the primary endpoint (HR 
1.10, 95% CI 0.74-1.64, p=0.637) (Table 3, Figure 3). Other secondary endpoints 
were also balanced. Definite/probable ST rates were low and similar between the 
groups (Figure 4). Aspirin compliance during 1-year was 97.6% in EES and 99.3% 
in SES (p=0.047). Thienopyridine compliance was 96.8% in EES and 97.5% in SES 
(p=0.518).
The p-value for interaction between randomized stent and presenting diagnosis 
(STEMI vs. other) was 0.104 (HR 1.76, 95% CI 0.89-3.46) for the primary endpoint. 
Figure 1. Two-year primary outcome according to randomized 
stent in STEMI patients. Primary composite endpoint = cardiac 
mortality, MI, TVR.
Figure 2. Definite/probable stent thrombosis with landmark  
analysis at 30-days in STEMI population.
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Figure 3. Two-year primary outcome according to randomized 
stent in patients without STEMI. Primary composite endpoint = 
cardiac mortality, MI, TVR.
Figure 4. Definite/probable stent thrombosis with landmark 
analysis at 30-days in population without STEMI.
Discussion
The present pooled analysis of the randomized XAMI and APPENDIX-AMI trials 
provided 2-year outcome data of EES and SES according to clinical presentation. 
The performance of the first and second generation DES was found to be similar and 
independent of clinical presentation. Importantly, despite wide inclusion criteria 
and a large sub-population of STEMI patients, both devices showed a comparable 
safety at long term follow-up.
Implantation of first generation DES in the previously off-label indication of acute 
MI was controversial until publication of the HORIZONS-AMI trial, which con-
firmed the safety and efficacy of PES compared to BMS in primary PCI.15 Supe-
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riority of second generation EES over PES in acute coronary syndromes has been 
established but data comparing EES with previous golden standard SES are less 
abundant, especially in setting of STEMI.16 In SORT OUT IV, EES and SES showed 
comparable outcomes up to 2 years, with the exception of a lower rate of definite 
ST in EES patients.7 However, only 10% of patients presented with STEMI. The other 
major trials that compared EES and SES showed no differences in outcome up to 
3-year follow-up.8-10 Also in these trials, the STEMI population was strongly un-
derrepresented, making randomized data of EES and SES in STEMI patients scarce 
beyond 1-year. In contrast, almost half of patients included in the current study 
presented with STEMI. 
In the STEMI population of the present study, event rates were lower than in the 
population without STEMI, likely explained by the more complex coronary artery 
disease in an all-comer population compared to the usually less complex thrombot-
ic lesions of STEMI patients. Although EES appeared to perform slightly better than 
SES, no significant differences in the primary outcome measure were observed. 
Nonetheless, a strong trend toward reduced early definite/probable ST hinted at a 
possible advantage of EES over SES in the early phase after MI. In contrast, clinical 
outcomes were balanced between EES and SES in patients presenting with a diag-
nosis other than STEMI, which is in accordance with previous trials.8-10 
Findings observed in the STEMI population were comparable to reports of the EX-
AMINATIONS trial, in which EES use resulted in a lower rate of early definite/
probable ST compared to BMS in STEMI patients.17 At 1-year, the definite/probable 
ST rate was 0.9% in the EES group; comparable to the 1.1% rate observed in this 
study. Additionally, Kalesan et al. performed a propensity matched comparison of 
EES and SES in ACS patients and found a reduction in both the primary endpoint 
and ST during 3-year follow-up.18
Important differences of EES compared to SES are the thin strut design (81 μm vs. 
140 μm) and the biocompatible polymer. In ex-vivo and in-vivo models, thin struts 
were less thrombogenic and the slim design of EES has been associated with faster 
endothelialization compared to SES.19,20 Also, the biocompatible polymer of EES 
may be associated with a reduced long term inflammatory response.  While the 
current study found reassuringly low rates of ST in both DES up to 2-year follow-up, 
very long term monitoring is necessary to establish a potential benefit of EES over 
SES. This is relevant because in the TYPHOON trial, SES showed a late ‘catch-up’ 
phenomenon for ST, i.e. the relatively low early ST rates were abolished by higher 
very late ST rates compared to BMS in STEMI patients during 4 year follow-up.21 
Although the polymer applied in EES is more biocompatible than the SES polymer 
coating, additional improvement may be achieved with a biodegradable polymer 
coating. The COMFORTABLE AMI trial compared biolimus-eluting stents with BMS 
in STEMI patients but did not find a reduction in 1-year definite/probable ST.22 How-
ever, long term follow-up will have to show if STEMI patients benefit from DES with 
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biodegradable polymer, as the main effect of a biodegradable polymer in reducing 
ST becomes evident after 1 year.23
Limitations
Our study is limited by its post hoc nature and therefore findings should be consid-
ered hypothesis-generating. XAMI included patients with STEMI or NSTEMI with 
emergency indication, while APPENDIX-AMI included all-comer patients. Further-
more, the randomization rate differed between XAMI (2:1) and APPENDIX-AMI 
(1:1) which created baseline misbalance between the groups, although multivari-
able corrections were performed to correct for these differences. Also, the analysis 
was underpowered to detect differences in the ST rates. 
Conclusions
The present pooled analysis of the XAMI and APPENDIX-AMI trials found similar 
outcomes between EES and SES during 2-year follow-up, regardless of presenting 
diagnosis. Long term ST rates were reassuringly low in both stent types. 
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Summary
The general introduction of this thesis (Chapter 1) provided an overview of the 
epidemiology, pathophysiology, risk factors and diagnosis of coronary heart disease 
with a focus on ST-elevation myocardial infarction (STEMI). Additionally, a histor-
ical background of STEMI treatment was provided, with an extensive overview on 
coronary stenting. The final section discussed risk stratification of STEMI patients.
The identification of patients at risk for recurrent events is more important than ever, 
in the current era of increasingly limited health care budgets and growing global 
burden of coronary heart disease. The first part of this thesis aimed to improve 
the care and risk stratification of STEMI patients, through identification of high risk 
sub-populations.
Additionally, novel technological developments in coronary stenting may proof 
beneficial for reducing patient morbidity and mortality and its associated health 
care costs. The second part of this thesis focused on the optimization of treatment of 
coronary heart disease by appliance of second generation drug-eluting stents (DES). 
Part 1
Chapters 2, 3 and 4 were based on data provided by a collaboration of 3 Dutch 
tertiary centers (the Leiden University Medical Center, the Medical Center Alkmaar 
and the Medical Center Leeuwarden), which supply STEMI care for a total area 
of approximately 1.85 million inhabitants. During a 4 year inclusion period, all 
patients treated with primary percutaneous coronary intervention (PCI) for STEMI 
were prospectively registered and pooled in a large patient-level database. Data on 
pre-hospital delay were collected through cooperation with local emergency med-
ical systems and vital status was obtained through municipality records. Chapter 2 
investigated the influence of gender on delay to treatment and outcome after STEMI. 
In total, 3483 patients were included in the multicenter registry, among which 868 
women (25%). At baseline, women were older, showed a higher risk factor burden 
and were more frequently known with non-cardiac comorbidity compared to men. 
In contrast, men showed higher rates of atherosclerosis-related disease. Median time 
between onset of symptoms and reperfusion therapy was almost 20 minutes longer 
in women. However, this delay could be explained by comorbidity and age. During 
1-year follow-up, mortality was significantly higher in women (9.9% vs. 6.6% in 
men), due to higher mortality in the first 7 days after primary PCI.  After adjustment 
for confounders, female gender was found to predict early but not long term mor-
tality. The reasons for the higher early mortality in women remain speculative, as 
none of the measured confounders could explain the effect on adverse outcome. 
In chapter 3, we sought to identify angiographic factors related to the occurrence 
and prognosis of a devastating complication of STEMI; out-of-hospital cardiac arrest 
(OHCA). OHCA patients were included in the registry if spontaneous circulation 
had returned on arrival at the catheterization laboratory. OHCA had occurred in 
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6.4% (N=224/3483) of patients undergoing primary PCI for STEMI. Cardiogenic 
shock was common in OHCA patients (30.8% vs. 4.8% in patients without OHCA). 
In two thirds of patients, OHCA had occurred before arrival of emergency medical 
systems and ventricular fibrillation was most commonly the first observed rhythm. 
Angiographic culprit lesion was associated with risk of OHCA: left coronary culprit 
lesions showed the highest risk of OHCA, with proximal lesions resulting in higher 
risk than non-proximal lesions. Risk was lowest for right coronary culprit lesions. 
In-hospital neurological outcome and 1-year survival did not differ according to 
culprit lesion. However, culprit location was associated with success of reperfusion 
and risk of cardiogenic shock, both of which were driving factors of prognosis after 
OHCA. Chapter 4 investigated the influence of cancer on the prognosis after STEMI. 
During the inclusion period, 208 patients had a known history of cancer (6.0%). In 
(previous) cancer patients, the last diagnosis was made ≤6 months ago in 20.7%, 6 
months-3 years ago in 21.7% and >3 years ago in 57.6% of patients. Patients with 
a history of cancer were older, more often female and more frequently known with 
hypertension and prior myocardial infarction. Additionally, comorbidity such as 
peripheral vascular disease, cerebrovascular disease, renal insufficiency and ane-
mia were more common. During PCI, cancer patients were treated less often with 
coronary stents, but procedural success was comparable to patients without cancer. 
As anticipated, cancer patients showed higher all-cause mortality during follow-up. 
However, also cardiac mortality was higher compared to patients without cancer, 
which was due to especially high early cardiac mortality in the population with a 
recent cancer diagnosis (HR 3.34, 95% CI 1.57-7.08). The effect on prognosis was 
partly explained by anemia and development of cardiogenic shock during PCI, 
while previous treatment with chemotherapy did not influence prognosis. Because 
part of the effect of cancer on STEMI prognosis remained unexplained, a cancer 
specific influence on prognosis was suspected. 
Chapter 5 described a study based on SCAAR (the Swedish Coronary Angiogra-
phy and Angioplasty Registry), a nationwide registry for angiography and PCI in 
Sweden. Using SCAAR, consecutive elderly patients (aged≥80 years) undergoing 
primary PCI for STEMI during a 10-year inclusion period were identified. Temporal 
trends in presentation, care and 1-year prognosis were investigated, as well as long 
term outcome compared to a control group of patients aged 70-79 years. Relative 
survival was calculated by dividing the observed survival rate with the expected sur-
vival rate of the general population. In total, 4876 elderly patients were included. 
Average age was observed to increase over time, and the share of nonagenarians 
more than doubled. Also, risk factor burden and comorbidity increased, while the 
rate of patients with prior MI decreased. Total ischemic time was found to improve 
markedly during the inclusion period, and also use of antithrombotic therapy be-
fore and during PCI increased. One-year rates of mortality, myocardial infarction 
and heart failure generally remained stable during the inclusion period, although 
a significant difference in mortality between the earliest and latest cohort was ob-
served. Additionally, stroke and bleeding risk were similar over time. Higher age 
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was associated with increased risk of adverse events such as stroke and bleeding 
after primary PCI. Nevertheless, elderly patients surviving the early phase after pri-
mary PCI showed a slightly higher survival compared to the general population up 
to 3-year follow-up.
Part 2
Part 2 focused on the comparison of drug-eluting stents using observational and 
randomized designs. In chapter 6, the long term performance of the second genera-
tion everolimus-eluting stents (EES) and Endeavor zotarolimus-eluting stents (E-ZES) 
were compared in 931 STEMI patients. In this observational study, consecutive 
patients treated in the Leiden University Medical Center between January 2007 
and October 2010 were stratified according to stent type, and followed up to 3 
year post-PCI. Adjusted endpoints were calculated using cox proportional hazards 
analyses. The two groups were largely comparable at baseline. At 1 year follow-up, 
EES patients showed lower rates of the device-oriented composite endpoint of 
cardiac death, target vessel-related MI and target lesion revascularization com-
pared to E-ZES patients; adjusted HR 0.56 (95% CI 0.32-0.97). This reduction was 
sustained up to 3-year follow-up (adjusted HR 0.64, 95% CI 0.42-0.99), and was 
mainly driven by reduced target lesion revascularization. Stent thrombosis (ST) rates 
were low and did not differ between the groups, supporting the safety of second 
generation DES in setting of STEMI. 
Chapter 7 described the results of the XAMI trial, a multicenter randomized clinical 
non-inferiority trial comparing EES and sirolimus-eluting stents (SES) in patients with 
acute MI (STEMI or Non-STEMI with emergency indication for PCI). The pre-defined 
non-inferiority margin was 6%. In total, 625 patients were randomized in a 2:1 
ratio, of which 404 to EES and 221 to SES. STEMI was the indication for PCI in 
96% of cases. The primary endpoint of cardiac death, non-fatal MI and target ves-
sel revascularization occurred in 4.0% of EES patients and 7.7% of SES patients at 
1-year, meeting the non-inferiority criterion. Moreover, superiority of EES over SES 
was suggested (RR 0.52, 95% CI 0.27-1.00, p=0.048) and primary endpoint curves 
were still diverging at one year follow-up. 
The evaluation of EES and SES was extended to the entire spectrum of coronary 
heart disease in chapter 8, which reported the results of the APPENDIX-AMI trial. 
This single center, all-comer, open-label trial randomized 977 patients to treatment 
with EES or SES. Initially aimed to include 2000 patients, this number was not 
reached due to slower than expected inclusion. At baseline, approximately half of 
the patient population presented with an acute coronary syndrome, with a slightly 
higher percentage of STEMI patients in the EES arm. Hypertension, prior cardiac 
interventions and heavy calcifications were more common in SES patients. Cox pro-
portional hazards analyses were performed to correct for these differences. During 
2-year follow-up, EES and SES showed no differences in the unadjusted and adjust-
ed primary endpoint of cardiac mortality, MI and target vessel revascularization. 
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Moreover, individual end points were balanced between the groups.
The final chapter explored the response of second and first generation DES im-
plantation in different clinical settings, to investigate the potential differences in 
outcome in patients with and without STEMI (chapter 9). To achieve this, the patient 
populations of XAMI and APPENDIX-AMI were pooled and followed for 2 years 
for the occurrence of events. After combination of the trials, a patient-level pooled 
population of 1602 patients was formed. Overall, EES and SES showed similar out-
come up to two-year follow-up. Subsequently, stratification was performed accord-
ing to clinical presentation. Almost half of the pooled population presented with 
STEMI, of which 455 EES patients and 257 SES patients. The rest of the population 
presented without STEMI (447 EES and 443 SES).  Minor differences in baseline 
characteristics were corrected using cox proportional hazards analysis. At 2-year 
follow-up, the primary endpoint of cardiac death, MI and TVR occurred in a similar 
rate between EES and SES, regardless of clinical presentation. A trend for reduced 
early definite/probable ST was observed in EES compared to SES in STEMI patients, 
but long term ST rates were low and comparable between the two devices. This 
analysis suggests that EES and SES are equally safe and efficacious in patients from 
the entire range of clinical practice, with no influence of clinical presentation. 
Conclusions and future perspectives
The rapid development of STEMI care has been one of the most impressive feats 
in medical history. Nevertheless, the global burden of coronary heart disease is 
increasing and continuous scientific effort is required to reduce the load.  The first 
part of this thesis identified several high-risk sub-populations to improve the care 
and risk stratification of STEMI patients. It was observed that common patient char-
acteristics such as female gender, cancer and old age have a strong impact on the 
delay to reperfusion therapy and prognosis of STEMI patients. The distinct nature of 
increased risk among these sub-populations indicates the need for further research 
on care tailored toward these high-risk individuals. Furthermore, the historically 
devastating complication of out-of-hospital cardiac arrest continues to have an im-
pact of the STEMI population. Angiographic determinants of the occurrence and 
prognosis of out-of-hospital cardiac arrest were identified, which may improve the 
care of these high-risk patients. 
The second part of this thesis investigated the use of second generation drug-eluting 
stents for the treatment of coronary heart disease. Among the second generation 
DES, EES showed superior results compared to E-ZES in a real world cohort of 
STEMI patients. A randomized acute MI trial subsequently established the non-in-
feriority of EES to the first generation SES, with results suggesting superiority. In 
contrast, EES and SES performed similarly in an all-comer trial, which prompted 
a pooling of the two trials to investigate the influence of clinical presentation on 
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outcomes. EES and SES were found to perform similarly during 2-year follow-up, 
regardless of clinical presentation. The low rates of stent thrombosis and the similar 
efficacy confirmed the usefulness of both stents in the entire range of patients with 
coronary heart disease, most notably those with STEMI. 
Despite these promising results, concerns remain about the effect of the permanent 
polymer layer on the coronary environment. Novel generation DES designs include 
polymer free stents and stents with biodegradable polymer. Theoretically, these 
stents offer the antirestenotic benefit of DES with a similar long term safety profile 
as bare-metal stents. Biodegradable scaffolds further extent this concept, leading to 
complete absorption of the stent within years after implantation. Future trials should 
explore the value of these promising devices in STEMI patients.  
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Samenvatting
De introductie van dit proefschrift (Hoofdstuk 1) geeft een overzicht van de 
epidemiologie, pathofysiologie, risicofactoren en diagnostiek van coronaire hart- 
ziekten, met speciale aandacht voor het ST-elevatie myocard infarct (STEMI). Daar-
naast werd een historisch overzicht van de STEMI-zorg gegeven, met uitgebreide 
achtergrondinformatie over coronary stents. Tot slot is ingegaan op de risico- 
stratificatie van STEMI patiënten.
Het identificeren van patiënten met risico op  herhaling van events is belangrijker 
dan ooit, in de huidige tijd van financiële beperkingen in de gezondheidszorg en de 
toenemende last van coronaire hartziekten wereldwijd. Deel 1 van dit proefschrift 
heeft als doel de zorg en risicostratificatie van STEMI patiënten te verbeteren, door 
middel van de identificatie van hoog-risico subpopulaties.
Daarnaast bieden nieuwe technologische ontwikkelingen op het gebied van 
coronary stents  mogelijk voordelen voor het verminderen van morbiditeit en 
mortaliteit en de daarmee geassocieerde kosten voor de gezondheidszorg. Deel 2 
van dit proefschrift richt zich op de optimalisatie van de behandeling van coronaire 
hartziekten door middel van tweede generatie drug-eluting stents.
Deel 1
De hoofdstukken 2,3 en 4 zijn gebaseerd op gegevens die verzameld werden via 
een samenwerking van 3 Nederlandse tertiaire ziekenhuizen (het Leids Univer- 
sitair Medisch Centrum, het Medisch Centrum Alkmaar en het Medisch Centrum 
Leeuwarden). Deze ziekenhuizen voorzien gezamenlijk een gebied van 1.85 mil-
joen inwoners van STEMI zorg. Alle patiënten die gedurende een periode van 4 
jaar een primaire percutane coronaire interventie (PCI) voor STEMI ondergingen 
werden prospectief geregistreerd en samengevoegd in een database. Gegevens 
over het voortraject werden verzameld door samenwerking met lokale ambulance-
diensten en overlevingsstatus werd verkregen door middel van de gemeentelijke 
basisadministratie. Hoofdstuk 2 onderzocht de invloed van geslacht op ischemie- 
tijden en de prognose na STEMI. In totaal werden er 3483 patiënten geïncludeerd 
in de multicenter registratie, waarvan 868 vrouwen (25%). Vrouwen waren 
ouder, toonden meer risicofactoren en waren vaker bekend met niet-cardiale co- 
morbiditeit vergeleken met mannen. Mannen hadden daarentegen vaker een voor-
geschiedenis van atherosclerose-gerelateerde aandoeningen. De mediane tijd tus-
sen het ontstaan van de klachten en reperfusie therapie was bijna 20 minuten langer 
bij vrouwen. Deze vertraging kon echter verklaard worden door hogere leeftijd en 
aanwezigheid van comorbiditeit. Mortaliteit was significant verhoogd bij vrouwen 
gedurende 1-jaars follow-up (9.9% vs. 6.6% bij mannen), door een hogere sterfte 
in de eerste 7 dagen na primaire PCI. Na correctie voor confounders bleek vrouwe- 
lijk geslacht een onafhankelijke voorspeller voor vroege maar niet late sterfte. De 
oorzaak van de hogere vroege sterfte in vrouwen blijft speculatief, omdat geen van 
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de gemeten confounders het effect op de uitkomsten kon verklaren. In hoofdstuk 
3 onderzochten we angiografische determinanten van het ontstaan en de prognose 
van een ernstige complicatie van STEMI: een acute hartstilstand buiten het zieken- 
huis, ook bekend als out-of-hospital cardiac arrest (OHCA).  OHCA patiënten 
werden geïncludeerd in de registratie indien herstel van spontane circulatie was 
opgetreden bij aankomst op het katheterisatie laboratorium. STEMI werd gecom-
pliceerd door OHCA in 6.4% (N=224/3483) van de met primaire PCI behandel-
de patiënten. Cardiogene shock was veelvoorkomend in OHCA patiënten (30.8% 
vs. 4.8% in patiënten zonder OHCA). OHCA vond plaats vóór aankomst van am-
bulance personeel in twee derde van de gevallen, en ventrikelfibrilleren was het 
meest geobserveerde eerste ritme. Angiografische culprit laesie was gerelateerd 
aan risico op OHCA: het hoogste risico op OHCA bestond bij culprit locaties in 
de linker coronairarterie. Dit risico steeg naarmate de culprit laesie zich meer 
proximaal in de arterie bevond. Risico op OHCA was het laagst voor patiënten met 
een culprit laesie in de rechter coronairarterie. Neurologisch herstel in het zieken-
huis en 1-jaars overleving verschilden niet tussen de verschillende culprit laesies. 
Locatie van de culprit laesie was echter wel gerelateerd aan het succes van re- 
perfusie therapie en het risico op cardiogene shock, welke drijvende factoren 
waren voor de prognose na OHCA. Hoofdstuk 4 onderzocht de invloed van 
kanker op de prognose na STEMI. Gedurende de inclusie periode hadden 208 
STEMI patiënten een voorgeschiedenis van kanker (6.0%). De meest recente dia- 
gnose van kanker was ≤6 maanden geleden in 20.7%, 6 maanden – 3 jaar geleden 
in 21.7% en meer dan 3 jaar geleden gemaakt in 57.6% van deze patiënten. 
Patiënten met een verleden van kanker waren ouder, vaker van het vrouwe- 
lijk geslacht en vaker bekend met hypertensie en eerdere hartinfarcten. Daarnaast 
kwamen comorbiditeit zoals perifeer vaatlijden, cerebrovasculaire ziekte, nier- 
insufficiëntie en anemie vaker voor. Tijdens primaire PCI werden patiënten met een 
verleden van kanker minder vaak behandeld met coronary stents, maar procedu-
reel succes was vergelijkbaar met patiënten zonder kanker. Zoals verwacht was de 
‘all-cause’ mortaliteit hoger in patiënten met een kanker diagnose. Maar daarnaast 
was ook de cardiale mortaliteit hoger in deze patiënten, als gevolg van een hogere 
vroege cardiale sterfte in patiënten met een recente kanker diagnose (HR 3.34, 95% 
CI 1.57-7.08). Het effect van kanker op de prognose kon deels verklaard worden 
door anemie en het ontwikkelen van cardiogene shock, terwijl eerdere behandel-
ing met chemotherapie geen invloed had op de prognose. Een kanker-specifieke 
invloed op de cardiale prognose werd vermoed, omdat een deel van het effect van 
kanker op de prognose van STEMI onverklaard bleef. 
Hoofdstuk 5 beschrijft een studie die gebaseerd was op gegevens van SCAAR (the 
Swedish Coronary Angiography en Angioplasty Registry), het nationale Zweedse 
register voor angiografie en PCI. Door middel van SCAAR werden alle STEMI pa-
tiënten van 80 jaar en ouder geïdentificeerd die gedurende een periode van 10 jaar 
met primaire PCI waren behandeld. Naast trends in veranderingen van presentatie, 
zorg en 1-jaars prognose werden de lange-termijn resultaten van de ouderen verge-
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leken met een controle groep van patiënten tussen de 70 en 80 jaar oud. Relatieve 
overleving werd berekend door de geobserveerde overleving te delen door de ver-
wachtte overleving van de algemene populatie. In totaal werden er 4876 oudere 
STEMI patiënten geïncludeerd. De gemiddelde leeftijd liep op tijdens de observatie 
periode, en het aandeel patiënten van 90 jaar of ouder verdubbelde. Daarnaast 
namen risicofactoren en comorbiditeit toe, terwijl het aantal patiënten met een eer-
der hartinfarct af nam. De totale ischemie tijd verbeterde sterk tijdens de inclusie 
periode, en het gebruik van antitrombotische therapie voor en tijdens PCI nam 
toe. Sterfte, myocardinfarcten en opnames voor hartfalen in het eerste jaar na PCI 
ble-ven vergelijkbaar tijdens de inclusie periode, al werd er wel een significant 
verschil in sterfte tussen het eerste en het meest recente cohort gezien. Daarnaast 
bleef het percentage patiënten met beroertes en bloedingen gelijk. Hogere leeftijd 
was geassocieerd met een sterk toegenomen risico op adverse events na primaire 
PCI. Desondanks was de langetermijnoverleving voor de ouderen STEMI populatie 
hoger vergeleken met de algemene populatie, indien de vroege fase na primaire 
PCI overleefd werd. 
Deel 2
Deel 2 richtte zich op de evaluatie van drug-eluting stents (DES) in zowel observationele 
als gerandomiseerde setting. Hoofdstuk 6 beschrijft de vergelijking van twee tweede 
generation DES, de everolimus-eluting stent (EES) en de Endeavor zotarolimus- 
eluting stent (E-ZES). Het observationele onderzoek includeerde 931 STEMI patiënten 
die werden behandeld met primaire PCI tussen januari 2007 en oktober 2010 in het 
Leids Universitair Medisch Centrum. Stratificatie vond plaats op basis van stent type 
en patiënten werden gevolgd tot 3 jaar na PCI. Gecorrigeerde eindpunten werden 
berekend door middel van cox proportional hazards analyses. De groepen waren 
grotendeels vergelijkbaar op baseline. Het gecombineerde eindpunt van cardiale 
sterfte, target-vessel gerelateerde MI en target lesion revascularization kwam sig-
nificant minder voor in de EES groep vergeleken met E-ZES na 1-jaar follow-up; 
gecorrigeerde HR 0.56 (95% CI 0.32-0.97). Deze vermindering werd doorgezet 
tot 3 jaar na PCI (gecorrigeerde HR 0.64, 95% CI 0.42-0.99), wat met name werd 
veroorzaakt door een vermindering in target lesion revascularization. De veiligheid 
van tweede generatie DES in STEMI werd gesteund door de lage incidentie van 
stent trombose (ST).
De resultaten van XAMI werden besproken in hoofdstuk 7. XAMI was een multi- 
center, klinische non-inferiority trial waarin patiënten met een acuut hartinfarct 
(STEMI of non-STEMI met een indicatie voor spoed PCI) gerandomiseerd werden 
naar behandeling met de eerste generatie sirolimus-eluting stents (SES) of de EES. 
De van te voren gedefinieerde non-inferiority grens lag op 6%. In totaal werden 
626 patiënten in een 2:1 ratio gerandomiseerd naar EES (N=404) of SES (N=221). In 
96% van de gevallen was STEMI de indicatie voor PCI. Het primaire eindpunt van 
cardiale sterfte, niet-fatale MI en target vessel revascularization vond plaats in 4.0% 
van de EES patiënten en 7.7% van de SES patiënten na 1-jaar follow-up, de non- 
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inferiority van EES bevestigend. Daarnaast suggereerden de resultaten superioriteit 
van EES over SES voor het primaire eindpunt (RR 0.52; 95% CI 0.27-1.00, p=0.048), 
en bleven de event curves verder uiteenlopen gedurende follow-up. 
Hoofdstuk 8 beschrijft de resultaten van de APPENDIX-AMI studie, een single- 
center, all-comer, open-label trial waarin 977 patiënten vanuit het gehele spectrum 
van coronaire hartziekten werden gerandomiseerd naar behandeling met EES of 
SES. Initieel had APPENDIX-AMI het doel om 2000 patiënten te includeren maar 
dit aantal werd niet gehaald als gevolg van een inclusie die langzamer verliep dan 
verwacht. Ongeveer de helft van de studiepopulatie presenteerde zich met een 
acuut coronair syndroom, waarvan een licht hoger percentage patiënten met STEMI 
in de EES groep. Daarnaast waren hypertensie, eerdere cardiale ingrepen en cal-
cificaties vaker voorkomend in de SES groep. Cox proportional hazards analyses 
werden uitgevoerd om te corrigeren voor deze baseline verschillen. Er werden geen 
verschillen tussen EES en SES in de primaire uitkomstmaat van cardiale sterfte, MI 
en target vessel revascularization gezien gedurende 2 jaar follow-up.  Daarnaast 
waren individuele uitkomsten vergelijkbaar tussen de groepen.
Het laatste hoofdstuk (hoofdstuk 9) onderzocht de response op eerste en tweede 
generatie DES implantatie in verschillende klinische settings, om potentiële ver-
schillen in uitkomsten bij patiënten met en zonder STEMI te onderzoeken. Om dit 
te bewerkstelligen werden de patiëntenpopulaties van de XAMI en APPENDIX-AMI 
trials gecombineerd en gevolgd gedurende 2 jaar follow-up. Na combinatie van de 
trials onderstond een populatie van 1602 patiënten. In de gecombineerde populatie 
toonden EES en SES geen verschillen in uitkomsten na 2 jaar. Vervolgens werden 
patiënten gestratificeerd op basis van klinische presentatie. Bijna de helft van de 
populatie presenteerde zich met STEMI, waarvan 455 EES patiënten en 257 SES 
patiënten. De rest van de populatie presenteerde zich zonder STEMI (447 EES en 
443 SES). Beperkte verschillen op baseline werden gecorrigeerd door middel van 
cox proportional hazards analyses. Twee jaar follow-up liet geen verschillen in het 
primaire eindpunt van cardiale sterfte, MI en target vessel revascularization zien 
tussen EES en SES, ongeacht de klinische presentatie. Alhoewel een trend tot een 
verlaging van definite/probable ST met EES werd gezien, kwam ST zelden voor in 
de beide groepen op de lange termijn. Deze analyse suggereerde dat EES en SES 
even veilig en werkzaam zijn voor de behandeling van de gehele breedte van pa-
tiënten, zonder beïnvloed te worden door klinische presentatie.
Conclusies en toekomstperspectieven
De opkomst van de STEMI zorg is een van de meest indrukwekkende ont- 
wikkelingen in de medische geschiedenis geweest. Desondanks blijft de wereld- 
wijde last van coronaire hartziekten toenemen en bestaat er een continue noodzaak 
voor wetenschappelijk onderzoek om deze last te verlichten. Het eerste deel van dit 
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proefschrift identificeerde hoog-risico subpopulaties van STEMI om de zorg en risi-
costratificatie van STEMI patiënten te verbeteren. Hierin werd duidelijk dat veel voor-
komende patiëntkenmerken zoals vrouwelijk geslacht, voorgeschiedenis van kanker 
en hoge leeftijd een sterke impact op de tijd tot ondergaan van reperfusie therapie en 
de prognose van STEMI patiënten hebben. De sterk wisselende aard van risicotoe-
name in de verschillende subpopulaties toont het belang van onderzoek naar tailored 
care, zorg op maat ingericht op de specifieke behoeftes van het hoog-risico indi- 
vidu. Daarnaast blijft de historische ernstige complicatie van STEMI, out-of-hospital 
cardiac arrest, een negatieve invloed houden op de prognose van STEMI patiënten. 
Angiografische determinanten van het optreden en de prognose van out-of-hospital 
cardiac arrest werden geïdentificeerd, wat mogelijk kan leiden tot verbetering van 
de zorg van deze hoog-risico patiënten. 
Het tweede deel van dit proefschrift onderzocht de waarde van tweede generatie 
drug-eluting stents voor de behandeling van coronaire hartziekten. De tweede 
generatie EES verbeterde de lange termijn resultaten vergeleken met E-ZES na 
primaire PCI in een real world observationeel cohort. Een gerandomiseerde non- 
inferiority myocardinfarct studie toonde vervolgens de gelijkwaardigheid van EES 
met de eerste generatie SES aan, met veelbelovende resultaten die superioriteit 
suggereerden. EES en SES toonden daarentegen vergelijkbare uitkomsten in een 
all-comer trial. De 2 trials werden gecombineerd om de invloed van klinische pre-
sentatie op de uitkomsten na percutane interventie verder te onderzoeken. Daaruit 
bleek dat EES en SES vergelijkbare uitkomsten hebben na 2-jaar follow-up, ongeacht 
de klinische presentatie. Stent trombose kwam zelden voor op de lange termijn in 
beide stent groepen, en de werkzaamheid van de stents was vergelijkbaar, wat het 
nut van de beide devices voor patiënten uit de gehele breedte van coronaire hart- 
ziekten steunt. Ondanks deze gunstige resultaten blijven er zorgen bestaan over de 
lange termijn effecten van de permanente polymeer op de coronaria. Nieuwe DES 
met biologisch afbreekbare of polymeer-vrije ontwerpen bieden in potentie het anti- 
restenotische voordeel van DES in combinatie met het gunstige langetermijn veilig- 
heidsprofiel van bare-metal stents. Volledig biologisch afbreekbare stents, welke 
binnen enkele jaren volledig geabsorbeerd zijn, gaan nog een stap verder met het 
concept van resorptie. Toekomstig onderzoek zal moeten aantonen wat de aanvul-
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Dit proefschrift is het eindresultaat van een leerzaam en veelzijdig promotietra-
ject. De leuke tijd die ik heb gehad en het behaalde resultaat waren niet tot stand 
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Allereest wil ik mijn promotor prof. Schalij bedanken voor de begeleiding van mijn 
projecten en de vrijheid om mijn eigen ideeën te volgen, waardoor ik de kans kreeg 
mij te ontwikkelen als onafhankelijk onderzoeker.   
Daarnaast wil ik de oorspronkelijke initiatiefnemers van mijn promotietraject be-
danken, mijn co-promotor Ad van Boven en Sjoerd Hofma. Zonder jullie plannen 
en gedachten  was dit proefschrift er nooit van gekomen, enorm bedankt voor jullie 
enthousiasme en betrokkenheid!
Ook mijn andere co-promotor Victor Umans wil ik bedanken voor de prettige 
samenwerking, de uitstekende bijdrage aan onze gezamenlijke projecten en de 
uitnodiging om in de werkgroep van NVVC Connect deel te nemen. 
Daarnaast wil ik de leden van de leescommissie bedanken voor het beoordelen van 
dit proefschrift. 
De dataverzameling die aan de basis van mijn promotie ligt was niet mogelijk ge-
weest zonder de hulp van het research team van het Medisch Centrum Leeuwar-
den, de ambulancediensten van Friesland en Hollands-Midden, de nurse practi-
tioners van het Medisch Centrum Alkmaar,  de queries van Enno, alle behandelende 
interventie-cardiologen, het hartkatheterisatie personeel, de patiënten waarop de 
gegevens gebaseerd zijn en waar we het uiteindelijk voor doen, en alle voorgangers 
van de Mission! Infarct in Leiden. 
Van de voorgangers wil ik speciaal Bas en Su-San bedanken, voor de gezelligheid 
en ondersteuning bij het opzetten van mijn onderzoek en de werkgroep bijeen-
komsten.
Talitha verdient een aparte regel voor haar administratieve ondersteuning in moei-
zame tijden, bedankt!
Zonder de mede-onderzoekers uit de tuin was mijn promotietijd nooit zo’n groot 
succes geworden, ik wil iedereen uit de tuin bedanken voor alle gezelligheid!
Van de tuin-collega’s wil ik speciaal nog Helèn en Ulas noemen, bedankt dat jullie 
mijn paranimfen willen zijn! Helèn, over de jaren hebben wij heel wat Mission lief-
en-leed gedeeld. De tijden van data-buffelen en boemerangs teruggooien zitten er 
gelukkig op! Ulas, alle binnen- en buitenlandse congressen waren nooit zo onver-
getelijk geworden zonder onze gezamenlijke avonturen, het was mooi! 
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Additionally, I would like to thank prof. Wallentin and prof. Lindahl for the  oppor-
tunity to do research at the Uppsala Clinical Research Center.  Dessutom vill jag 
tacka Stefan James och Bo Lagerqvist,  era kunskaper, färdigheter och vänlighet har 
imponerat mycket på mig, tack för allting! Jag vill även tacka alla andra på UCR! 
Jag har lärt mig så otroligt mycket i Sverige och jag har känt mig väldigt välkommen 
på UCR. 
Ik wil alle vrienden bedanken die het leven ook buiten het onderzoek doen mooi 
maken! Vanuit het hoge Noorden is het wat lastiger regelmatig contact te houden 
maar weet dat jullie altijd welkom zijn in Zweden! 
Alex en Tineke, Fleur en Sebas, Elin en Moira,  de onvoorwaardelijke liefde en steun 
die jullie mij bieden geeft mij de kracht om geen berg te hoog te vinden! 
Sara, this small page can’t hold all the reasons why you are important to me, let’s 
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